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1 Complement and renal transplantation:  from donor to recipient
Jeffrey Damman 
Theo A. Schuurs 
Rutger J. Ploeg  
Marc A. Seelen




Long-term kidney graft survival is affected by different variables including donor condition, 
ischemia-reperfusion injury and graft rejection during the transplantation process. The 
complement system is an important mediator of renal ischemia-reperfusion injury and in 
rejecting allografts. However, donor complement C3 seems to be crucial in renal transplantation 
related injury as renal injury is attenuated in C3 deficient kidney grafts. Interestingly, before 
ischemia-reperfusion induced C3 expression, C3 is already induced in donors suffering from 
brain death. Therefore, strategies targeting complement activation in the brain-dead donor 
may increase graft viability and transplant outcome. 
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Introduction
Long-term graft survival of renal transplants is determined by different variables including 
donor condition, kidney preservation, human leukocyte antigen (HLA) matching, duration 
of cold and warm ischemia, and injury caused by reperfusion during transplantation (1). For 
years, several research groups have focused on the impact of ischemia-reperfusion injury 
(IRI) on long-term kidney graft survival. Besides the importance of IRI, also the condition 
of the donor does determine long-term graft survival. Terasaki et al. showed that kidneys 
obtained from living donors, despite a high degree of HLA mismatching, had higher survival 
rates compared to deceased grafts obtained from brain-dead or non-heart beating donors. 
These results did not depend on the duration of cold ischemia, so other causes had to be 
considered (2). As the majority of deceased grafts are derived from brain-dead donors, the 
hypothesis was formulated and subsequently confirmed during the past years that brain death 
(BD) should be regarded as a risk factor for long-term graft survival. Our group and others 
have shown the negative influence of donor BD on organ viability and survival rates after 
transplantation in various organs (3-6).
Recently, several groups investigated the role of complement in clinical renal transplantation. 
Complement component C3 is the central complement component on which all complement 
pathways converge. Local renal production of complement C3 seems important in graft 
rejection, because the absence of locally synthesized C3 significantly reduces renal 
allograft rejection (7). These studies emphasize the pathogenic role of complement in renal 
transplantation-related injury and indicate that strategies targeting complement induction 
during the transplantation process could improve transplant outcome. In this review we will 
discuss three moments of complement activation during the transplant process: at the time of 
rejection, IRI and as a result of donor condition.
The complement system
The complement system is an important part of the innate immune response and has diverse 
roles in defensive immunity. Essentially, the complement system is involved in the elimination 
of pyogenic bacteria, the interaction between innate and adaptive immunity, and the 
clearance of cellular debris and immune complexes after inflammatory injury. Three different 
complement pathways can be distinguished: the alternative pathway, the classical pathway 
and the lectin pathway. The alternative pathway cascade is activated when hydrolysed C3, 
which is continuously formed through cleavage of systemic C3 (“C3 tickover”), binds to 
microbe cell surface components in vicinity. The classical pathway is activated after the 
binding of C1 to antibody-antigen complexes, damaged cells or cell particles. The lectin 
pathway is activated when circulating lectins such as mannose binding lectin (MBL) and 
ficolins bind to carbohydrate mannose residues on certain microbes. Activation of the three 
pathways results in the formation of a C3- and subsequently a C5 convertase eventually 
leading to the formation of the membrane attack complex (MAC) C5b-C9. In addition to 
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Rejection
Schematically, renal allograft rejection can be divided in humoral (i.e. B-cell dependent) 
and cellular (i.e. T-cell dependent) rejection. Interaction between complement and the B-cell 
response in renal transplantation has been extensively described; however, the pathogenesis 
of complement mediated T-cell responses still remains unclear (10-13). Recently, it is shown 
that donor proximal epithelium cell-bound C3 and dendritic C3 are able to potentiate the 
T-cell response in vitro, whereas macrophages deficient for C3 have an impaired potency 
to stimulate allo-reactive T-cells (14-16). These results suggest that C3 is able to interact 
with allo-reactive T-cells, enhancing the alloimmune response. Evidence exists that C3 is 
activated through the alternative pathway, as increased synthesis of alternative pathway 
components are observed at the interaction between antigen presenting cells (APCs) and 
T-cells (17). Moreover, absence of donor factor B and D showed impaired T-cell responses 
whereas absence of C4 in vivo or in vitro does not influence, respectively, T-cell responses 
or allograft rejection (16-18).
Once C3 is activated, C3a and C5a are generated which are able to potentiate the T-cell 
response through their receptors. In this context, Heeger et al. showed that decay accelerating 
factor (DAF), which dissociates C3- and C5-convertases on the cell surface, is a potent 
regulator of T-cell differentiation. Absence of decay accelerating factor on APCs enhances 
C5a dependent IL-12 secretion by APCs thereby stimulating T-cell differentiation (19). 
Besides, also C3a is able to regulate the alloimmune response through its receptor on APCs 
(20). Extensive review articles on the role of T-cells and complement in allograft rejection are 
recently published by Sacks et al. and Zhou et al. (21;22).
Ischemia-reperfusion injury
Renal IRI occurs when a reduced or deprived blood flow exists through the renal artery 
followed by recovery of blood perfusion, provoking an inflammatory response. The process 
is complex and poorly understood but is, among other factors, characterised by infiltration 
of neutrophils, induction of pro-inflammatory proteins on vascular endothelial cells, reactive 
oxygen species formation and complement activation (23-25). Regarding complement, Zhou 
et al. showed that C3-, C5- and C6-deficient mice were protected from renal IRI, whereas C4 
deficient mice remained susceptible for IRI. Substitution of C6-deficient mice with C6 did 
indeed reestablish sensitivity for IRI whereas treatment with C5a antibodies did not show 
additional renal protection (26). These findings indicate that the injury seen after renal IR is 
probably regulated by the MAC and less by C5a mediated neutrophil recruitment. However, 
de Vries et al showed that a C5a-receptor-antagonist (C5aRA) was capable to attenuate renal 
IRI. Protective effects of C5aRA were shown to be independent of neutrophil influx pointing 
at other mechanisms of C5a through the C5a receptor (C5aR) (27). Possibly, there is a direct 
effect of C5a on the renal tubular epithelium with induction of several pro-inflammatory 
genes. Also Arumugam et al. showed a marked reduction of renal IRI after treatment with a 
C5aRA (28). 
Thus it seems that C5a and the MAC are both involved in the pathogenesis of IRI in the 
kidney. Although Zhou et al. showed full protection against renal IRI in C3 deficient mice, 
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other studies showed only partial protection (29). The differences might be explained by the 
use of different durations of IRI. Although Zhou et al. and de Vries et al. used models with 45 
to 60 minutes of IRI, IRI induced by Park et al. took only 20 to 30 minutes. Evidence exists 
that the injury caused by short time periods of ischemia followed by reperfusion are mediated 
by neutrophils whereas longer time periods are mediated by apoptosis (30;31). Therefore 
in the studies using longer ischemia times, contribution of complement, and especially 
contribution of the MAC, to IRI seems to be more significant. Besides differences in duration 
of IR also different mouse strains, different models of IRI and the unknown secondary effects 
of knock-outs might explain the differences in observed outcomes.
It is important to know through which complement pathways IRI is mediated as it disguises 
its initiation. The study carried out by Zhou et al., showed that mice deficient in C4 were 
not protected against renal IRI (26). In addition, absence of C4 in the donor or recipient 
fails to prevent renal allograft rejection in mice (18). These data indicate that renal IRI is 
most probably not mediated through the classical pathway as C4 is an essential component 
of the classical complement pathway. Furthermore, Park et al. demonstrated that renal IRI 
is independent from immunoglobulins and T-lymphocytes, although others determined an 
important role for T- and B-cells in IRI (29;32;33). However, B-cell mediated IRI seems to 
occur independent of complement (32). Confirming the importance of the alternative pathway, 
additional studies show less IRI, a decline of tubulo-interstitial C3 deposition and neutrophil 
influx in factor B deficient mice (34). Also increased alternative pathway activation in kidney 
biopsies from patients with acute tubular necrosis was observed (35). Recently, involvement 
of the MBL-pathway in renal IRI was demonstrated in a mouse renal IRI model and in clinical 
posttransplant acute renal failure (ARF). A strong co-localization was seen between MBL-A 
and –C depositions and C6 deposition, indicating MBL involvement of renal complement 
activation (36). Furthermore, knock-out mice for MBL-A and MBL-C were protected from 
kidney damage after IR. Reconstitution of knock-out mice with recombinant human MBL 
before surgery restored renal damage after IR, confirming the importance of the MBL-
pathway in renal IRI (37). Probably, MBL mediated renal IRI acts through direct splicing of 
C3 by mannan-binding lectin serine peptidase 1 and not through C4, as C4 knock-out mice 
were not protected against renal IRI. Thus several studies indicate a prominent role of both 
the alternative- and MBL pathway and less for the classical pathway in renal IRI. 
Renal IRI mainly involves tubular epithelium and thus, if circulating complement components 
are important in renal IRI, penetration through the vascular endothelium into the extravascular 
compartment is needed. However, some of the major complement components have such a 
large molecular size that penetration through the basal membrane is probably very poor if 
not impossible. Therefore, involvement of locally produced complement in the extravascular 
compartment seems more likely, whereas circulating complement components possibly 
have a more prominent role in vascular endothelial damage after reperfusion of an ischemic 
kidney. Although most complement components are synthesized in the liver by hepatocytes 
during the acute phase response, the kidney itself is a prominent producer of complement. 
Endothelial cells, mesangial cells, glomerular epithelial cells and tubular epithelial cells 
are capable of producing complement components in vitro (38-44). One reason that locally 
extravascular produced C3 is such a major factor responsible for renal IRI, might be the lack 
of regulator proteins on the tubular epithelium. Normally, the complement system is tightly 
regulated due to the presence of complement regulator proteins (45;46). These proteins 
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protect complement mediated injury in the host and deficiency of these proteins is associated 
with several renal diseases (47-50). CR1/related gene-protein y (Crry) is expressed on rodent 
tubular epithelial cells being most susceptible for IRI (51). Crry is a complement inhibitor, 
binding C3 and C5 convertases, thereby reducing both classical and alternative complement 
pathway activity. Decreased Crry expression leads to increased sensitivity for IRI and poorer 
graft function (51;52). Moreover, mice overexpressing Crry are protected from acute renal 
failure. In contrast, treatment with Crry-Ig did not influence renal IRI outcome, which can 
be explained by the short time period of IR and the use of heparin, a potent complement 
inhibitor, obscuring possible benefits (53). In summary, these results indicate that endogenous 
Crry expression regulates complement activation on the tubular epithelium. As complement 
is highly expressed on the renal tubular epithelium in IRI, it is likely that Crry complement 
regulation is overwhelmed by tubular complement deposition or tubular Crry is lost because 
of ischemia. 
Donor condition
During the past years more and more evidence has been found that not only posttransplantation 
factors, but also the condition of the donor is of major importance for long-term kidney graft 
survival (2). In kidney transplantation, grafts are retrieved from living, heart beating and 
non-heart-beating donors. The majority of donor kidneys are retrieved from heart beating 
or brain-dead donors who suffer from hemodynamic and hormonal instabilities resulting in 
immune activation, thereby affecting organ viability before transplantation. The nature of 
organ immune activation in brain-dead patients was first investigated using rat brain-dead 
models. A series of animal studies by different groups have shown upregulation of pro-
inflammatory molecules and influx of polymorphonuclear cells (PMN’s) and MØ in the kidney 
(5;6;54). Also in human brain-dead donors, an identical immune activation was observed in 
donor kidneys (55). Furthermore, kidneys having suffered from BD show poorer function 
and lower graft survival rates after transplantation (56;57). Therefore, appropriate treatment 
in the donor will be effective to improve donor organ quality and subsequently transplant 
outcome. A better insight however in the processes of BD is essential to determine the target 
of intervention. Successful intervention strategies to reduce the pro-inflammatory response 
induced by BD have been reported. Dopamine has been shown to reduce major MHC class 
II and P-selectin expression and prevented up-regulation of TNF-alpha and MCP-1 (58). 
Furthermore, P-selectin blockade therapy has been demonstrated to improve renal allograft 
function from brain-dead donors (59). Interestingly, enhanced complement production 
is required for up-regulation of P-selectin and CXC chemokines (such as MCP-1) in IR 
models (60;61). Furthermore, Pratt et al. demonstrated the importance of local complement 
C3 synthesis in the pathogenesis of renal injury after transplantation. Local production of 
complement already in the donor kidney might have devastating consequences for kidney 
viability (7). Interestingly, also donor C3 allotype influences long-term renal transplant 
outcome (62). Kusaka et al. were the first to demonstrate the presence of complement in 
kidneys of rat brain-dead donors (6). Recently, our group observed comparable results in a 
time course experiment of BD. Briefly, BD was induced in rats and organs were retrieved after 
0.5, 1 and 4 hours of BD. Kidneys showed an eight times upregulation of complement C3 
gene expression after 4 hours of BD compared to sham operated animals (data not published). 
These data suggest involvement of the complement system in the pathogenesis of renal injury 
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caused by BD. To evaluate the clinical validity of complement expression in rat brain-dead 
donors, we examined C3 expression in human kidney biopsies obtained from human brain-
dead and living donors during organ procurement. Gene expression of C3 was significantly 
higher (eightfold) in kidney biopsies obtained from brain-dead donors compared to living 
(un)related donors. Furthermore, additional experiments suggested no enhanced renal C3 
expression due to injury related to cold ischemia or reperfusion following the pre-existing 
upregulation after BD. Most interestingly, we also demonstrated an association between C3 
gene expression and renal transplant function in allograft from brain-dead donors early after 
transplantation: High C3 expression in kidneys from brain-dead donors after transplantation 
is negatively associated with early posttransplant renal function. 
These findings suggest that after reperfusion of the renal allograft, large amounts of 
complement, already induced by the BD insult before transplantation, are present in vicinity 
of damaged tissue. Besides, no additional C3 expression is found due to reperfusion following 
BD. For that reason, the intervention in complement activation in allografts from BD donors 
before transplantation is potentially more effective to improve allograft function than at the 
time point of reperfusion injury after transplantation.
Targeting the complement system
Because involvement of complement in renal transplantation becomes more clear, strategies 
targeting the complement system might become a promising approach in reducing renal 
allograft injury with subsequent improvement of transplant outcome. The complement 
activation cascade can be targeted at different levels to attenuate complement mediated injury 
using, for example, soluble complement receptor 1 (sCR1), C5 antibodies, or a C5aRA.
sCR1 is a complement regulator protein and has two important functions in diminishing 
complement cascade activation: acting as a cofactor for C3b and C4b breakdown and 
acceleration of C3- and C5-convertase degradation (63). In a rat model of intestinal IRI, 
treatment with sCR1 reduced intestinal myeloperoxidase activity and mucosal injury 
significantly (64). sCR1 administration also ameliorated the protection of the rat liver from IRI 
(65;66). In renal transplantation, sCR1 has been shown to prevent acute rejection and to extend 
kidney allograft survival (67;68). In clinical practise, sCR1 has already been successfully 
used in the treatment of myocardial IRI thereby reducing myocardial infarct size by at least 
44% (69-71). Moreover, TP10 (a sCR1) did significantly decrease incidence of mortality and 
myocardial infarction in high risk male patients undergoing cardiac surgery or cardiopulmonary 
bypass, although primary endpoints of the study were not improved (myocardial infarction, 
prolonged intra-aortic balloon pump support, prolonged intubation) (72).
Other complement regulator proteins (e.g. CD59, CD55 or CD46) or agents upregulating 
these proteins are possible mechanisms for intervention. Zhang et al., for example, managed 
to produce a fusion protein of an immunoglobulin with CD59 (CD59-Ig) which has the ability 
to inhibit MAC-formation in a site-specific manner (73). Because MAC formation plays a 
role in renal IRI, this might be a tool preventing MAC-induced renal injury during IR.
Another approach to inhibit complement activation more downstream in the cascade is 
by blocking the conversion of C5 and thereby inhibiting formation of C5a and the MAC. 
Amsterdam et al. were the first to investigate the influence of monoclonal antibody 
administration against C5a during myocardial infarction in pigs. They found an inhibition 
of neutrophil cytotoxic activity after treatment with mAb against C5a (74). Furthermore, 
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Vakeva et al. observed decreased myocardial IRI when rats were treated with mAb against 
complement C5 (75). Also in a mouse model of renal IRI, treatment with a monoclonal 
antibody against C5 prevented late inflammation and apoptosis (76). Concerning renal IRI, 
as described before, several groups managed to reduce kidney injury (28) and even renal 
function (27) after treatment with C5aRA in different models of renal IRI.
Another strategy to target complement-mediated injury is by using small interfering 
RNA (siRNA) thereby silencing C3 or C5, consequently attenuating or inhibiting further 
complement mediated injury (77;78). Furthermore, blocking the alternative pathway of 
complement, reduced serum urea nitrogen levels and extent of apoptosis after IRI in treated 
mice compared to controls (79).
Thus, several strategies can be effectively used to target the complement system in different 
models of IRI. Targeting complement activation should be focused on alternative pathway and 
MBL-pathway dependent activation of the terminal pathway, and production of chemokines 
such as C5a and C3a.  Finally, recent findings suggest that interventions may be even more 
efficient when given already to brain-dead donors. 
Conclusion
Absence of C3 in transplanted kidneys greatly improves kidney survival after transplantation, 
indicating the importance of local complement production by the donor kidney. It is proven 
that complement has important mediator functions during kidney rejection and renal IRI. 
However, complement is already induced after the onset of BD in the donor, before kidney 
transplantation. Therefore, if contribution of BD-induced complement seems to be substantial, 
intervening in complement induction has to occur before or shortly after the onset of BD. 
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Two central pathways of innate immunity, complement and Toll-like receptors (TLRs), 
play an important role in the pathogenesis of renal injury inherent to kidney transplantation. 
Recent findings indicate close crosstalk between complement and TLR signaling pathways. 
It is suggested that mitogen activated protein kinases (MAPKs) might be the key molecules 
linking both the complement and TLR pathways together. Complement and TLRs are 
important mediators of renal ischemia-reperfusion injury (IRI). Besides IRI, complement C3 
can also be upregulated and activated in the kidney before transplantation as a direct result 
of brain death (BD) in the donor. This local upregulation and activation of complement in 
the donor kidney has been proven to be detrimental for renal allograft outcome. Also TLR4 
and several of its major ligands are upregulated by donor BD compared to living donors. 
Important and in line with the observations above, kidney transplant recipients have a benefit 
when receiving a kidney from a TLR4 Asp299Gly/Thr399Ile genotypic donor. 
The role of complement and TLRs and crosstalk between these two innate immune systems 
in relation to renal injury during donor BD and ischemia-reperfusion are focus of this review. 
Future strategies to target complement and TLR activation in kidney transplantation are 
considered. 
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Introduction
Long-term renal allograft survival after kidney transplantation remains unsatisfactory, 
which can mainly be attributed to the development of chronic allograft nephropathy (CAN). 
Noxious stimuli such as donor brain death (BD) and age, cold ischemia, organ preservation 
methods, HLA-matching, reperfusion and acute rejection are independent risk factors for 
the development of CAN (1-4). Different pathophysiological mechanisms are triggered by 
these noxious insults leading to loss of allograft function. The complement system (CS) and 
Toll-like receptors (TLRs), as part of the innate immune system, are two important effector 
mechanisms that play a crucial role in the pathogenesis of renal injury related to renal 
transplantation. The CS and TLRs, both critical for first-line host defense, can be promptly 
activated upon threat from outside, by invading micro-organisms, or from within, by tissue 
ischemia-reperfusion (IR). The contribution of the CS and TLRs as a response on IR on 
tissue injury has been demonstrated in various animal models, however to date its role in 
clinical transplantation remains unclear. Recently, complement activation induced by BD 
in renal allograft donors has also been suggested to contribute to loss of allograft function 
after transplantation (5;6). These findings could have major implications for intervention 
strategies. Thus far, activation of TLRs during BD is unknown. However, by the emerging 
body of publications on crosstalk between the CS and TLRs, activation of the TLR system 
could be anticipated. 
This review discusses the role and crosstalk between complement and TLRs in relation to 
pre-transplant renal injury by donor BD and early post-transplant renal ischemia-reperfusion 
injury (IRI). The reader is referred to more detailed publications regarding complement and/
or TLR activation in relation to adaptive immunity (7;8). 
The complement system 
The CS consists of more than 30 proteins in the plasma and on the cell surface. Activation of 
complement is amongst others involved in the elimination of pyogenic bacteria, the interaction 
between innate and adaptive immunity, and the clearance of cellular debris and immune 
complexes. There are three known pathways of complement activation: The classical, lectin 
and alternative pathway (Figure 1).
Toll-like receptors
TLRs are transmembrane receptors which can be activated by danger associated molecular 
patterns (DAMPs) and pathogen associated molecular patterns (PAMPs). TLRs are present 
on a variety of cell types including epithelial cells, endothelial cells, leukocytes and dendritic 
cells. Once TLRs are activated, downstream signaling pathways are initiated leading to 
enhanced expression of cytokines and chemokines thereby bridging innate and adaptive 
immunity (Figure 2). 
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Figure 1:  Schematic overview of the three known pathways of complement activation and its  
major ligands.
There are three known pathways of complement activation: The classical, lectin and alternative pathway. 
Classical pathway activation occurs after binding of the C1 complex to antibody-antigen complexes, cell 
particles or certain acute phase proteins such as CRP or serum amyloid P (SAP). Once activated, the C1 
complex can cleave respectively C4 and C2 leading to the formation of a C3 convertase and thereby C3 
activation. The lectin pathway is activated when MBL and/or ficolins interact with carbohydrate ligands. 
Consequently, this activates MBL-associated serine proteases (MASPs), cleaving C4 and C2 and activating 
C3. The alternative pathway is activated by lowgrade spontaneous hydrolysis of systemic C3 (“C3 tickover”). 
Hydrolyzed C3 (C3(H
2
O)) can associate with factor B, which is subsequently activated by factor D, finally 
cleaving C3. The cleavage product of C3, C3b, can bind to hydroxyl groups on cell-surface carbohydrates and 
proteins thereby enhancing alternative pathway activation. Alternative pathway activation can also be initiated 
as an amplification loop when bound C3b, generated by classical, alternative and lectin pathway activation, 
binds factor B. This C3bBb complex is stabilized by factor P or properdin. Activation of the  three pathways 
results in the formation of a C3- and subsequently a C5 convertase eventually leading to the formation of the 
membrane attack complex (MAC). In addition to the capacity to generate the MAC, the split products of C3, 
C4 and C5 are known to have immunomodulating functions (9;10).
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Figure 2: Toll-Like receptor signaling and its major ligands.
Unique PAMPs are exogenous ligands present on groups of pathogens and include LPS, flagellin, lipoteichoic 
acid and double stranded RNA (viruses). DAMPs are intracellular proteins which are released outside the 
cell upon cellular injury, such as heat-shock proteins and HMGB1 (11;12). Different TLRs recognize specific 
PAMPs and DAMPs thereby orchestrating immune responses with a high specificity. Downstream activation 
of TLR signaling can couple five known adaptor molecules: MyD88, Toll-interleukin 1 receptor domain 
containing adaptor protein (TIRAP), TIR-domain-containing adaptor protein including IFN-β (TRIF or 
TICAM-1), TRIF-related adaptor molecule (TRAM or TICAM2) and sterile α- and armadillo motif-containing 
protein (SARM) (13). MyD88 is used by all TLRs except for TLR3, which signals through TRIF. TLR2 and 
TLR4 are able to couple MyD88 through TIRAP subsequently activating NF-kβ leading to the expression of 
several pro-inflammatory cytokines, chemokines and adhesion molecules. Activation through TRIF by TLR3 
also activates NF-kβ as well as IFN regulatory factor 3 (IRF3) (14). TLR 3, 7, 8 and 9 are specific for detection 
of viral or bacterial nucleic acid and are localized inside the endosome.
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Complement and renal IRI
Renal IR is an inevitable consequence of kidney transplantation. The immunological 
process is among others characterized by recruitment of leukocytes, upregulation of vascular 
pro-inflammatory molecules and formation of reactive oxygen species (ROS) (15-17). 
Complement activation has shown to be one of a number of factors to participate in renal IRI. 
During the last decade, several studies have focused on the role of complement activation 
in renal IRI in a variety of animal models and in different species as summarized in Table 1.
A central role for the terminal complement cascade in renal IRI was demonstrated in C6 -/- 
mice, which were protected from renal IRI. A less important role was ascribed to the release 
of C5a and subsequent recruitment of neutrophils into the kidney since treatment with C5a 
antibodies did not show additional protection against renal IRI in C6 -/- mice (18). In contrast, 
de Vries et al. also found that inhibition of C5 with a monoclonal antibody protects against 
renal IRI with reduced neutrophil influx into the kidney (19). In line with these findings, 
treatment with a C5a receptor antagonist (C5aRA) showed a marked reduction in renal IRI 
(20). However, de Vries et al found that the protective effects of a C5aRA occurs independent 
of neutrophil influx (21). Therefore, other functions of C5a rather than inflammation through 
chemokinesis have been suggested. Possibly, C5a has a direct effect on renal vascular 
endothelium or tubular epithelium thereby enhancing kidney immunogenicity. In vitro studies 
support this hypothesis since there is a direct pro-inflammatory effect of C5a on endothelial 
as well as tubular epithelial cells through C5a receptor (C5aR) signaling (22-24). Thus it can 
be concluded from these studies that both C5a as well as the terminal complement cascade 
are the primary mediators of complement dependent renal IRI in mice. On the other hand, 
Zhou et al. found no prominent role of C5a during renal IRI, which can possibly be explained 
by the fact that these investigators used a more severe IRI model in contrast to others (18). 
A short period of renal IRI has shown to be dependent on neutrophil influx while longer 
time periods of IRI seem to be associated with apoptosis (25;26). Therefore, differences in 
contribution of the membrane attack complement (MAC) in renal IRI could be ascribed to 
models of severe or moderate renal injury. Notably, the differences between studies in mice 
might also depend on the use of different strains, different models of renal IRI (duration, bi/
unilateral clamping) and the use of knock-outs with unknown secondary effects. 
Elucidation of the pathways of complement that are activated is crucial to obtain insight in the 
initiating factors during renal IRI. In mice, it was found that absence of C4 does not protect 
against renal IRI and therefore, classical pathway activation is unlikely to be involved in the 
course of renal IRI (18). On the other hand, in a swine model of renal IRI, Castellano et al. 
found evidence for activation of the classical, lectin and alternative pathways (27). Besides 
classical pathway activation, also lectin pathway activation was demonstrated in a mouse 
model of renal IRI and in patients suffering from post-transplant acute renal failure (28). 
Others found that mannan binding lectin (MBL)-A and MBL-C deficient mice are protected 
from renal IRI (29). Possibly, since C4 -/- mice were not protected against renal IRI, MBL 
mediated injury may act through direct activation of C3 by MBL-associated serine protease 1 
(MASP1) and not through C4. The important role of MBL is supported by studies in kidney 
transplant recipients, in which high serum MBL was found to be associated with inferior 
transplant survival (30;31). 
Following classical pathway activation, the alternative pathway amplification loop might be 
triggered, or is activated by endogenous or exogenous ligands. In line with Castellano et al. 
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who found activation of the alternative pathway in their swine model, also others have shown 
less renal IRI, a decline of tubulo-interstitial C3 deposition and neutrophil influx in factor 
B deficient mice (32). Moreover, increased alternative pathway activation was observed in 
kidney biopsies from patients with acute tubular necrosis (33). 
Altogether, these studies emphasize that there is a clear difference between complement 
activation patterns among species. This questions whether the results in animals are also 
applicable to humans. There is a great demand for clinical studies analyzing the expression 
and activation of complement in human kidney transplantation. Ultimately, clinical trials 
have to be initiated targeting complement activation. The C1-esterase inhibitor, which is 
already widely used in humans to treat hereditary angioedema seems to be the obvious first 
choice (34). However, downstream C5aR blockade is more favourable, leaving most of the 
complement pathways intact because of its major role in host defense.
TLRs and renal IRI
Similar to complement, also TLRs (TLR 1, 2, 3, 4 and 6) are primarily expressed by tubular 
epithelial cells and mesangial cells (35). Wolfs et al. were the first to demonstrate that TLR2 
and TLR4 are constitutively expressed by the kidney in proximal and distal epithelial cells. 
Moreover, enhanced expression of TLR2 and TLR4 was found after renal IRI in renal 
epithelial cells of distal tubules, the thin limb of the loops of Henle and collecting ducts. 
Induction of both TLR2 and TLR4 was shown to be largely dependent on TNF-alpha and 
IFN-gamma (36). Comparable findings of TLR2 and TLR4 induction were found in a rat 
model of renal IRI (37). Interestingly, both studies found almost identical kinetics of TLR2 
and TLR4 induction, 3-5 days after reperfusion. To investigate the role of TLRs in renal IRI 
in a more physiological manner, many groups have performed experiments using knock-outs 
as summarized in Table 1. 
Investigating the role of TLR2 in renal IRI, Leemans et al. demonstrated that TLR2 deficient 
mice have less renal inflammation and injury after renal IRI. They clearly demonstrated that 
not TLR2 expression on leukocytes but renal TLR2 expression is the main mediator of TLR2 
dependent renal IRI. Furthermore, treatment of mice with TLR2 antisense oligonucleotides 
resulted in protection against renal IRI (38). 
Since several intracellular signaling pathways are linked to TLR signaling, Shigeoka et al. 
investigated the deficiency of TLR2, myeloid differentiation factor 88 (MyD88), TIR-domain-
containing adaptor protein including IFN-β (TRIF) and MyD88 x TRIF in a mouse renal 
IRI model. They found that deficiency of respectively TLR2, MyD88 and MyD88 x TRIF 
protected against renal IRI (39). However, protection in TLR2 -/- mice was more profound 
compared to MyD88 -/- animals, suggesting TLR2/MyD88 independent pathways of TLR 
mediated renal injury. However, mice deficient in TRIF remained susceptible for renal IRI. 
Therefore, other TLR2 signaling pathways independent from MyD88 and TRIF signaling 
have been proposed. 
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Table 1: Overview of the role of complement and TLRs in animal IR studies.
CS or TLR Study Species Knock-out or treatment IRI 
CS




Zhou et al. (18) Mouse C4 -/- -
De Vries et al. (19) Mouse C5a mAb ↓
Arumugam et al. (20) Rat C5aR antagonist ↓
De Vries et al. (21) Mouse C5aR antagonist ↓
Castellano et al. (27) Swine C1-inhibitor ↓




Thurman et al. (32) Mouse Factor B -/- ↓
Thurman et al. (80) Mouse Factor B mAb ↓
Zheng X et al. (78;79) Mouse siRNA against C3, C5aR ↓








Shigeoka et al. (39) Mouse
TLR2 -/-
↓MyD88 -/-
MyD88 x TRIF -/-
Shigeoka et al. (39) Mouse TRIF -




Pulskens et al. (41) Mouse TLR4 -/- ↓




Reduced renal IRI (↓), no effect on renal IRI (-).
Similar to TLR2, Wu et al found that also TLR4 knock-outs are protected against renal 
IRI. This seems to be regulated through activation of MyD88 since MyD88 deficient mice 
were also protected against renal IRI. Moreover it was shown that not TLR4 expressed by 
leukocytes but intrinsic kidney cells are responsible for renal IRI. The same study shows that 
endogenous ligands for TLR such as high-mobility group protein 1 (HMGB1), hyaluronan 
and biglycan are upregulated after IRI, providing evidence that one of these ligands might 
be responsible for TLR4 activation (40). Unfortunately, this study did not examine the co-
expression of these ligands with TLR4 activation. Pulskens et al. found similar results in the 
protection of IRI in a TLR4 knock-out (41). However, in contrast to Wu et al, no protection 
was found against renal IRI in MyD88 or TRIF deficient mice. This suggests the existence 
of another signaling pathway, besides MyD88 and TRIF-signaling, as suggested in TLR2 
signaling. Another explanation could be the enhanced activation of parallel pathways that 
also make use of MyD88, thereby neutralizing the pro-inflammatory signal of TLR4. Besides, 
the use of a more severe IRI model by Pulskens et al. might explain the difference in findings. 
This may also clarify why there was no difference in protection of leukocyte or renal TLR 
deficient cells after renal IRI. Abundant infiltration of leukocytes into the kidney in the severe 
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model of Pulskens et al. might thereby abolish TLR4 dependent leukocyte infiltration. 
Future studies have to explore the unknown, MyD88 and TRIF independent pathways 
underlying TLR2 and TLR4 activation in renal IRI. Also, co-expression studies of TLR 
ligands with TLRs are needed since this could unravel the initiating factors contributing to 
TLR mediated damage. Finally, expression and activation of TLR2, TLR4 and possibly other 
TLRs have to be analyzed in human renal transplantation. 
Crosstalk between complement and TLRs
Complement and TLRs are both activated by common ligands suggesting a potential 
crosstalk between the two systems. Both complement and TLRs can be activated in response 
to infection or by microbial structures such as lipopolysaccharide (LPS) and CpG DNA (42). 
The two systems might be able to synergize each other thereby shaping and validating the 
innate immune response against genuine danger signals. Today, however, to our knowledge 
no studies have been published which analyzed the interplay between complement and TLR 
activation in renal injury, let alone in renal IRI or transplantation. Therefore, our current 
knowledge on this interaction is based on studies performed either in models of experimental 
sepsis or in vitro cell culture systems. 
In vivo, Zhang and colleagues found that decay accelerating factor (DAF) deficient mice, 
when treated with LPS (TLR4 agonist), showed increased levels of IL-6, TNF-alpha, IL-1beta, 
IL-10 and decreased levels of IL-12 compared to wild-type mice. The LPS-induced cytokine 
release was absent in dual knockouts for both DAF and C3, which indicates that this response 
was strongly dependent on complement. Besides, enhanced cytokine production was found 
in wild-type mice which were co-treated with LPS and cobra venom factor, a potent activator 
of complement. Dual knockouts for DAF and TLR4 were non-responsive to LPS stimulation, 
indicating that the LPS-induced cytokine production was also TLR4 dependent. Interestingly, 
also zymosan (TLR2/6 agonist) and CpG DNA (TLR9 agonist) enhanced systemic cytokine 
levels in DAF deficient mice. These results suggest that the crosstalk between TLR and 
complement occurs mainly through MyD88 since only TLR4 can act independently from 
MyD88 (Figure 2). Downstream, the synergistic effect of complement and TLR4 activation 
was found to be mainly dependent on C5aR and less on C3a receptor (C3aR) signaling. 
In whole spleen lysates, increased activation of NF-kβ and phosphorylation of the mitogen 
activated protein kinases (MAPKs) ERK1/2 and JNK was found in LPS stimulated DAF -/- 
mice (43). 
Further evidence for TLR4 signaling through C5aR was found in a model of experimental 
sepsis. Absence or blockade of the C5aR significantly reduced serum levels of IL-6 during 
sepsis. Furthermore, in vitro, it was shown that the enhanced effects of C5a on LPS-induced 
IL-6 from neutrophils is dependent on the phosphorylation of p38 and ERK/12 MAPKs (44). 
Recently Wang et al. observed similar responses of C5a on the release of IL-8 in vivo during 
experimental sepsis and in vitro in human whole blood cells (45).  Interestingly, C5a induced 
IL-8 generation was enhanced by several TLR agonists. TLR4 enhanced C5a induced IL-8 
production was dependent on ERK1/2 and p38 but independent of JNK signaling. These 
studies clearly show that the signaling pathways underlying the enhanced effects of C5a on 




In line with the findings in vivo by Wang et al, Hawlisch et al. found that complement (C5a) 
negatively regulates TLR4 induced synthesis of IL-12 family members such as IL-12, IL-
23 and IL-27 from inflammatory macrophages (46). Also decreased IL-12 production by 
macrophages after C5a treatment was found by others (47). Because the IL-12 family members 
are involved in the regulation of T-cell differentiation and development, the interplay between 
complement and TLR might play a role in triggering adaptive immune responses. For a more 
extensive review about the crosstalk between TLRs and complement and regulation of T-cell 
immunity we refer to a recent publication by Hajishengallis and Lambris (48).  
Altogether, the above mentioned reports suggest that MAPKs might be the key molecules 
linking both complement and TLR pathways together. Although no studies have focused 
on the interplay between complement and TLR activation in renal IRI, a recent publication 
shows that such an interaction is evident in intestinal IRI. Complement C3 and factor B were 
upregulated in the intestine after IRI in wild type mice but not in TLR4 knock-out mice. 
Furthermore, C5a in the serum and intestinal C3 deposition were markedly decreased in TLR4 
deficient compared to wild-type mice after intestinal IRI. Treatment with CR2-Crry, which 
inhibits complement locally, significantly reduced TLR4 gene expression after intestinal IRI, 
suggesting that complement also regulates TLR4 expression (49). Whether such a crosstalk 
between complement and TLRs also occurs during renal IRI has to be investigated.
Complement activation by the donor
In their landmark paper, Pratt et al. clearly showed that local C3 expression by the donor 
kidney is detrimental for renal allograft survival. Absence of local C3 production in the 
donor kidney greatly improved kidney allograft survival after transplantation. Complement 
C3 deficient kidneys survived up to more than 100 days compared to wild type kidneys, 
which were rejected from 10 days on. In contrast, when kidneys from wild-type mice were 
transplanted into C3 -/- mice, renal allograft rejection could not be prevented (50). Also, 
absence of local C3 synthesis by the donor kidney, instead of circulating C3 by the recipient, 
was found to prevent complement-mediated reperfusion damage (51). These results indicate 
that not circulating C3 in the recipient but locally produced C3 by the donor kidney is an 
important mediator of early post-reperfusion and late rejection associated allograft injury. 
This can be explained by the large molecular size of C3 and the consequent poor penetration 
of C3 from the circulation through the basal membrane into the kidney. Besides the main 
production of C3 by the liver, the kidney itself is a prominent producer of complement. 
Endothelial cells, mesangial cells, glomerular epithelial cells and especially tubular epithelial 
cells are capable of producing complement components in vitro (52-58). 
Although the study by Pratt and colleagues is interesting, it is not taken into account that in 
clinical practice, most kidneys are recovered from deceased donors. Still, the majority of 
the kidneys that are finally transplanted are recovered from brain-dead donors. It is known 
that these kidneys have an inferior transplant function and survival when compared to living 
donors (59). Recently, our group showed local renal upregulation of C3 in a rat model of 
BD before organ recovery prior to transplantation (5). Also, Kusaka et al. demonstrated the 
presence of complement deposition in kidneys of rat brain-dead donors (60). In humans, we 
also demonstrated a higher gene expression of C3 and increased deposition of C3d in kidney 
biopsies taken before organ recovery from brain-dead donors. Interestingly, no additional 
renal C3 expression was found after cold ischemia or reperfusion upon the induction of 
Complement and toll-like reCeptor aCtivation in kidney transplantation
36
C3 by BD (5). In line with our findings, Naesens et al. showed induction of complement 
components in kidneys from deceased donors after cold ischemia. Furthermore, renal 
C3 expression in pre-implantation biopsies was associated with both early and late graft 
function in terms of superior glomerular filtration rates after transplantation (6). Our findings, 
however, discriminate between the significance of BD induced C3 rather than C3 induction 
due to cold ischemia. In future studies, BD induction should be performed in C3 knock-
out animals to investigate the contribution of complement dependent renal injury during 
donor BD. Furthermore, C3 deficient brain-dead donor kidneys transplanted into wild-type 
recipients would indicate the significance of BD-induced renal C3 in the donor. In humans, 
a first approach would be the analysis of gene expression rates of complement components 
in a large set of deceased donor and reperfusion biopsies to assess the routes of complement 
activation and its association with clinical outcome. 
Previous studies have focused on the influence of local complement activation by the donor 
kidney. However, it was shown in a mouse model of BD that also systemic complement 
becomes activated after BD in the donor (61). Moreover, in human deceased donors, a high 
C5b-9 level is associated with a higher rate of acute rejection in the recipient (62). Since 
activation of local and systemic complement occurs already before organ donation in brain-
dead donors, strategies targeting complement activation should be considered shortly after 
the diagnosis of BD. 
Besides local and systemic complement activation by donor BD, the important role of 
donor complement is also illustrated by functional polymorphism studies. After kidney 
transplantation, Brown et al. found an increased long-term graft survival when donors carrying 
the F allele were transplanted into S recipients (63). However, a recent study, comprising a 
larger transplant cohort with a superior follow-up, demonstrated no difference in allograft 
survival when a F allele carrying donor kidney was transplanted into a S carrying recipient 
(64). It is possible that the initial study by Brown and colleagues was a false positive result as 
can be encountered in genetic studies. These findings are supported by a recent publication in 
which no association was found between donor and recipient C4 allotype and renal allograft 
outcome (65). Therefore it can be concluded that chronic renal allograft deterioration is a 
multifactorial process which is not affected by functional polymorphisms in the C3 and C4 
gene. Table 2 summarizes studies on the role of complement activation in deceased donors 
on renal allograft outcome in the recipient.
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Table 2: Summary of animal and patient studies: The influence of complement and 
TLRs in deceased donors on renal transplant outcome in the recipient.
CS or TLR Study Species Model Outcome 
CS Pratt et al. (50;51) Mouse Allograft transplant:C3 -/- to C3 wild type
Improved GS Less 
ARF
Pratt et al. (50;51) Mouse Allograft transplant:C3 wild type to C3 -/-
No difference in 
GS or ARF
Naesens et al. (6) Human C3 induction in cold biopsies Worse GF
Damman et al. (5) Rat C3 induction in brain-dead donor kidneys NA
Damman et al. (5) Human C3 induction and activation in BD donor and cold biopsies Worse GF
Kusaka et al. (60) Rat Complement deposition in brain-dead donors NA
Brown et al. (63) Human F allele donors into S allele recipients Improved GS
Varagunam et al. 
(64) Human
F allele donors into S allele 
recipients
No difference in 
GS
Wahrmann et al. 
(65) Human
C4 donor and recipient gene copy 
number
No difference in 
GS
Atkinson et al. (61) Mouse Systemic complement activation after donor BD NA
Damman et al. (62) Human High deceased donor plasma C5b-9
Increased risk of 
AR
TLR Palmer et al. (67) Human TLR4 299/399 donor genotype in deceased donors
Decreased risk to 
develop AR
Nogueira et al. (68) Human TLR4 299/399 donor genotype in deceased donors
No influence on 
the risk to develop 
AR
Krüger et al. (72) Human TLR4 upregulation in pre-transplant cold biopsies vs living. NA
Krüger et al. (72) Human TLR4 299/399 donor genotype in deceased donors
Higher incidence 
of direct GF
Abbreviations: Graft survival (GS), acute renal failure (ARF), not assessed (NA), graft function (GF), acute rejection (AR).
TLR activation by the donor
Today, the role of TLRs in human kidney transplantation is mainly assessed by analysis 
of functional single nucleotide polymorphisms (SNPs) in the donor and recipient. Two 
functional SNPs have been described in the TLR4 gene, affecting the extracellular domain 
of the receptor. The occurrence of both variants, Asp299Gly and Thr399Ile, leads to a 
blunted immunological response after inhalation of LPS (66). Although Palmer et al found 
no association between recipient TLR4 299/399 polymorphism and transplant outcome, an 
association between donor TLR4 genotype and outcome was demonstrated. It was found that 
TLR4 genotype of deceased donors protects the allograft from developing biopsy proven 
acute rejection after transplantation (67). However, the protective effect of this TLR4 mutant 
genotype could not be confirmed by Nogueira and colleagues (68). This is likely explained by 
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the relative large proportion of living donors in their transplant cohort. One of the proposed 
mechanisms is the activation of TLRs in deceased donors by PAMPs and DAMPs that are 
released and locally upregulated upon brain damage and finally BD in the donor. Our group 
showed that BD leads to an increased intestinal permeability with subsequently elevated 
levels of circulating LPS (69). Furthermore, also other ligands of TLRs such as HSP70 are 
locally upregulated in the kidney after experimental and clinical donor BD (70;71). Recently, 
Krüger et al. found that TLR4 was significantly upregulated as a consequence of BD and/or 
cold ischemia in pre-transplant cold biopsies compared to living donors. Besides, a stronger 
staining for the endogenous TLR ligand HMGB1 was found in kidney biopsies from deceased 
donors compared to biopsies from living donors (72). HMGB1 could therefore be a candidate 
protein to serve as an endogenous ligand, contributing to TLR4 signaling in kidneys from 
brain-dead donors. Besides, Krüger et al. found that kidneys of donors with a 299/399 TLR4 
genotype have lower gene expression rates of TNF-alpha, MCP-1 and a higher expression of 
HO-1 compared to wildtype. Moreover, deceased donors with the 299/399 TLR4 genotype 
have a higher incidence of immediate graft function after transplantation. Thus, these studies 
indicate that kidney transplant recipient might benefit from receiving a kidney from a TLR4 
299/399 donor. Confirmative studies are needed to validate the protective findings of the 
donor 299/399 TLR4 genotype in a second independent cohort of patients to better assure 
this association with transplant outcome. Also, renal upregulation of TLR2, TLR4 and co-
expression with their ligands in deceased donor kidneys has to be confirmed in other donor 
cohorts. Table 2 summarizes studies on the role of TLR4 in deceased donors on renal allograft 
outcome in the recipient.
Intervention strategies
Pharmacological intervention in complement and TLR pathway activation of both the donor 
and recipient might be a promising strategy to improve renal allograft outcome. Today, most 
studies have focused on the inhibition of complement activation to reduce renal injury, while 
targeting TLR activation is emerging. 
Targeting complement
Soluble complement receptor 1 (SCR1) is a complement regulator protein and accelerates the 
decay of C3 and C5 convertases and serves as a cofactor for factor I mediated degradation 
of C3b and C4b, thereby inhibiting C3 and C5 convertase. In a rat allograft model, Pratt 
et al. demonstrated less vascular injury and leukocyte infiltration in allografts of recipient 
rats pretreated with recombinant humanized sCR1 (TP10) (73). Also, a modified form of 
complement receptor 1 (CR1) which was targeted to renal endothelium and epithelium reduced 
the amount of complement deposition, histological signs of renal injury and improved renal 
function after transplantation (74). Further, administration or targeting of other complement 
regulator proteins such as CD59, CD55 or CD46 might be a potential way to reduce renal 
injury during renal transplantation.
Since complement also plays a role in tolerance and clearance of pathogens, ideally one 
would inhibit complement activation at the level of C5 or C5aR, thereby leaving most of the 
complement pathway intact. Blocking the conversion of C5 consequently prevents the release 
of C5a and formation of the MAC. As described previously, blocking C5 activation or the 
C5aR reduces renal IRI (19-21). In addition, improved graft survival was observed of mice 
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kidneys treated with a C5aR inhibitor during preservation (75). Others showed improved 
long term graft survival in mice when recipients were treated with C5aR inhibitor before or 
even after transplantation (76).
An alternative strategy to target complement mediated injury is by the administration of 
small interfering RNA (siRNA) thereby silencing C3 or C5aR and consequently attenuating 
renal IRI (77-79). Furthermore, blockade of the alternative complement pathway improved 
renal function and decreased apoptosis after renal IRI (80). 
Targeting TLRs
Currently, several drugs are being developed to inhibit TLR2 and/or TLR4 expression or 
signaling. Since LPS is a specific ligand for TLR4, particular attention has been made to 
TLR4 in sepsis, These drugs have successfully been used to treat sepsis in animal models or 
in patients with sepsis (reviewed in (81)). Only one study has performed a TLR4 inhibition 
study in renal IRI. It was shown that blockade of TLR4 by eritoran reduces renal IRI in terms 
of renal function and histology (82). Furthermore, in a mouse model of myocardial IRI, pre-
treatment with the same drug decreased infarction size and cytokine expression (83). Future 
experiments have to investigate whether inhibitors of TLR2 and TLR4 activation, currently 
being used to treat experimental sepsis, can also prevent renal IRI or transplant related injury. 
The ultimate goal would be the use of such agents in clinical renal transplantation. 
Conclusion
Two pathways of the innate immune system namely complement and TLRs, play an important 
role in the pathogenesis of renal injury inherent to kidney transplantation. Recent studies have 
indicated an important crosstalk between both systems thereby resulting in immune responses 
with a high specificity. Both complement and TLR activation play an important role in the 
pre-transplant renal injury induced by donor BD and early post-transplant injury as a result of 
renal IRI. Therefore, modulating complement and TLR activation in kidney transplantation 
could be a useful strategy to improve graft outcome. Pre-treatment of brain-dead donors as 
well as the recipient before transplantation might be beneficial for renal allograft outcome 
after transplantation. Whether the combined use of complement and TLR blocking agents 
will be successful in humans remains to be investigated. 
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Today, kidney transplantation is still the first choice of treatment in the end stage of renal disease. 
Although multifactorial in origin, it is known that immunological and non-immunological 
factors play an important role in long term renal allograft deterioration. Donor factors such 
as brain death (BD) and age, but also kidney preservation methods, ischemia-reperfusion 
injury (IRI) and acute rejection have shown to be independent risk factors for long-term renal 
allograft survival. As part of the innate immune system, activation of the complement system 
has been shown to play a substantial role in renal transplantation related injury. Although 
the important role of complement activation in renal ischemia-reperfusion injury and acute 
rejection is acknowledged, its contribution in the donor on transplant related injury remains 
underexposed. 
In Chapter 1 the current knowledge of complement activation in cellular and humoral 
rejection and renal IRI is outlined. Moreover, the first results that complement is activated as 
a direct consequence of BD in the donor are shown. In Chapter 2 an overview is given of the 
role of two arms of the innate immune system, the complement system and Toll-like receptors 
(TLRs), in renal transplantation. It was already demonstrated that complement and TLRs are 
two important mediators of renal IRI. Recent studies have indicated a potential crosstalk 
between both systems thereby orchestrating the immune response with a high specificity. It 
is suggested that mitogen activated protein kinases might be the key molecules linking the 
complement and TLR pathways. In addition to renal IRI, local upregulation and activation of 
complement in the donor kidney by BD has been proven to be detrimental for renal allograft 
outcome. Furthermore, TLR4 and several of its major ligands are upregulated in brain-dead 
donors compared to living donors. Modulation of complement and TLR activation in brain-
dead donors as well as recipients before transplantation might be beneficial for renal allograft 
outcome after transplantation. Whether the use of complement and TLR blocking agents will 
be successful in humans remains to be investigated. 
In Chapter 4 the nature of systemic and local renal immune responses following experimental 
and clinical BD in the donor was investigated. In a rat brain-dead model, as well as in human 
brain-dead donors, serum cytokine levels after BD were determined. Furthermore, expression 
rates of acute phase proteins were determined in both the liver and kidneys from rat brain-
dead donors. To investigate the contribution of renal C3 induction by donor BD during kidney 
transplantation, post-transplant C3 levels were compared to C3 expression levels in the donor. 
In addition, gene expression and protein expression of complement C3 and fibrinogen were 
analyzed in human kidney biopsies from living and brain-dead donors and associated with renal 
transplant outcome in the recipient. 
Local renal complement deposition in deceased donors might either be a result of local or 
systemic complement activation. Therefore, in Chapter 5, the activation of systemic complement 
in deceased donors compared to living donors and healthy controls was analyzed. Furthermore, 
the level of complement activation products in the donor was associated with renal allograft 
outcome after transplantation in the recipient. We hypothesized that complement activation 
products might induce renal injury through different mechanisms: Anaphylatoxins C3a and 
C5a are able to activate their receptors present on renal endothelium or epithelium thereby 
provoking inflammation and injury. Furthermore, the direct lytic effect of the C5b-9 complex 
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through disturbance of the cellular membrane potential is a potent mechanism of injury to the 
graft itself. 
In Chapter 6 the extent and nature of systemic complement activation in human brain-dead 
donors, and the expression of C5a receptor in kidneys from living and brain-dead donors, was 
investigated. First, it was analyzed whether activation of systemic complement by donor BD 
can be translated to functional complement changes in blood of human brain-dead donors 
versus living donors. Gene expression levels of the C5a receptor in human kidney biopsies 
from brain-dead and living donors were analyzed and associated with graft outcome. Also C5a 
receptor protein expression and localisation were analyzed.
Since it was found that local and systemic complement activation by donor BD is associated 
with allograft outcome in the recipient, modulation of complement activation after BD might be 
a promising target for intervention during the donor phase in the intensive care unit. Therefore, 
in Chapter 7, the complement system was targeted in rat brain-dead donors with soluble 
complement receptor 1 (sCR1), which inhibits complement activation at the level of C3. Brain-
dead donor animals were treated one hour before or one hour after BD and outcome was assessed 
in terms of renal function and acute rejection grades after transplantation in an allograft model. 
Donor treatment with sCR1 might have consequences for donor management protocols and can 
facilitate treatment in the hospital setting in a non-declared donor. From a clinical point of view, 
it is recommended to treat the donor shortly after the diagnosis of BD with sCR1. 
Complement C3 is the central complement component on which all complement pathways 
converge. Hence, functional polymorphisms in the C3 gene might be suitable for matching donor 
grafts to renal transplant recipients and could reveal the importance of C3 in the pathogenesis 
of renal injury in human kidney transplantation. Contradictory results were reported about the 
protective effects of the donor C3F allele on transplant outcome of deceased donor kidneys. 
Since local and systemic complement are significantly activated in deceased brain dead (DBD) 
as well as deceased cardiac dead (DCD) donors, the disparity between the previous studies 
might be explained by an unequal distribution of both donor types among the study cohorts. 
Therefore, in Chapter 8, C3 allotypes of the donor and recipient of 1265 kidney transplantations 
were determined and associated with renal allograft outcome, particularly taking all donor types 
into account.
In the final Chapter 9 the role of the lectin gene profile of the donor and recipient on post-
transplant outcome was investigated. The lectin complement pathway can be activated upon 
pattern recognition by mannan binding lectin (MBL) or ficolins. Functional single nucleotide 
polymorphisms (SNPs) in the genes encoding the lectin pathway determine their functional 
protein activity and serum levels. In this chapter we investigated the role of SNPs in the MBL2, 
ficolin-2 and MBL-associated serine proteases 2 (MASP2) genes in the donor and recipient on 
post-transplant outcome in the recipient. 
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Kidneys derived from brain-dead donors have inferior outcomes after transplantation 
compared to kidneys from living donors. Strikingly, early and profound serum levels of IL-6 
in brain-dead donors are observed. IL-6 is the main regulator of the acute phase response 
(APR). The aim of this translational study was to investigate the expression of renal acute 
phase proteins (APPs) following brain death (BD) and to assess the association with renal 
allograft outcome after transplantation.
Methods
BD was induced in rats by inflating a subdurally placed balloon catheter. Kidney biopsies 
were obtained from human living and brain-dead donors at donation, after cold preservation 
and reperfusion. In vitro, renal proximal tubular epithelial cells (HK-2 cells) were stimulated 
with IL-6. 
Results
Both in human and rat brain-dead donors, C3 and FBG expression was enhanced at donation 
compared to living donors and sham-operated animals. In human donors, no additional 
expression was found after cold ischemia or reperfusion. C3 expression after reperfusion was 
independently associated with decreased short-term function after transplantation in grafts 
from brain-dead donors. In cultured HK-2 cells, C3 production was induced in the presence 
of IL-6. 
Conclusions
In conclusion, BD induces renal C3 and FBG expression. Moreover, C3 expression is associated 
with a worse allograft function early after transplantation. Therefore, targeting renal APPs in 
brain-dead donors, especially complement C3, may improve transplant outcome.   
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Introduction
Brain death (BD) in the donor is known to be a risk factor for successful kidney transplantation. 
Kidneys recovered from brain-dead donors have inferior outcomes and lower survival rates 
compared to kidneys recovered from living donors (1). This difference may be attributed to 
hormonal and haemodynamic instabilities and by the induction of an inflammatory reaction 
associated with BD (2-11). Previously, we and others have investigated the nature of this 
inflammatory response induced by BD in rat models. These studies showed upregulation 
of many cytokines and cell adhesion molecules involved in inflammation, and influx of 
polymorphonuclear cells (PMN’s) and macrophages in the liver, kidney, heart and lung (8-12). 
Also, levels of inflammatory serum cytokines were markedly elevated (7;10). Interestingly, 
many studies found serum IL-6 to be strongly elevated both after experimental and clinical 
BD but also after cerebral trauma without BD, while IL-1beta and TNF-alpha levels were 
increased only marginally (5;13-17). In the light of these findings we hypothesized that IL-6 
plays a crucial role in the pathogenesis of renal injury seen in brain-dead donors. 
It is well known that circulating IL-6 is a main inducer of the acute phase response (APR). 
The APR is characterized by fever, neutrophilia, changes in lipid metabolism, activation 
of complement and coagulation pathways as well as the induction of acute phase proteins 
(APPs). APPs are predominantly synthesized in the liver upon stimulation by IL-6, although 
synthesis in other organs has also been described (18;19). The functions of APPs are diverse 
and mainly involved in cytolysis and phagocytosis (complement components), coagulation 
(fibrinogen), clearing of haemoglobin (haptoglobin) and inhibition of thrombosis (alpa-1-
acidic glycoprotein (AGP)) and proteases (alpha-2-macroglobulin) (20;21). On the short 
term, the function of the APR is to restore homeostasis; however, this might become harmful 
when prolonged and/or dysregulated (22). Although most APPs are produced in the liver 
by hepatocytes, extra-hepatic expression has been described occasionally in kidney, heart, 
lung, spleen and brain (23). Extra-hepatic renal APP expression, such as complement C3 and 
fibrinogen, might play a role in the renal injury observed in BD donors.
The aim of this study was to investigate the renal APR in response to the stress associated 
with BD in the donor. Also, possible mechanisms of renal APP induction during BD and 





For this experiment, male adult Fisher F344 rats (250-300 g) were used. BD was induced as 
described previously (57). Briefly, the procedure was as follows: animals were anaesthetized 
using isoflurane with O
2
. A cannula was inserted in the femoral artery for blood pressure 
monitoring. Animals were intubated via a tracheostomy and ventilated throughout the 
experiment. Through a frontolateral borehole in the skull a no. 4 Fogarty catheter (Edwards 
Lifesciences Co., Irvine, CA) was placed subdurally and slowly inflated (16 μL/min) with 
saline using a syringe pump (Terufusion, Termo Co., Tokyo, Japan). Inflation of the balloon 
was stopped during the subsequent sharp rise in blood pressure, which reflects the autonomic 
storm at the beginning of BD. BD was confirmed by the absence of corneal and pupillary 
reflexes and an apnea test. During BD, animals received no anaesthesia. If blood pressure 
fell below 80 mmHg, it was restored by the administration of HAES 10% (Fresenius Kabi 
AG, Bad Homburg, Germany). Temperature was monitored rectally and kept constant. At 
the end of the BD period, donors were heparinized with 500 IU heparin. A laparotomy was 
performed and blood was collected from the aorta. Next, organs were flushed with saline and 
snap frozen in liquid nitrogen. Blood was centrifuged for 10 min. at 960g. Blood plasma was 
collected and stored at -80°C. Tissue from the right kidney was snap frozen in liquid nitrogen. 
Animals were sacrificed 0.5, 1 or 4 h after BD induction. Rats were randomly divided, each 
group consisting of six animals. Sham-operated rats served as controls.  
Renal transplantation  
In a separate experiment, kidneys from living or brain-dead Dark Agouti (DA) donors (using 
the same BD model) were transplanted into Lewis recipients using standard microsurgical 
techniques. A fixed period of cold ischemia was maintained for all rat allografts before 
transplantation. The kidneys were transplanted orthotopically to recipient renal vessels and 
ureter by end-to-end anastomoses using 10–0 prolene after the left kidney has been mobilized 
and removed, while the right kidney was left in situ. No immunosuppressive therapy was 
given. Transplanted kidneys were harvested 24 h after transplantation and snap frozen.
Patients, serum samples and kidney biopsies
Kidney biopsy specimens were obtained from brain-dead (n=20) or living donors (n=20) 
at three different time points: just before donation (before kidney recovery and start of 
preservation), at the end of cold ischemia and approximately 45 min after reperfusion in the 
recipient. Biopsy specimens were taken using a 16-gauge needle (Acecut®, TSK Laboratory, 
Japan), preserved in RNALater (Sigma, St. Louis, MO, USA) and subsequently stored at 
-80°C until analysis. Serum samples from brain-dead donors were obtained directly after the 
declaration of BD (T0) and just before start of organ perfusion, at the moment of donation 
(T1). In living donors, baseline serum samples were obtained before start of operation (T0) 
and a second sample before kidney donation (T1). 
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Cell culture
Cell culture experiments were performed with HK-2 cells (American Type Culture Collection 
(ATCC), Rockville, MD, USA). HK-2 cells were cultured in a monolayer in a 1:1 mixture 
of HAM’s F12 and DMEM supplemented with 1% penicillin, 1% streptomycin (Invitrogen), 
supplemented with 0.01 mg/L epidermal growth factor (Preprotech), ITS (10 mg/L insulin, 
5.5 mg/L transferrin, 6.7 μg/L sodium selenite), 36 μg/L hydrocortisone (Sigma), Glutamax 
(2 mM, Invitrogen) and 10% fetal bovine serum (FBS; Biowhittaker) in humidified air with 
5% CO2 at 37 °C.
HK-2 cells (1 x 105) were seeded in 12-wells plates and serum starved for 24 h before 
stimulation with either IL-6 (100 ng/mL), IL-8 (100 ng/mL), MCP-1 (100 ng/mL) (Invitrogen) 
or combinations for 0, 24, 48 and 72 h under serum-free conditions. Dose-response and 
blocking experiments were performed with IL-6 alone (10 ng/mL, 48 h). Blocking experiments 
were performed by 30 min of pre-incubation and during IL-6 stimulation, using a mouse 
monoclonal anti-human IL-6 receptor antibody (IL-6 RA, Abcam, Cambridge, UK). After 
incubation, cells were counted and supernatants were harvested and analysed for C3 and 
FBG production by ELISA.
Human and rat serum cytokine analysis
Levels of human and rat serum cytokines were analysed by multiplex bead technology using 
the 13-plex kit (LINCOplex: HCYTO-60K, Linco, St. Louis, MO) for the rat and a multiplex 
bead sandwich immunoassay (Biosource, Invitrogen) for human. Briefly, beads were incubated 
with 25 μL serum for 30 min at room temperature (RT), secondary biotinylated mAb was 
added and incubated for 30 min. followed by a 30 min-incubation with PE-Streptavidin and 
analysed using Luminex 100TM equipment (Linco, ST. Louis, MO).  The cytokine protein 
values were expressed in pg/mL.
RNA isolation and cDNA synthesis
Rat kidney and liver RNA were isolated using the SV Total RNA Isolation Kit (Promega, 
Madison, WI) following the manufacturer’s instructions. For human kidney biopsy specimens, 
biopsies were mechanically disrupted before lysis. RNA samples were verified for absence 
of genomic DNA contamination by performing RT-PCR reactions in which the addition of 
reverse transcriptase was omitted, using GAPDH primers. For cDNA synthesis, 1 μL T
11
VN 
Oligo-dT (0,5 μg/μL) and 1 μg mRNA were incubated for 10 min. at 70°C and cooled 
directly after that. cDNA was synthesized by adding a mixture containing 0.5 μL RNase 
water (Promega), 0.5 μL RnaseOUT® Ribonuclease inhibitor, 4 μL 5x first strand buffer, 2 
μL DTT, 1 μL dNTP’s and 1 μL M-MLV reverse transcriptase (200U) (Invitrogen, Carlsbad, 
USA). For human RNA, 200 ng was used and SuperscriptTM II Reverse Transcriptase Kit 
(Invitrogen) was used for cDNA synthesis. The mixture was incubated at 37°C for 50 min. 
Next, reverse-transcriptase was inactivated by incubating the mixture for 15 min. at 70°C. 




Fragments of several APP-genes were amplified with the primer sets outlined in Table 1.
Pooled cDNA obtained from sham-operated and brain-dead rats were used as internal 
references. Gene expression was normalized using mean β-actin mRNA content. Real-
Time PCR was carried out in reaction volumes of 15 μL containing 10 μL of SYBR Green 
mastermix (Applied Biosystems, Foster City, USA), 0.4 μL of each primer (50 μM), 4.2 μL 
of nuclease-free water and 10 ng of cDNA. For human cDNA, only 2.5 ng was used because 
of lower RNA yields from biopsy specimens. All samples were analysed in triplicate. 
Thermal cycling was performed on the Taqman Applied Biosystems 7900HT Real-Time PCR 
System with a hot start for 2 min. at 50°C followed by 10 min. at 95°C. Afterwards, 40 cycles 
were performed consisting of a denaturation step for 15 s at 95°C followed by an annealing 
step for 60 s at 60°C. A last step was included to detect formation of primer dimers (melting 
curve), starting with 15 s at 95°C followed by 60 s at 60°C and 15 s at 95°C. 
Table 1: Primer sequences used





































Primers were designed with Primer Express software (Applied Biosystems), and primer 
efficiencies were tested by a standard curve for the primer pair resulting from the amplification 
of serially diluted cDNA samples (10 ng, 5 ng, 2.5 ng, 1.25 ng and 0.625 ng) obtained from 
brain-dead rats. PCR efficiency was found to be 1.8 < ε < 2.0. Real-time PCR products were 
checked for product specificity on a 1.5 % agarose gel.
Results were expressed as 2-Δ ΔCT (CT: Threshold Cycle).
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Immunohistochemistry 
For human kidney immunohistochemistry, kidney paraffin sections (5 μm) were deparaffinized 
and antigen retrieval was performed by 0,4% pepsin (C3d) or 0,1% protease digestion (FBG). 
Subsequently, sections were incubated with a primary antibody (Table 2) for 1 h at RT. 
After washing, sections were incubated with appropriate horseradish peroxidase-conjugated 
secondary and tertiary antibodies (Dako, Glostrup Denmark). The reaction was developed by 
the addition of 3-amino-9-ethylcarbazole (AEC) and 0,035 % hydrogen peroxide. Sections 
were counterstained with Mayer’s haematoxylin solution (Merck, Darmstadt, Germany). 
Table 2: Primary antibodies used for immunohistochemistry
Specificity Antibody Supplier Dilution Sec/Tert antibodies
C3d
Polyclonal Rabbit




Dako, Glostrup, Denmark 1:200 GαRPO / RαGPOAnti-human
Fibrinogen (A0080)
C3 and FBG ELISA
Complement C3 was quantified by sandwich ELISA. Nunc Maxisorp 96-well plates were 
coated with goat-anti-human polyclonal C3 (Lifespan Biosciences) for 1 h at RT. After 
washing, samples were incubated for 1 h at RT. After washing, wells were subsequently 
incubated with monoclonal mouse-anti-human C3 (Lifespan Biosciences), biotin-labelled 
rabbit-anti-mouse, peroxidase-labelled streptavidin and O-phenylene-diamine as a substrate. 
Between incubation steps wells were washed with PBS containing 0,1 % Tween-20. After the 
reaction had been stopped with 0,5 M H2SO4, the amount of reacted substrate was measured 
at OD 490 nm. A standard curve was made using serial dilutions of a human plasma pool. 
The amount of C3 in measured samples was determined from the standard curve. Human 
FBG was quantified by sandwich ELISA using matched-pair antibodies against human FBG 
antigen (Enzyme Research Laboratories, South Bend, IN USA). The amount of FBG in 
measured samples was determined from the standard curve made of a human plasma pool. 
Values were expressed as U/mL.
Statistical analysis
For statistical analysis of more than two groups, the Kruskal-Wallis test was performed, 
followed by the Mann-Whitney post-test. For comparison of two groups, only Mann-Whitney 
test was performed. All the statistical tests were 2-tailed with P < 0.05 regarded as significant. 
Results are presented as mean ± SEM (standard error of the mean). 
To associate C3 and FBG gene expression levels in kidney biopsies with serum creatinine levels 
after transplantation, stepwise multivariate regression analysis was performed. Spearmann 
correlation coefficients were calculated to determine which variables were significantly 
associated with serum creatinine 14 days after transplantation. For linear regression, normal 




Rat serum cytokine analysis
Using a multiplex assay, IL-6, IL-1beta and TNF-alpha were determined in serum samples of 
0.5-, 1- and 4-h brain-dead rats. Serum IL-6 was significantly increased already after 1 h of 
BD (1870 pg/mL, P < 0.01) compared to sham-operated animals (55 pg/mL), and increased 
to 9773 pg/mL after 4 h of BD. In contrast, levels of IL-1beta and TNF-alpha did not change 
significantly over time (Figure 1). 
Figure 1: Rat serum cytokine analysis for IL-6, IL-1beta and TNF-alpha. Cytokine levels were expressed as 
mean values ± SEM. Although TNF-alpha and IL-1beta serum concentrations did not change during BD, IL-6 
was elevated in the serum already after 1 h of BD (* P < 0.01). 
Rat renal APP gene expression
In the kidney, a significant upregulation of complement C3 (8 fold), FBG (54 fold), alpha-
2-macroglobulin (7 fold) and haptoglobin (7 fold) was observed after 4 h of BD, but not at 
earlier time points, compared to sham-operated rats (P < 0.01). We found no upregulation of 
AGP gene expression compared to sham (Figure 2 A). 
A fully mismatched rat allograft model was used to assess the contribution of BD-induced 
C3 gene expression in relation to C3 expressed after transplantation. Similar to our time 
series experiment, kidneys from 4-h brain-dead DA donors showed highest serum IL-6 levels 
(data not shown) and higher C3 expression rates before transplantation compared to living 
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donors. In kidneys from brain-dead donors, no additional C3 expression was found after 
transplantation upon C3 expression already induced during the donor phase. Living donor 
grafts showed renal C3 upregulation after transplantation compared to C3 expression levels 
in the donor. No significant difference was found between C3 expression in kidneys from 
living or brain-dead donors, 24 h after transplantation (Figure 3).
Figure 2: Renal (A) and hepatic (B) APP gene expression levels after 4 h of BD. Data are shown as relative 
fold induction compared to sham and expressed as mean values ± SEM.  No significant induction was seen 
before 4 h of BD (data not shown). Significant differences between gene expression levels in livers of BD 
donors and sham-operated animals are indicated (* P < 0.01).  
Rat hepatic APP gene expression
In general, basal expression levels of genes encoding APPs were higher in liver than in kidney. 
In the liver, FBG (3 fold), alpha-2-macroglobulin (21 fold), haptoglobin (2 fold) and AGP 
(4 fold) gene expression were upregulated after 4 h of BD, as compared to sham-operated 
animals (Figure 2 B, P < 0.01). Complement C3 gene expression did not change over time in 
livers from brain-dead animals. At all earlier time points no significant upregulation of APP 
gene expression was observed. 
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Figure 3: Gene expression of complement C3 before and after transplantation in a rat allograft transplant 
model. Data are shown as relative fold induction compared to living donors and expressed as mean values ± 
SEM. C3 is upregulated before transplantation in brain-dead donors, no additional C3 was found 24 h after 
transplantation of a BD graft. Living donors showed only C3 induction due to transplantation. Significant dif-
ferences are indicated (* P <0.01). 
Human serum cytokine analysis
In line with our findings in the rat BD model, same inducers of the APR in serum of human 
brain-dead (20) and living (20) donors were measured. In addition, IL-8 and MCP-1, known 
to be elevated early after BD in the rat, were analysed. We found a similar pattern of systemic 
cytokine elevation in human brain-dead donors compared to our findings in the rat. Serum 
levels of TNF-alpha and IL-1beta were not elevated in brain-dead donors compared to living 
donors at both time points. IL-8 and MCP-1 were elevated shortly after the diagnosis of BD 
while IL-6 increased during BD, reaching the highest concentrations at donation (Figure 4). 
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Figure 4: Human serum cytokine analysis for IL-6, IL-1beta, TNF-alpha, IL-8 and MCP-1 in living donors 
at start of operation (T0) and organ recovery (T1) and in brain-dead donors at the declaration of BD (T0) and 
organ recovery (T1). Cytokine levels were expressed as mean values ± SEM. Data shows significant elevation 
of IL-6, IL-8 and MCP-1 at T0 and T1 in brain-dead donors compared to living donors (* P < 0.05). 
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Human renal complement C3 and FBG gene expression
To evaluate the clinical validity of our observations in the rat model, changes in expression 
of two APPs, complement C3 and FBG, were studied in human donors. Demographics of 
human donors are listed in Table 3. Complement C3 gene expression was significantly higher 
in kidney biopsies taken from brain-dead donors compared to living donors (8 fold, P < 0.01). 
We found no additional C3 expression caused by cold ischemia or reperfusion. Similarly, FBG 
expression was increased after BD compared to living (5 fold, P < 0.01) and no additional 
FBG was expressed due to cold ischemia or reperfusion (Figure 5).
Multivariate linear regression analysis showed an independent association of C3 expression 
in reperfusion biopsies of brain-dead donor grafts, with higher serum creatinine levels at day 
14 after transplantation (P =0.020, R2 = 0.278, Table 4). Although there was no difference 
in renal C3 induction at donation, cold ischemia and reperfusion, only C3 expression after 
reperfusion was significantly associated with post-transplant creatinine. This is caused by 
a larger variation in C3 expression at donation. No association was found between FBG 
expression and posttransplant outcome.
Figure 5: Gene expression of complement C3 and FBG in kidney biopsies obtained from living and brain-
dead donor patients at donation, cold ischemia (CI) and reperfusion. Data are shown as relative fold induction 
compared to living donors at T1. Data are expressed as mean values ± SEM. Data shows a significant induc-
tion of complement C3 (8 fold) and FBG (5 fold) after BD compared to living donors at same time points (* 
P <0.01).
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Table 3: Demographics of human donors
BD (n=20) Living (n=20) p-Value
Gender (M/F) 7/13 7/13
Age (years)a 50 (44-57) 50 (45-58) 0.6b
Death: CVA 11 0
Death: Trauma 6 0
Death: Other 3 0
Cold ischemia time (min) a 1117 (926-1322) 155 (140-174) <0.001b
Duration of BD (min)a 666 (569-765) 0
Hospital stay (h)a 37 (25-71) 24c




Serum creatinine at day 14a
151 (121-354) 133 (116-189) 0.182b
(μmol/L)
aMedian (interquartile range) 
bMann-Whitney U-test
cLiving donors were routinely admitted 1 day before donor operation.
Human C3d and FBG protein expression     
To confirm C3 and FBG expression rates on the protein level in renal biopsies, we performed 
immunohistochemistry on biopsy paraffin sections. C3d was used as a marker for local C3 
activation as it is not easily cleared from the cellular wall. C3d staining was found in the renal 
interstitium in grafts from brain-dead donors at donation but not in living donors (Figure 6A, 
B). No additional staining was observed after cold ischemia (Figure 6C, D) or reperfusion 
(Figure 6E, F), confirming our findings on the transcription level. Also, we found a stronger 
staining for FBG in the peritubular capillaries, tubular brush border, glomeruli and renal 
interstitium in brain-dead donors compared to living donors (Figure 6G, H). No additional 
staining was found after cold ischemia or reperfusion (Figure 6I-L).
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Table 4: Multivariate regression analysis for serum creatinine 14 days after transplantation
Univariate analysis Multivariate analysis (R2 = 0.278)
           Beta                                  Pra                               P
C3 expression after
0.333 0.163 0.528 0.020reperfusion in BD
grafts
Donor age 0.673 0.002 0.385 0.066
Donor gender -0.153 0.532 -0.158 0.498
Cold ischemia time 0.343 0.150 0.332 0.113
aSpearmann’s correlation coefficient
In vitro C3 and FBG synthesis in HK-2 cells
To analyse possible mechanisms by which renal C3 and FBG expression is induced in brain-
dead donors, in vitro culture experiments were performed. As the proximal tubular epithelial 
cell is the main producer of C3 in the kidney, HK-2 cells (immortalized proximal tubular 
epithelial cells) were stimulated in vitro with IL-6, IL-8 and MCP-1, cytokines which we 
found to be elevated early in the serum after BD. It was shown that under the influence of 
IL-6, C3 production was significantly enhanced compared to medium alone (Figure 7A). In 
contrast, neither IL-8 nor MCP-1, or combinations of these cytokines were able to enhance C3 
production in vitro. Furthermore, both IL-8 and MCP-1, combined with IL-6 did not increase 
C3 production as observed by stimulation with IL-6 alone (data not shown). Dose-response 
relationship was observed between IL-6 stimulation and C3 production (7B). Moreover, C3 
production under IL-6 stimulation (10 ng/mL) was blocked after pre-incubation and in the 
presence of an IL-6 receptor antagonist (IL-6 RA), confirming the specific properties of IL-6 
to induce C3 synthesis through its receptor (7C). No significant amount of FBG was detected 
in medium alone or under cytokine stimulation (data not shown).
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Figure 6: Representative photographs of C3d and FBG staining in sections from living or BD kidney biopsies. 
Grafts from brain-dead donors show stronger staining of C3d in renal interstitium (arrows) at donation (A, 
B), after cold ischemia (CI) (C, D) and reperfusion (E, F) compared to living donors. Also, stronger staining 
for FBG was found in peritubular capillaries (arrows c), tubular brush border (b), glomeruli (g) and renal 
interstitium (i) in brain-dead donor grafts compared to living grafts at all three time points (G-L). Original 











Figure 7: (A) C3 production by HK-2 cells in the presence of IL-6. Significant increase of C3 produced by 
HK-2 cells was observed under IL-6 stimulation from 24 h on compared to medium alone. (B) Dose-response 
of C3 production in the presence of increasing IL-6 concentration compared to medium. (C) C3 production 
is inhibited by selectively blocking the IL-6 receptor by an IL-6 receptor antagonist (RA, 1 μg/mL). Decreas-
ing IL-6 RA concentration (100 ng/mL) again increases C3 production under IL-6 stimulation. Values are the 
mean ± SEM of duplicate determinations of triplicate cultures. Significant differences are indicated (* P < 
0.05).
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Discussion
This study shows that renal complement C3 and FBG are induced as a direct result of BD in 
the organ donor, already before transplantation. In both human and rat kidneys we found a 
significant induction of C3 and FBG after BD with no further increase after transplantation. 
In our human donor group, high C3 gene expression after reperfusion of BD grafts was 
negatively associated with short-term renal transplant function after transplantation. In both 
clinical and experimental BD, IL-6 was strongly increased after BD and is able to regulate 
renal C3 production in cultured HK-2 cells.
After an early and profound rise in serum IL-6, the kidney showed a renal APR with enhanced 
expression of complement C3, FBG, alpha-2-macroglobulin and haptoglobin after 4 h of BD. 
The cytokine expression pattern of the liver in our model resembles a type 2/IL-6 driven APR, 
without the induction of C3 gene expression (18;19;24;25). However, several studies have 
observed an IL-6-dependent hepatic induction of C3 gene expression (26;27). The relative 
short time of exposure (4 h) and the need for TNF-alpha as a co-stimulator (not elevated in 
our model) may explain our findings (28-31). 
In relation to the pleiotropic function of the APR, the question is which consequences renal 
APP induction will have in brain-dead donors. Initially, the APR should be beneficial but might 
become harmful if prolonged or dysregulated (32). Haptoglobin and alpha-2-macroglobulin 
are known to have cytoprotective capacities, and enhanced APP gene expression of these 
proteins may therefore lead to protection of the kidney through the APR (21;33-35). However, 
excessive, uncontrolled local expression of complement C3 and/or FBG may have harmful 
consequences.   
The important role of local renal complement C3 synthesis in the pathogenesis of renal 
injury after transplantation has been well described by several groups (36-38). Pratt et al. 
have shown that donor kidneys derived from C3 knock-out mice have significantly better 
survival rates after transplantation compared to kidneys derived from wild-type mice (37). 
Furthermore, strategies targeting complement activation proved to attenuate renal ischemia-
reperfusion injury (IRI) and to improve kidney graft survival (39-42). Although induction 
of renal complement C3 gene expression has mainly been attributed to renal IRI during 
transplantation, the importance of donor C3 has been noticed (43-46). In line with our 
findings, others have recently shown induction of complement components in kidneys from 
deceased donors after cold ischemia (47). Our findings discriminate, however, between the 
importance of BD-induced C3 rather than C3 induction due to cold ischemia. Nevertheless, 
these results indicate that local renal complement synthesis in grafts recovered from brain-
dead donors, is important for outcome after transplantation. Early intervention in local renal 
complement activation in brain-dead donors might actually improve transplant results. 
In addition to C3, we also found that FBG was induced in both human and rat kidneys as a 
consequence of BD. Extra-hepatic expression of FBG has been observed in epithelial cells 
of different tissues (48;49). However, enhanced renal expression of FBG has been described 
very poorly (50;51). It is known that FBG is involved in coagulation and is correlated by 
means of fibrin deposition with rat renal allograft rejection (52). Locally produced renal 
FBG may have devastating consequences because it is susceptible to fibrin clot formation, 
resulting in impaired graft perfusion. Besides its main role in coagulation, soluble FBG seems 
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to enhance phagocytosis, antibody-dependent cellular cytotoxicity and delays apoptosis (53). 
Possibly, once FBG has accumulated in the peritubular capillaries of the kidney as a result of 
BD, it may enhance functional capacity and life time of recruited neutrophils which finally 
may cause renal injury.
Induction of C3 and FBG as part of the renal APR is likely to be IL-6 regulated. In human 
and rat brain-dead donors, we found serum IL-6 to be significantly elevated, while other 
potential inducers of the APR e.g. IL-1beta and TNF-alpha, did not increase due to BD. In 
contrast with our findings, others have found elevated TNF-alpha and/or IL-1beta levels after 
experimental BD (11;54). This disparity can be explained by the use of different BD models, 
as we use a slow induction model of BD versus the acute, explosive model applied by others 
(7). As we also found absence of TNF-alpha and IL-1beta increase in human BD donors, the 
validity of our model is indicated. 
To obtain a better mechanistic insight in the induction of renal APPs during BD, tubular 
cells were stimulated with cytokines of which we found to be early and strongly elevated 
in the serum after the onset of clinical and experimental BD (IL-6, IL-8 and MCP-1) (10). 
In the kidney, tubular cells are the main producers of C3, while less is known about renal 
production of FBG. In vitro, it has been shown that tubular C3 production can be induced by 
different cytokines but we found none of these to be elevated in the serum after BD (55;56). 
Of the serum cytokines increased after BD (IL-6, IL-8 and MCP-1), we found that only IL-6 
was able to enhance C3 production in vitro. To mimic the clinical situation in which there 
is a constant circulation of IL-6 through the kidney, a higher IL-6 concentration was used 
in culture than measured at donation (±1200 pg/mL). As far as we know, IL-6-dependent 
production of C3 by renal epithelial cells has never been demonstrated before. No detectable 
FBG was produced by HK-2 cells in medium alone or under single cytokine stimulation 
and/or cytokine combinations. This indicates that other renal cell types are involved in FBG 
production, most probably endothelial cells. 
In conclusion, this study demonstrates that BD causes elevated serum IL-6, followed by the 
induction of a renal APR in the donor. The time-dependent changes, pattern of APP expression 
and the stimulatory effects in culture, point towards an IL-6- driven renal APR during BD. 
Our results suggest that strategies targeting local renal APP expression or activation in brain-
dead donors, especially complement C3, should be initiated before transplantation to improve 
transplant outcome.    
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Acute rejection after renal transplantation has been shown to be negatively associated with 
long-term graft survival. Identifying donor factors that are associated with acute rejection in 
the recipient could help to a better understanding of the relevant underlying processes that 
lead to graft injury. Complement activation has been shown to be an important mediator of 
renal transplant related injury. In this study, we analyzed the effect of systemic complement 
activation in deceased donors prior to transplantation of their kidneys on posttransplant 
outcome in the recipient.
Methods
Plasma from 232 deceased brain-dead and deceased cardiac-dead donors were analyzed for 
the complement activation markers C5b-9, C4d, Bb and complement component mannan 
binding lectin by ELISA. The association of these parameters with posttransplant outcome in 
recipients was analyzed in a multivariate regression model. 
Results
It was found that C5b-9 level in donor plasma is associated with biopsy proven acute rejection 
in the recipient during the first year after renal transplantation (P=0.035). Both in deceased 
brain-dead and deceased cardiac-dead donors increased complement activation was found. 
Conclusions
In conclusion, we found C5b-9 in the donor to be associated with acute rejection of renal 
transplants in the recipient. Whether targeting complement activation in the donor may 
ameliorate acute rejection in the recipient needs to be studied.
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Introduction
Patients suffering from severe renal diseases for a variety of reasons may finally progress to 
develop end-stage renal failure. During the last decades, kidney transplantation has become 
the first choice of treatment for these patients; however because of donor organ shortage, 
patients are still dying on the waiting list. The major donor pool consists of kidneys recovered 
from deceased brain-dead donors (DBD), although living donation and donation after cardiac 
death (DCD) have emerged as alternative sources. Kidneys from deceased donors have 
an inferior transplant function, decreased survival rates and a higher risk to develop acute 
rejection as compared with kidneys obtained from healthy living (un)related donors (1-4). 
Despite the beneficial effects of modern immunosuppressive drugs, acute rejection can still 
not be completely prevented (5). One of the major goals in renal transplantation is to minimize 
the use of immunosuppressants because of toxic side effects, cardiovascular sequelae, and 
infectious complications. Also, identifying biomarkers associated with acute rejection will 
contribute to a better understanding of the relevant underlying processes leading to graft 
injury. Consequently, this might result in the development of new drug targets to prevent or 
treat acute rejection after renal transplantation. Currently, only recipient related biomarkers 
such as donor- specific antibodies and panel reactive antibodies are associated with acute 
rejection. Although it is well established that donor parameters play an important role in graft 
injury and posttransplant survival, to our knowledge no specific biomarkers in the donor 
which are associated with acute rejection after transplantation in the recipient have been 
identified yet. 
Activation of the complement system has been shown to be an important mediator of renal 
transplant related injury. During transplantation, both ischemia and ischemia-reperfusion 
mediated injury result in complement activation. Consequently, complement activation 
products such as C5b-9 may induce renal damage. Furthermore, complement activation 
products are able to induce upregulation of proinflammatory substances and chemokinesis 
of infiltrating leukocytes in the kidney (6;7). Also after transplantation, the complement split 
products C3a and C5a are potent activators of T-cells by enhancing the capacity of dendritic 
cells for allospecific T cell stimulation through specific receptors (8;9).
The aim of this study was to asses the role of complement activation in the donor on the 




Patients and plasma samples 
Between November 1, 2005 and August 17, 2007, a total of 376 deceased kidney donors 16 
years of age or older were included in the trial. In this study cohort, 232 kidney donors were 
used while 144 donors were excluded, because no donor plasma samples were available. 
Donor characteristics of the 232 donors (and 464 recipients) with available plasma samples 
are shown in Table 1. Baseline characteristics of donors and recipients included in the present 
study cohort were checked for selection bias and did not differ significantly from the overall 
group.
C5b-9, C4d, Bb and Mannan Binding Lectin Plasma Levels
As complement activation by all three pathways finally result in activation of the terminal 
complement sequence, we first measured levels of C5b-9. Significantly higher levels of 
C5b-9 were found in deceased donors compared with plasma levels from living donors and 
controls (Table 2, Figure 1). No significant complement activation was found in living donors 
compared with controls. Additionally, Spearman’s correlation showed that donor C5b-9 was 
not significantly correlated with donor serum creatinine (r=-0.020, P=0.670).
To determine the contribution of the classical/lectin and/or alternative pathway of complement 
activation, C4d and Bb were analyzed, respectively. Both C4d and Bb were significantly 
higher in deceased donors as compared with living donors and controls. The median mannan 
binding lectin (MBL) concentration in our donor cohort was 653 ng/ml which is comparable 
with populations studied by others (10;11). Levels of MBL were not significantly higher 
compared with controls. However, MBL levels were significantly lower in living donors 
compared with deceased donors and controls due to the relatively large amount of MBL-
deficient living donors (Table 2, Figure 1). 
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Table 1: Donor, recipient, and transplant demographics and overall post-transplant outcome. 
(N = 464 recipients)
Donor demographics
Donor agea (yr) 51 (16–81)
Female donor (%) 38
DCD donor (%) 14
ECD donor (%) 32
Traumatic cause of death (%) 23
Donor history of hypertension (%) 23
Donor history of diabetes mellitus (%) 5
Recipient demographics
Recipient agea (yr) 53 (8–77)
Female recipient (%) 40
Total time spent on the waiting list1 (yr) 5 (1–8)
Previous transplants (% ≥1) 31
PRA level >5% (%) 9.5
Immunosuppressive drugs (%)
       Prednisolone 98
       Cyclosporine 50
       Tacrolimus 47
       Azathioprine 1
       Mycophenolate mofetil 86
       Antithymocyte globulin 14
Transplant demographics
HLA mismatches (% of 0 mismatches) 16
Cold ischemic timea (h) 15 (2–47)
Organ preservation method (%)
       Static cold storage 50
       Hypothermic machine perfusion 50
Post-transplant outcome
Delayed graft function (%) 23
Primary non-function (%) 3
Any acute rejection in first year (%) 24
1 year death censored graft survival (%) 91
aValues are expressed as median (range).




Figure 1: Significantly higher levels of C5b-9, C4d and Bb in plasma from deceased donors compared 
with living donors and healthy controls. Levels of mannan binding lectin (MBL) were significantly lower 
in living donors compared with controls and deceased donors. Horizontal solid lines indicate the median.  
Significant differences are indicated (* P <0.001, ** P<0.01). 
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Table 2: Univariate analysis of C5b-9, C4d, Bb and MBL. Values are expressed as median (interquartile range). 
Increased levels of donor C5b-9, C4d and Bb were found in deceased donors compared with living donors and 
controls. Donor C5b-9 was significantly higher in recipients suffering from acute rejection. No association was 
found between C5b-9 and DGF, PNF and first years graft survival. Other complement activation markers were not 
associated with post-transplant outcome. 
Plasma 
concentration (ng/ml): Deceased donors Living donors Controls P-value
C5b-9 858 (592-1203) 343 (125-551) 237 (187-351) < 0.001a
C4d 4514 (2973-6659) 832 (619-1359) 836 (773-1038) < 0.001a
Bb 1546 (984-2351) 728 (501-897) 577 (361-894) < 0.001a
MBL 653 (224-1209) 221 (28-409) 660 (211-1125) < 0.01b
Plasma 
concentration (ng/ml): no rejection rejection P-value
c
C5b-9 811 (579-1164) 953 (714-1359) 0.013
C4d 4514 (2973-6660) 5218 (3290-7193) 0.218
Bb 1545 (984-2351) 1669 (1019-2510) 0.531
MBL 653 (224-1209) 398 (145-1139) 0.160
% Graft
survival (1st year) Low level High level P-value
d
C5b-9e 92.7 90.1 0.316
C4de 93.5 88.8 0.082
Bbe 92.1 90.2 0.480
MBLe 89.4 92.8 0.208
MBLf 88.6 92.8 0.116
aMann-Whitney test, deceased donors vs living donors or controls. All P-values are two-sided.
bMann-Whitney test, living donors vs deceased donors or controls. All P-values are two-sided.
cMann-Whitney test, All P-values are two-sided.
dLog rank test
eSplit by median
fSplit by 400 ng/ml
DGF, delayed graft function; MBL, mannan binding lectin; PNF, primary non-function.
Donor complement activation and transplant outcome
For recipients whose kidney had biopsy-proven acute rejection, donor C5b-9 levels were 
significantly higher compared with donor levels from nonrejecting kidneys (Table 2). 
Univariate regression analysis showed a significant association between higher donor C5b-9 
levels and acute graft rejection. Of donors with C5b-9 levels above the median, 31% (71/232) 
developed acute rejection compared with 17% (40/232) in donors with a C5b-9 level below 
the median. Next, a multivariate analysis was performed with covariates that were found to 
be significantly associated with acute rejection by univariate analysis. These included in the 
following: preservation method (machine perfusion (MP) vs cold storage), human leukocyte 
antigen (HLA) mismatches, donor type (DCD vs. DBD), donor age, recipient age, panel 
reactive antibodies percentage, the number of previous transplants of the recipient, cold 
ischemic time, duration of pretransplant dialysis and the cause of death of the donor (trauma 
versus other causes). The use of immunosuppressive drugs was not included as a covariate in 
our model, as univariate analyses revealed that this was not a risk factor for acute rejection in 
our study. When a multivariate regression model analysis was applied, C5b-9 was found to be 
an independent factor associated with acute graft rejection (odds ratio 1.506, 95% confidence 
interval 1.037 – 2.187, Table 3), next to human HLA mismatching (odds ratio 1.316, 95% 
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confidence interval 1.111 – 1.560, Table 3). 
A receiver operator characteristic (ROC) curve was constructed to assess cut-off points for 
C5b-9 as a predictor of acute rejection (Figure 2). ROC curve analysis demonstrated an area 
under the curve estimate of 0.57 which indicates that donor C5b-9 is not a strong predictor of 
acute rejection. When the median (858 ng/ml) was applied, the positive predictive value was 
30% and the negative predictive value 83%.
No association was found between levels of donor C5b-9 and primary non-function (PNF), 
delayed graft function (DGF) and graft survival during the first year after transplantation 
(Table 2). 
The type of rejection was documented according to the Banff classification of a subset of 33 
of the 111 rejecting kidneys. Interestingly, this subset revealed that donor kidneys exposed to 
high C5b-9 levels in deceased donors are prone to develop vascular rejection more frequently 
in the recipient (Table 4).
Spearman’s correlation showed that both C4d and Bb levels were significantly correlated 
with C5b-9 in donor plasma (C4d/C5b-9 r=0.416, P<0.001; Bb/C5b-9 r=0.582 P<0.001). 
However, C4d and Bb were not associated with acute rejection, PNF, DGF and graft survival 
after renal transplantation in the recipient. Partial correlation showed that C4d is associated 
with C5b-9 independent of MBL (C4d/C5b-9 corrected for MBL r=0.385, P<0.001). Also, 
MBL levels in the donor were not associated with posttransplant outcome. For additional 
analysis we divided our study population into a group above and below 400 ng/ml. MBL 
levels below 400 ng/ml was shown earlier to be closely related to MBL variant alleles (A/O, 
O/O), while MBL above 400 ng/ml was related to MBL wild type (A/A)(10). Using this 
cut-off of 400 ng/ml 40.4% of our donor population had a low MBL and 59.6% a high MBL 
level, which is comparable to the frequency of variant alleles determined by others (11). No 
significant difference in graft survival was observed in the first year after transplantation 
using both median and 400 ng/ml of MBL as a cutoff (Table 2).
Figure 2: Receiver operator characteristic  curve for plasma C5b-9. The area under the curve is 0.58 (95% 
confidence interval 0.52 - 0.64).
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Table 3: Multivariate analysis for the risk of acute rejection after renal transplantation. Donor complement C5b-9 
is an independent factor associated with acute rejection after transplantation, next to HLA mismatch (P=0.035). 
Variable Odds ratio(95% CI) P value
Machine perfusion vs. cold storage 0.903 (0.580 – 1.405) 0.645
HLA mismatches (no.) 1.316 (1.111 – 1.560) 0.002
Donortype (DBD/DCD) 0.754 (0.357 – 1.592) 0.412
Donor age (years) 1.012 (0.992 – 1.032) 0.249
Recipient age (years) 0.987 (0.969 – 1.005) 0.163
Panel-reactive antibody level (%) 1.012 (0.997 – 1.029) 0.108
Second or later transplantation vs first transplantation 1.158 (0.758 – 1.769) 0.386
Cold ischemic time (hrs) 0.987 (0.941 – 1.034) 0.532
Duration of pretransplantation dialysis (years) 1.035 (0.933 – 1.147) 0.560
Trauma vs other cause of death 0.897 (0.502 – 1.604) 0.672
C5b-9 concentration (ng/ml) 1.506 (1.037 – 2.187) 0.035
Table 4: Type of rejection according to the Banff classification. 
Borderline Banff Ia, Ib Banff IIa, IIb, III
Low donor C5b-9 6 4 2
High donor C5b-9 0 9 12





This study shows that complement C5b-9 levels in deceased donor plasma is associated 
with acute rejection in the recipient after renal transplantation. In DBD and DCD donors, 
significant complement activation was found. No significant association was found between 
donor complement activation levels and PNF, DGF or graft survival in the first year after 
transplantation in recipients.
Chronic allograft failure is affected by different variables including donor condition, ischemia-
reperfusion injury and graft rejection. Acute rejection has been shown to be negatively 
associated with long term renal allograft dysfunction. Despite HLA-matching in clinical renal 
transplantation and better immunosuppression, the occurrence of acute rejection episodes can 
still not be completely prevented. Independent of HLA-matching, we found that C5b-9 in the 
plasma of the deceased donor is significantly associated with acute rejection in the first year 
after transplantation in the recipient. 
As part of the innate immune system, complement activation is an important mediator of renal 
transplant-related injury in the recipient. It has been shown that renal ischemia-reperfusion 
injury is in part complement mediated and that local expression of the central complement 
component C3 is involved in graft rejection and affects graft survival after transplantation 
(12;13). Moreover, inhibition of complement activation in animal models has been shown to 
prevent rejection associated injury (14;15). In humans, complement activation in the recipient 
has been demonstrated as evidenced by the deposition of C4d in peritubular capillaries in 
rejecting allografts, now part of the Banff classification (16). Also, activation of the lectin 
pathway is important, as low recipient MBL levels are beneficial for graft survival (10). 
Taken together, these studies clearly show that complement is involved in renal transplant 
rejection in the recipient. 
In contrast to the previous studies that focused on the recipient, we now demonstrated that 
activation of systemic complement in deceased donors partially determines the risk of 
transplant rejection in the recipient. In living donors, no significant complement activation 
was found, which indicates that anaesthesia or hospitalization are not responsible for the 
increased C5b-9 levels found in deceased donors. To determine which complement pathways 
are activated in the donor, both C4d (classical/lectin) and Bb (alternative) were correlated 
with the extent of C5b-9 generation. The association of C4d with C5b-9 was independent 
of MBL, suggesting that generation of C4d can be ascribed mainly to classical pathway 
activation. However the role of ficolins, potent activators of the lectin pathway, can not be 
excluded. How the classical pathway is triggered in deceased donors remains unclear but 
it might be activated by C-reactive protein, although no association between complement 
activation and C-reactive protein was found in this study (17). After classical pathway 
activation, the alternative pathway amplification loop may be triggered, leading to generation 
of Bb. Besides, the alternative pathway might have been activated by lipopolysaccharide, 
which may be found in some deceased donors (18). 
We reason that complement activation products are generated in deceased donors and may 
directly or indirectly initiate renal injury. Recently we found that complement becomes 
deposited in the kidney already before organ retrieval in kidneys from brain-dead donors (19). 
In addition, also Naesens et al. found increased complement deposition in preimplantation 
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biopsies (20). Besides local expression of complement as found by our group and Naesens et al., 
also systemic complement activation might be responsible for the deposition of complement 
in the kidney before organ recovery. This is supported by the finding that donor kidneys 
exposed to high C5b-9 levels in deceased donors are prone to develop vascular rejection more 
frequently in the recipient. We envision that complement activation products in the blood, C3a, 
C5a and C5b-9, induce immune activation in the donor kidney. First, mainly C5a, but also 
C3a, are potent chemotactic complement split products which are able to activate primarily 
peripheral neutrophils, monocytes and macrophages through specific receptors (21;22). This 
might explain for instance the finding of an increased polymorphonuclear neutrophil influx 
in kidneys from brain-dead donors (23). Second, anaphylatoxins and sC5b-9 upregulate 
several immunomodulatory factors on vascular endothelium through their receptors, 
including P-selectin, IL-8 and MCP-1 (24-27). Third, the direct lytic effect of the C5b-9 
complex through disturbance of the cellular membrane potential on the renal vaculature is a 
potent mechanism of injury to the graft itself. Fourth, complement split products, covalently 
deposited in the donor kidney, could be potent activators of B and T cells in the recipient 
after transplantation (28-30). Finally, both C3a and C5a are able to stimulate dendritic cells 
through their receptors, increasing T-cell responses (8;9). We are aware that the association 
found in this study does not necessarily reflect causality and that the proposed mechanisms 
of complement-dependent renal injury described here are only speculative. 
Taken together, our results indicate that systemic complement is activated in both DBD and 
DCD donors and that a higher C5b-9 level is associated acute rejection after transplantation 
in the recipient. Although an independent significant association was found, one has to be 
cautious in the interpretation of our data since our results are preliminary and have to be 
validated in other study cohorts. Furthermore, as revealed by ROC-curve analysis, C5b-9 
is unlikely to be a good predictor of acute rejection in the recipient. However, complement 
activation in the donor might be involved in the pathogenesis of renal injury leading to acute 
rejection in the recipient. Whether targeting complement activation in the donor may reduce 




Patients and study design
This study is a substudy of the international randomized controlled trial which investigated 
the effect of hypothermic MP versus static cold storage preservation in kidney transplantation 
and included the Netherlands, Belgium, and the federal state of North Rhine-Westphalia in 
Germany (The Machine Preservation Trial). Between November 1, 2005 and August 17, 
2007, all consecutive deceased donor kidney pairs that met the initial inclusion criteria were 
eligible for randomization by Eurotransplant, an international organ exchange organization in 
Europe. Both DBD and controlled DCD donors (Maastricht category III) were included (31). 
From each donor, one kidney was randomly assigned to MP and the contralateral kidney to 
cold storage. The organs could be transplanted into any recipient within the Eurotransplant 
region (32). For further details on study design, inclusion criteria, and recipient follow up we 
refer to our previous publication (33).
Sample collection
Whole blood samples were drawn from 232 DBD and DCD donors prior to organ recovery 
in the donor and collected in EDTA tubes to prevent further in vitro complement activation. 
In DCD donors, samples were taken just before ventilator switch-off. In brain-dead donors, 
samples were taken prior to systemic cold perfusion. In 20 living donors, plasma samples 
were obtained shortly before kidney donation. Plasma from 20 healthy volunteers served as 
controls. Samples were transported on ice, centrifuged to obtain plasma, and the plasma’s 
were stored in aliquots at -80°C until further analysis. In each assay, fresh frozen plasma 
samples were used for analysis.
C5b-9 ELISA
Nunc Maxisorp 96-well plates were coated with monoclonal mouse anti human C5b-9 (Dako, 
Glostrup, Denmark) overnight at 4°C. After 1 hr blocking and washing, plasma samples were 
incubated for 1 hr at 37°C. After washing, wells were subsequently incubated with polyclonal 
goat-anti-human C5 (Quidel, San Diego, USA), horseradish peroxidase-conjugated rabbit 
anti-goat immunoglobulin and tetramethylbenzidine as a substrate. Between incubation 
steps, wells were washed with PBS containing 0.05 % Tween-20. After the reaction was 




, the amount of reacted substrate was measured at OD 450 nm. A 
standard curve was made using serial dilutions of a Zymosan activated human serum pool. 
The amount of C5b-9 in measured samples was determined from the standard curve with a 
known concentration of C5b-9. 
C4d, Bb and MBL ELISA
To differentiate between complement activation pathways we determined stable activation 
products of the three known pathways: C4d (classical/lectin) and Bb (alternative). 
Additionally, MBL plasma concentrations were measured because earlier studies have 
shown an involvement of MBL levels in renal allograft survival (10). C4d and Bb were 
determined using commercially available modified enzyme-immunoassays according to the 
manufacturer’s protocol (Quidel, CA). Plasma levels of MBL were quantified by sandwich 
ELISA. Nunc Maxisorp 96-well plates were coated with monoclonal mouse anti human 
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MBL 3E7 (Hycult, Uden, The Netherlands) overnight at room temperature. After 1 hr 
blocking and washing, plasma samples were incubated for 1 hr at 37°C. After washing, wells 
were subsequently incubated with polyclonal goat-anti-human MBL 3E7-DIG, horseradish 
peroxidase-conjugated sheep anti-DIG immunoglobulin and tetramethylbenzidine as a 
substrate. Between incubation steps, wells were washed with PBS containing 0.05 % 




, the amount of reacted substrate 
was measured at OD 450 nm. A standard curve was made using serial dilutions of a human 
serum pool with known MBL concentration. MBL in plasma samples was determined from 
the standard curve against an internal control. 
Study end points
The primary end points in this study were: delayed graft function (DGF, defined as the 
need for dialysis during the first week after transplantation), primary non-function (PNF, 
defined as non-functioning of the allograft from transplantation onwards), death censored 
graft survival and biopsy proven acute rejection during the first year after transplantation. 
Statistical analysis
The nonparametric Kruskal-Wallis test, followed by Mann-Whitney U tests were performed 
to compare C5b-9, C4d, Bb and MBL concentrations between controls, living and deceased 
donors. Spearman’s correlation analysis was used to associate C5b-9 levels with respectively 
C4d, Bb or MBL levels in deceased donors. Mann-Whitney U tests were performed to 
compare donor C5b-9, C4d, Bb and MBL concentrations between recipients with and 
without acute rejection, DGF and PNF. Kaplan-Meier survival curves and logrank tests were 
performed to assess whether 1 year death censored graft survival was significantly different in 
recipients whose kidney donor had C5b-9, C4d, Bb and MBL concentrations above or under 
the median. For those univariate associations that were found to be statistically significant, 
a multivariate model was built. Since one donor gave kidneys to two recipients, this could 
potentially have biased our results. Therefore, we incorporated a normal gamma frailty term 
in the multivariate analysis, to account for the within-donor dependence structure of our data 
(for each left + right kidney in a pair, donor characteristics were by definition exactly the 
same, but recipients were different).
Statistical analyses were performed using SPSS (version 16.0) and R (version 2.7.1) software 
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Renal grafts derived from brain-dead donors show inferior transplant outcome as compared 
to living donors. We have shown that local and systemic complement activation occurs 
after donor brain death (BD) and is associated with inferior graft function in the recipient. 
Expression of C5a receptor (C5aR) has been reported in human kidneys. We hypothesized 
that BD induces renal C5aR expression in human patients. In human living and brain-dead 
donors, complement pathway activity was analyzed before organ retrieval. Renal C5aR gene 
expression was analyzed by Real-Time qPCR in biopsies obtained at donation, after cold 
preservation and after reperfusion. C5aR protein expression and localization were analyzed 
by immunohistochemistry. Decreased serum complement activity was found after BD 
(P<0.05). Gene and protein expression levels of renal C5aR were higher at all three time 
points in brain-dead vs living donors. C5aR expression was predominantly found in the thick 
ascending limb of Henle’s loop. C5aR gene expression in brain-dead grafts was associated 
with reduced renal function shortly after transplantation (P<0.01). This study shows that BD 
induces systemic complement activation and enhances renal C5aR expression. C5aR mRNA 
expression after reperfusion of brain-dead grafts was associated with reduced renal function 
early after transplantation. We propose that systemic complement activation contributes to 
renal injury in brain-dead donors through renal C5aR activation.
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Introduction
During the last decades, renal transplantation has become the first choice of treatment for 
end-stage renal disease. Despite an increasing number of living and non-heart beating donors, 
most kidneys are still derived from heart beating, brain-dead donors. However, brain-dead 
donor kidneys give inferior results compared to living donor kidneys in terms of rejection 
rates and graft survival (1). This difference is independent of the number of HLA mismatches, 
donor age and cold ischemia times, and could therefore be attributed to the state of donor 
brain death (BD). 
It is well documented that BD triggers both a systemic and local renal inflammatory response 
(2-9). Elevated serum levels of pro-inflammatory chemokines and cytokines have been 
observed in both brain-dead rats and human patients. In addition, intragraft induction of 
adhesion molecules, chemokines and cytokines has been demonstrated. This inflammatory 
state might partly be responsible for the renal injury observed in brain-dead donors. 
Recently, we and others showed that an important part of the immune activation after BD can 
be ascribed to systemic and local complement activation (10-12). The complement system can 
be activated through three different pathways: the classical, alternative and lectin pathway. 
Initiation of each of the three pathways leads to activation of C3 and C5, and subsequent 
formation of the membrane attack complex. Inherent to complement activation is the 
generation of anaphylatoxins C3a and C5a, which have chemokinetic and pro-inflammatory 
properties (13,14). 
When compared to their living counterparts, local complement C3 was found to be 
upregulated and activated in brain-dead donor kidneys prior to organ recovery and this was 
associated with reduced allograft function after transplantation (10). In addition, systemic 
complement is activated by donor BD and is associated with acute rejection in the recipient 
(15). Moreover, targeting complement activation in brain-dead donors did improve renal 
function after transplantation (11). Until now, the mechanism behind these associations 
remains to be elucidated.
Besides local renal production of C3, several groups observed expression of C5a receptor 
(C5aR) in the kidney. Expression of this receptor has primarily been reported on proximal 
tubular epithelial cells, but also on distal tubuli, both on mRNA and protein level (16-20). 
In addition, inhibition or deficiency of C5 or C5aR in murine and rat models of ischemia-
reperfusion injury (21-23) and renal transplantation (19,24,25) has shown to protect renal 
allografts from apoptosis and inflammation, and improve their survival. In this study, we 
therefore investigated the extent and nature of systemic complement activation in human 
brain-dead donors, and the expression of C5aR in kidneys from living and brain-dead donors, 




Patient serum complement measurements 
The functional complement activity of the three complement pathways in serum from human 
living and brain-dead donors was examined using the WIELISA-technique. As shown in 
Figure 1, both the classical and alternative complement pathway showed a significantly 
decreased functionality in serum from brain-dead donors compared to serum from living 
donors (P<0.01). Decreased levels of functional complement components in serum from 
brain-dead donors strongly suggest consumption of complement components in BD. In 
contrast, MBL pathway activity was not altered by BD. 
Figure 1: Functional complement pathway analysis by the WIELISA technique. Both the classical (CP) 
and alternative (AP) pathway of complement in serum from brain-dead donors show a decreased functionality 
compared to serum from living donors (*P<0.05). No difference is observed in mannose binding lectin path-
way (MBL) functionality in brain-dead (BD) versus living donors. Data are expressed as mean values ± SEM.
Renal C5aR gene expression
To examine whether C5aR gene expression levels are influenced by donor BD, we examined 
expression rates in renal tissue from both living and brain-dead donors. Gene expression 
was analyzed by Real-Time qPCR in lysates of renal biopsy obtained from living and brain-
dead donors. As showed in Figure 2, C5aR gene expression rate was higher in brain-dead 
donors compared to living donors, reaching statistical significance after cold ischemia. In 
brain-dead donor kidneys, the increased C5aR gene expression level after reperfusion was 
significantly associated with higher serum creatinine levels 14 days after transplantation 
(P=0.003, R2=0.336, Table 1). 
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Figure 2: Gene expression of the C5aR in renal biopsies obtained from living and brain-dead donor 
patients at time of donation, after cold ischemia (CI) and after reperfusion. Data are shown as relative 
fold induction compared to living donors at time of donation. Data are expressed as mean values ± SEM. 
These data show a significant induction of the C5aR after BD compared to living donors after cold ischemia 
and reperfusion (*P<0.05).
Table 1: Multivariate regression analysis for serum creatinine 14 days after transplantation
Univariate analysis
             r1         P
Multivariate analysis (R2 = 0.336)
           Beta                                 P
C5aR expression
0.470 0.021 0.580 0.003after reperfusion in
BD grafts
Donor age 0.735 0.000 0.426 0.016
Donor gender -0.062 0.767 0.516 0.516
Cold ischemia time 0.129 0.540 0.116 0.524
1Spearmann’s correlation coefficient
Renal C5aR protein expression
To confirm our gene expression data on protein level, we examined C5aR protein expression 
in renal biopsies from living and brain-dead donors, using the monoclonal antibody S5/1 
directed against the extracellular N-terminal region of C5aR. 
Since epithelial staining  of renal C5aR using this particular antibody is controversial (26), 
we used two antibodies directed against different regions of the C5aR: (I) S5/1, a monoclonal 
antibody directed against aa 15-21 of the extracellular N-terminal region, and (II) a polyclonal 
antibody directed against N-terminal aa 9-29 (N 9-29). It has been described that C5a binding 
results in C5a-C5aR complex internalization (27,28). Therefore, IHC analysis of C5a was 
performed using antiserum to C5, of which the ligand C5a is a split product. Both in frozen 
and paraffin sections of renal tissue, S5/1 stained granulocytes, which are known to express 
C5aR abundantly (Fig 3A). In addition, S5/1 revealed C5aR expression by distal tubuli in 
both frozen (Fig 3B) and paraffin embedded sections (Fig 3C). The C5aR expression was 
localized at the basolateral site of these tubular cells. Morphological similar distal tubuli 
were stained in paraffin sections using S5/1 (Fig 3C), N 9-29 (Fig 3D), and anti-C5 (Fig 3E) 





using anti-C5 revealed an endosomal or vesicular pattern in distal tubuli. Next to strong 
expression in distal tubuli, a weaker basolateral C5aR expression by proximal tubuli was 
observed, although not present in all tissues. The C5aR staining in the majority of distal tubuli 
showed co-localization with uromodulin (Fig 3F), a specific marker for the thick ascending 
limb of Henle’s loop (TAL). The remaining minority of tubuli that were C5aR positive, but 
uromodulin negative, resembled a distal convoluted tubule morphology. The IHC analyses 
named above were all performed in sections from unaffected areas of kidneys following 
surgical tumor excision. 
C5aR expression in living and brain-dead donor kidneys
To assess the C5aR expression in renal tissue from living and brain-dead donors, sections 
from paraffin embedded renal biopsies obtained at donation, after cold ischemia and after 
reperfusion were analyzed using S5/1. Biopsies at time of donation were taken with the kidney 
still in situ, before clamping of arterial and venous circulation. Representative pictures of 
renal C5aR expression in living and brain-dead donors are shown in Figure 4A and 4B. Since 
experiments outlined in Figure 3 indicated predominant renal C5aR expression by TALs, the 
percentage of positive TALs and the intensity of the TAL staining were scored in a blinded 
semi-quantative approach, by three individual observers. The TALs were discriminated based 
on morphology and intensity was scored as no staining (-), weak (+), moderate (++), and 
strong (+++). Although percentages of C5aR-expressing TALs were not different between 
living and brain-dead donors, the intensity of C5aR expression by TALs was significantly 
higher in biopsies from brain-dead donors when compared to living donors (P<0.01, Fig 4C 
and 4D). 
As has been stated above, C5a induces C5a-C5aR complex internalization. To investigate 
the presence of internalized C5a-C5aR complex, renal biopsies from living and brain-dead 
donors were stained for C5. Representative pictures of TAL C5 staining in kidneys from 
living and brain-dead donors are shown in Figure 5A and 5B respectively. The percentage of 
TALs positive for C5 and the intensity of these TALs were scored in a similar approach as 
described above. In concordance with elevated expression levels of the C5aR, an increased 
percentage of TALs stained positive for C5 (Fig 5C). In addition, staining intensity for C5 
was higher in biopsies from brain-dead donors when compared to living donors (Fig 5D). 
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Figure 3: Immunohistochemical analysis of C5aR expression in human renal tissue using multiple 
antibodies. (A-C) Monoclonal antibody S5/1 directed against N-terminal aa 15-21, (D)  polyclonal antibody 
directed against N-terminal aa 9-29 and (E) antiserum against C5. (A) The arrow indicates a granulocyte 
stained by S5/1, paraffin tissue. (B) S5/1 stains distal tubuli in frozen tissue. (C-E) Morphological similar distal 
tubuli are stained in paraffin tissue using different anti-C5aR and anti-C5 antibodies. (F) Immunofluorescent 
double staining in paraffin tissue for C5aR S5/1 (red) and uromodulin (green), a marker for the TAL. Stainings 
are performed in sections obtained from unaffected areas of kidneys following surgical tumor excision. 
Magnifications: A-E 400x, F 200x. 
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Figure 4: Immunohistochemical analysis of C5aR expression in renal biopsies from living and brain-
dead donors. Renal biopsies taken from brain-dead and living donors at three different time points: at 
donation: before retrieval with kidney in situ and before clamping arterial and venous circulation (T1), at the 
end of cold ischemia (T2) and approximately 45 min after reperfusion (T3), were stained for C5aR using S5/1. 
Representative pictures of (A) living and (B) brain-dead donors. (C) Percentage of C5aR positive TALs and 
(D) intensity of TALs were scored in a blinded semi-quantative way by three individual observers. The TALs 
were discriminated based on morphology and intensity of the staining was scored as no staining (-), weak 
(+), moderate (++), and strong (+++). TAL positivity and intensity indicated with “Living” and “Brain death” 
reflect the combined T1, T2 and T3 data for kidneys obtained from living and brain dead donors respectively. 
Data are shown as mean values ± SEM. These data show a significant induction of renal C5aR expression in 
brain-dead donors compared to living donors (*P<0.01).
Figure 5: Immunohistochemical analysis of C5 in renal biopsies from living and brain-dead donors. 
Representative pictures of C5 staining in (A) living and (B) brain-dead donors. (C) Percentage of C5 positive 
TALs and (D) intensity of TALs were scored in a blinded semi-quantative way by three individual observers. 
The TALs were discriminated based on morphology and intensity of the staining was scored as no staining 
(-), weak (+), moderate (++), and strong (+++). Data are shown as mean values ± SEM. These data show a 
significant increase of the number of C5 positive TALs and increase in C5 intensity of TALs in kidneys of 
brain-dead donors compare to living donors (*P<0.01, **P<0.05).
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Discussion
Brain death (BD) in the donor significantly affects kidney graft survival and function after 
transplantation (1). Recently, we showed that local and systemic complement is activated 
in deceased donors, which is associated with inferior transplant outcome in the recipient 
(10,11). This study shows that complement is primarily activated in brain-dead donors via 
the classical and alternative pathways, leading to decreased complement functionality in 
serum of brain-dead donors. In theory, complement deficiencies in the classical, alternative 
or common terminal  pathway could explain decreased complement functionality in serum 
of brain dead donors. Although functional MBL deficiency has been reported in up to 40% 
of the population, deficiencies of complement components in the classical, alternative and 
common terminal pathway are very rare. Deficiency of complement component C6 is the 
most prevalent deficiency in these pathways, of which 80 cases have been reported (29). 
Therefore, our data reflect consumption of complement components by systemic complement 
activation rather than pre-existing complement deficiency. 
Systemic release of C5a due to systemic complement activation in brain-dead donors 
potentially leads to activation of renal C5a receptor (C5aR). Although several groups have 
reported C5aR expression on proximal tubular epithelial cells (16-18), expression of this 
receptor in renal tissue remained controversial. It has been suggested that staining of renal 
tubular epithelial cells in paraffin sections using the monoclonal antibody anti-C5aR S5/1, 
is due to cross reactivity to a non-C5aR antigen (26). This suggestion was based on the 
observation that this antibody did not stain granulocytes in frozen sections, which are known 
to express C5aR abundantly. We showed that this antibody does stain granulocytes in both 
cryo and paraffin sections. In addition, cross reactivity of S5/1 has only been reported with 
a desmosomal antigen in skin and epidermal cells, which was not characterized further 
(31). To our knowledge, cross reactivity of S5/1 with a non-C5aR antigen in renal tissue 
has never been confirmed. Using multiple antibodies directed against different portions of 
C5aR and the ligand of this receptor, we confirmed C5aR expression on both proximal and 
distal tubular epithelial cells. Whereas the S5/1 stained the basolateral side of distal tubular 
epithelial cells, anti-C5 showed an intracellular vesicular pattern. Although endogenous C5 
production by tubular epithelial cells can not be ruled out, this endosome-like staining is 
in concordance with the statement that the C5a-C5aR complex is internalized upon ligand 
binding and therefore suggests activation of the C5aR. In addition, this vesicular staining 
resembles the pattern observed in C5a-stimulated granulocytes stained for C5aR (27,28). The 
absence of this vesicular pattern in the S5/1 and N 9-29 staining can be explained by steric 
hindrance of C5a, preventing epitope recognition. 
Expression of C5aR in renal tissue has predominantly been described on proximal tubuli (16-
18). Here, we report an intense staining for C5aR on distal tubuli, besides a weaker staining 
of proximal tubuli. Although not further characterizing the type of distal tubuli, Gueler 
et al reported C5aR expression on distal tubuli as well (19). Besides expression in distal 
convoluted tubules, we characterized the predominant distal tubuli expressing C5aR as being 
thick ascending limbs of Henle’s loop (TAL), by showing co-localization with uromodulin. 
Our study shows an increased C5aR expression in TALs of brain-dead donor kidneys in 
comparison to kidneys from living donors. BD-induced C5aR expression is likely to be 
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caused by the systemic inflammation in brain-dead donors. Among multiple cytokines and 
chemokines, serum levels of interleukin-6 (IL-6) are significantly increased during BD 
(5,7,10,11). In addition, lipopolysaccharide (LPS), which is significantly elevated in brain-
dead donors, has been shown to induce hepatic C5aR expression in an IL-6 dependent 
manner (32,33). Furthermore, treatment with an IL-6 blocking antibody resulted in reduced 
expression of renal C5aR in septic mice (20). Possibly, elevated serum levels of IL-6 in brain-
dead donors are responsible for the upregulation of renal C5aR in the potential donor kidney. 
Besides donor BD, renal allografts are exposed to multiple harmful conditions, such as 
ischemia-reperfusion injury and rejection episodes. The renal medulla seems to be more 
susceptible to transplantation related injury than the cortical region. The TAL is primarily 
localized in the medulla (mTAL), but can partly be found in the cortex (cTAL). Since the TAL 
has a high O
2
 consumption rate, it is likely that these cells are susceptible to hypoxia (34). 
In acute rejection episodes, infiltrating leukocytes are found near distal tubuli (unpublished 
observations). We showed upregulation of the C5aR specifically in distal tubular cells in brain-
dead donor kidneys. It is possible that the C5aR plays a role in distal tubular injury in general, 
and that inhibition of this receptor has a positive effect on kidney function and renal graft 
survival. Indeed, inhibition of the C5aR has been shown to protect kidneys against ischemia-
reperfusion injury (21-23). On top, inhibition of the C5aR has been shown to reduce rejection 
rates and to improve renal allograft survival (19,21,24,25). Inhibition of complement at the 
level of C3 in rat brain-dead donors, thereby preventing C5a release, resulted in improved 
renal function after transplantation (11). 
Next to upregulation of the C5aR, strong expression of C5 was found in TALs of brain-
dead versus living donor kidneys. These observations implicate C5a-C5aR activation with 
subsequent C5aR internalization in kidneys from brain-dead donors. Possibly, local and 
systemic generation of C5a, together with local upregulation of C5aR in kidneys from brain-
dead donors might enhance inflammation in the donor organ to-be. This might explain the 
increased immunogenicity of brain-dead donor kidneys and inferior transplant outcome after 
transplantation of brain-dead grafts. 
In conclusion, this study shows that BD induces systemic complement activation and is 
associated with enhanced C5aR expression in the kidney, especially in the TAL. Increased 
presence of C5 in morphologically similar tubuli suggests activation of the renal C5aR. C5aR 
expression after reperfusion of brain-dead grafts was associated with a worse renal function 
early after transplantation. We propose that systemic complement activation through renal 
C5aR engagement contributes to renal injury observed in brain-dead donors. Therefore, 
inhibition of the renal C5aR in brain-dead donors might improve renal allograft function and 
survival after transplantation. 
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Methods
Patients, serum samples and kidney biopsies 
Serum samples were collected from 30 brain-dead and 20 healthy living donors, of which 
demographic characteristics are listed in Table 2. Serum samples from brain-dead donors 
were obtained just before start of cold organ perfusion, at time of donation. In living donors, 
serum samples were obtained before the kidney was explanted. Kidney biopsies were 
taken from brain-dead and living donors at three different time points: at donation (before 
retrieval with kidney in situ and before clamping arterial and venous circulation), at the end 
of cold ischemia and 45 min after reperfusion. Biopsies were taken using a 16-gauge needle 
(Acecut®, TSK Laboratory, Japan), partially preserved in RNALater (Sigma, St. Louis, MO, 
USA), and stored at -80°C until analysis. 
Table 2: Demographics of human donors
BD (n=30) Living (n=20) P-Value
Gender (M/F) 10/20 7/13 0.903
Age (years)a 42 (49-57) 52 (45-58) 0.306b
Death: CVA 19 NA
Death: Trauma/other 11 NA
Cold ischemia time (min) a 1096 (832-1387) 155 (140-174) <0.001b
Duration of BD (min)a 697 (589-765) NA




Serum creatinine at day 14a
166 (114-556) 133 (117-182) 0.111b
(μmol/L)
aMedian (interquartile range) 
bMann-Whitney U test
NA: not applicable
DGF: Delayed graft function
Complement pathway activity in human serum
The Wielisa Total Complement System Screen (Wieslab AB, Malmö, Sweden), as described 
previously, was used for assessment of serum complement functional activity in classical, 
alternative, and lectin pathway, following the manufacturer’s protocol (35).
RNA isolation and cDNA synthesis
RNA from human kidney biopsies was isolated using the SV Total RNA Isolation Kit 
(Promega, Madison, WI, USA), following the manufacturer’s instructions. RNA samples 
were verified for absence of genomic DNA contamination by RT-PCR reactions, in which 
addition of reverse transcriptase was omitted, using GAPDH primers. For cDNA synthesis, 
1 μl T
11
VN Oligo-dT (0.5 μg/μl) and 200 ng mRNA were incubated for 5 min at 65°C and 
cooled directly. cDNA was synthesized by adding a mixture containing 0.5 μl RnaseOUT® 
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Ribonuclease inhibitor (Invitrogen, Carlsbad, CA, USA), 0.5 μl RNase water (Promega), 4 μl 
5x first strand buffer (Invitrogen), 2 μl DTT (Invitrogen), 1 μl dNTP’s and 1 μl SuperscriptTM 
II Reverse Transcriptase Kit (Invitrogen). The mixture was held for 50 min at 42°C. Reverse-
transcriptase was inactivated by incubating the mixture for 15 min at 70°C. Samples were 
stored at -20°C.
Real-Time qPCR 
Fragments of genes were amplified with primer sets outlined in Table 3. Gene expression was 
normalized with mean β-actin mRNA content. Real-Time qPCR was performed in reaction 
volumes of 15 μL containing 10 μL SYBR Green mastermix (Applied Biosystems, Foster 
City, CA, USA), 0.4 μl of each primer (50 μM), 4.2 μl nuclease free water and 10 ng cDNA. 
All samples were analyzed in triplicate. 
Thermal cycling was performed on the Taqman Applied Biosystems 7900HT Real-Time 
qPCR System with a start for 2 min at 50°C, followed by 10 min at 95°C. The following PCR 
cycle was used for 40 cycles: 15 s at 95°C (denaturation) and 60 s at 60°C (annealing and 
elongation). 
Primers were designed with Primer Express software (Applied Biosystems) and primer 
efficiencies were tested by a standard curve for the primer pair resulting from amplification 
of serially diluted cDNA samples (10 ng, 5 ng, 2.5 ng, 1.25 ng and 0.625 ng). PCR efficiency 
was found to be 1.8 < ε < 2.0. Real-time PCR product specificity (amplicon size) was checked 
on 1.5% agarose gel. 
Results were expressed as 2-Δ ΔCT (CT: Threshold Cycle).
Table 3: Primer sequences










Paraffin sections (3 μm) from unaffected areas of kidneys following surgical tumor excision, 
human living (n = 10) or brain-dead (n = 10) donor kidneys were deparaffinized and antigen 
retrieval was performed using 10mM citrate buffer pH 6 or 0.1M Tris/HCl buffer pH 9. Cryo 
sections (4 μm), obtained from unaffected areas of kidneys following surgical tumor excision, 
were fixed with acetone for 10 min at RT. Sections were incubated with primary monoclonal 
antibody to human C5aR, clone S5/1 (Hycult, Uden, The Netherlands), polyclonal antibody 
to human C5aR (provided by M.R. Daha from Leiden University Medical Center, Leiden, The 
Netherlands) or serum anti human C5 (Quidel, San Diego, CA, USA) for 1 h at RT. Sections 
were incubated with appropriate horseradish peroxidase-conjugated secondary and tertiary 
antibodies (Dako, Glostrup Denmark). The reaction was developed by addition of 3-amino-
9-ethylcarbazole (AEC) and 0.035% hydrogen peroxide. Sections were counterstained with 
Mayer’s haematoxylin solution (Merck, Darmstadt, Germany). 
For immunofluorescent double staining of C5aR and Uromodulin, human kidney paraffin 
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sections were treated as described above and incubated with primary antibodies mouse-
anti-human C5aR S5/1 and sheep-anti-human Uromodulin. Sections were incubated with 
an appropriate horseradish peroxidase-conjugated secondary and tertiary antibody for C5aR 
and a FITC-conjugated secondary antibody for Uromodulin. C5aR staining was visualized 
using TSA Tetramethylrhodamine System (PerkinElmer LAS, Boston, USA). Sections were 
counterstained and embedded using Vectashield with DAPI (Vector Laboratories, Burlingame, 
Canada). 
The C5aR and C5 positivity and intensity of thick ascending limbs of Henle’s loop were 
scored in a blinded semi-quantative approach by three individual observers. In paraffin 
sections, thick ascending limbs of Henle’s loop were discriminated based on morphology and 
intensity of the staining was scored as no staining (-), weak (+), moderate (++), and strong 
(+++). 
Statistical analysis
For statistical analysis of more than two groups, the Kruskal-Wallis test was performed, 
followed by the Mann-Whitney post test. For comparison of two groups, a Mann-Whitney 
test was performed. All the statistical tests were 2-tailed, with P<0.05 regarded as significant. 
Results are presented as mean±SEM (standard error of the mean). 
To associate C5aR gene expression levels in kidney biopsies with serum creatinine levels 
after transplantation, stepwise multivariate regression analysis was performed. Spearman 
correlation coefficients were calculated to determine which variables were significantly 
associated with serum creatinine 14 days after transplantation. For linear regression analysis, 
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targeting Complement aCtivation in brain-dead donors improves renal funCtion after transplantation.
Abstract
Kidneys recovered from brain-dead donors have inferior outcomes after transplantation 
compared to kidneys from living donors. Since complement activation plays an important 
role in renal transplant related injury, targeting complement activation in brain-dead donors 
might improve renal function after transplantation. 
Brain death (BD) was induced in Fisher rats by inflation of an epidurally placed balloon 
catheter and ventilated for 6 h. BD animals were treated with soluble complement receptor 
1 (sCR1) 1 h before or 1 h after BD. Kidney transplantation was performed and 7 days after 
transplantation animals were sacrificed. Plasma creatinine and urea were measured at days 0, 
1, 3, 5 and 7 after transplantation. 
Renal function was significantly better at day 1 after transplantation in recipients receiving 
a sCR1 pre-treated donor kidney compared to recipients of a non-treated donor graft. Also 
treatment with sCR1, 1 h after the diagnosis of BD, resulted in a better renal function after 
transplantation. Gene expression of IL-6, IL-1beta and TGF-beta were significantly lower in 
renal allografts recovered from treated donors.
This study shows that targeting complement activation, during BD in the donor, leads to an 
improved renal function after transplantation in the recipient. 
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Introduction
Despite an increasing pool of living and donation after cardiac death (DCD) donors, most 
kidneys that are finally transplanted are still recovered from heart-beating, brain-dead donors. It 
is now well established that brain death (BD) itself is an independent risk factor which affects 
successful organ transplantation, with grafts from brain-dead donors showing inferior renal 
function and poorer survival rates after transplantation (1;2). In several animal models mimicking 
BD and in brain-dead patients, systemic and local organ inflammation has been shown (3-6). 
In previous studies we demonstrated local renal complement activation in experimental and 
clinical brain-dead donors (7). Furthermore, we found that systemic complement is activated 
in deceased human donors and predisposes the kidney graft for a higher risk of acute rejection 
after transplantation (unpublished data).
The complement system can be activated through three different pathways, respectively: The 
classical, the alternative and the lectin pathway. Activation of each of the three pathways 
finally leads to activation of C3, subsequently leading to activation of C5 and formation of the 
membrane attack complex (MAC). Inherent to complement activation is the generation of the 
anaphylatoxins C3a and C5a which have chemokinetic and pro-inflammatory properties (8;9). 
In renal transplantation, the important role of complement activation in the recipient has been 
extensively shown in models of renal ischemia-reperfusion-injury (IRI). In knock-out models 
of several complement components, it was possible to prevent renal IRI (10). In addition, local 
expression of complement C3 by the donor kidney enhances graft rejection and results in a 
decreased graft survival after renal transplantation (11). After renal transplantation, complement 
has also shown to be activated in rejecting grafts (12). In the past, several strategies have been 
used to target renal complement activation in animal models of IRI and kidney transplantation. 
Systemic administration of complement regulator proteins (soluble complement receptor 1 
(sCR1)), monoclonal antibodies against C5/C5a receptor (C5aR) or silencing of C3 and C5aR 
by small interfering RNA has been successfully used to prevent renal IRI or acute rejection 
(13-18). TP10, a soluble derivative of human complement receptor 1, acts as an inhibitor of 
the classical, alternative and lectin complement pathway. SCR1 accelerates the decay of the 
convertases that activate C3 and C5, thereby intervening in the production of C3a, C5a and 
C5b-9. In addition, sCR1 serves as a cofactor in the proteolysis of C3b and C4b by factor I, 
further down-regulating the activation of the three complement pathways (19).
Hypothesis
In this study, we hypothesized that systemic and local renal complement activation in brain-
dead donors leads to structural changes in the donor kidney, which results in a worse transplant 
outcome after transplantation. Therefore, inhibition of complement activation in brain-dead 
donors is likely to prevent the BD-induced renal changes and to improve renal function early 
after transplantation. To validate our hypothesis we treated brain-dead donor rats with sCR1, a 





Inbred male Lewis (LEW, RT11) and Fisher (F344, RT11vr) rats weighing 200–250 g 
were obtained from Charles River (Sulzfeld, Germany). Animals were kept under standard 
conditions and fed standard rodent chow and water ad libitum. All procedures were performed 
according to the Guide for the Care and Use of Laboratory Animals published by the National 
Academy of Sciences and were approved by the local authorities (RP Karlsruhe, AZ 35–
9185.81/142/08).
Experimental protocol 
Before induction of BD, donor animals were anesthetized with ketamine (Ketanest, Pfizer, 
Karlsruhe, Germany; 100 mg/kg intraperitoneally) and xylazine (Rompun, BayerVital, 
Leverkusen, Germany; 6 mg/kg intraperitoneally) and placed on a heating table to keep their 
body temperature constant. A 3F Fogarty catheter was inserted epidurally in an occipital burr 
hole and gradually inflated during 1 min with 300 μl of saline. The state of BD was verified by 
the occurrence of autonomic storm, the absence of corneal reflexes and by an apnea test. All 
animals were mechanically ventilated by a tracheostoma with a rodent ventilator (Ugo Basile, 
Comerio, Italy). Systemic blood pressure (mean arterial pressure, mmHg) was continuously 
measured (6 h) in donors using a femoral arterial catheter (Statham pressure transducer 
P23Db and a Gould pressure processor; FMI, Ober-Beerbach, Germany). Recipients were 
anesthetized with enflurane (Ethrane; Aca Mueller/Adag Pharma, Gottmadingen, Germany). 
Experiments were performed in the allogeneic Fisher–Lewis rat model. Animals were 
divided into three groups. Donor animals were treated intravenously by microinjection 
pumps (CMA/100, CMA/ Microdialysis, Solna, Sweden) through the tail vein according to 
the following scheme:
Group 1: BD was induced in donor Fisher rats. BD lasted 6 h; the animals were ventilated 
and treated with NaCl 0.9% (BD group).
Group 2: Fisher donor rats were pre-treated with a single dose of 25 mg/kg sCR1 (Celldex 
Therapeutics, Inc. of Needham, MA, USA) 1 h before BD induction. BD lasted 6 hours and 
animals were ventilated during the BD period (pre-treatment group).
Group 3: BD was induced in donor Fisher rats. One hour after BD induction animals received 
a single dose of 25 mg/kg sCR1. BD lasted 6 h and animals were ventilated during the BD 
period (after-treatment group). 
Non-BD, living donor kidney transplantation from Fisher to Lewis, served as a historic 
control group. In each group, the left kidney was harvested after 6 h, flushed with 1 ml 
of cold University of Wisconsin (UW) solution and transplanted in allogeneic bilaterally 
nephrectomised Lewis rats. The transplantation was performed as previously published 
(20-22). No immunosuppression was administered. Each group consisted of a minimum of 
six animals. From donors, a blood sample was drawn at baseline and 6 hours after BD in 
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all three groups. From recipients, blood samples were drawn at day 0, 1, 3, 5 and 7 after 
transplantation. Blood samples were collected in hirudin tubes to prevent further in vitro 
complement activation. Samples were stored on ice, centrifuged to obtain plasma, and the 
plasma’s were stored in aliquots at -80°C until further analysis. In each assay, fresh frozen 
plasma samples were used for analysis.
Renal function
Renal function was assessed both in donors and in recipients. In recipients, plasma creatinine 
and urea were measured on day 0, 1, 3, 5, and 7 after transplantation. In donors, plasma 
creatinine was measured at baseline before BD induction and at the end of the BD period. 
C3d ELISA
Complement C3d was quantified by sandwich ELISA. Nunc Maxisorp 96-well plates were 
coated with monoclonal mouse-anti-rat C3 (Santa Cruz) overnight at 4°C. After washing, 
plasma samples were prepared as described below and incubated in EDTA containing sample 
buffer for 1 h at RT. After washing, wells were subsequently incubated with polyclonal rabbit-
anti-human C3d (with cross-reactivity for rat, DAKO), goat-anti-rabbit-peroxidase and TMB 
as a substrate. Between incubation steps, wells were washed with PBS containing 0.05 % 




, the amount of reacted substrate 
was measured at OD 450 nm. 
A standard curve was made using serial dilutions of a Zymosan activated rat plasma pool. Since 
free C3d shares epitopes with intact C3, separation of free plasma C3d from intact plasma C3 
by PEG-precipitation is required before ELISA quantitation of free C3d. Zymosan activated 
plasma was 1:1 diluted in 22% PEG (6000) 0.1M Borate-EDTA buffer (pH 8.32) for 3 h at 
4°C. Subsequently, samples were centrifuged for 10 min at 4000 rpm (4°C). Supernatants 
were collected and diluted to construct a standard curve. No signal was detected when non-
Zymosan activated PEG precipitated plasma samples were used for ELISA. This indicates 
that the ELISA does specifically react with the C3d neo-epitope after PEG precipitation 
and not with the C3d epitope shared with intact C3. Same sample preparation was used 
for C3d determination of samples from baseline, sCR1 pre-treated and sCR1 after-treated 
animals. The amount of C3d in measured samples was determined from the standard curve 
and expressed in units relative to an internal control. The internal control was defined as the 
dilution of the plasma pool giving half the maximum optical density in the ELISA. 
RNA isolation and cDNA synthesis
Total RNA was isolated from whole kidneys by using TRIzol (Life Technologies, Gaithersburg, 
MD). RNA samples were verified for absence of genomic DNA contamination by performing 
RT-PCR reactions in which the addition of reverse transcriptase was omitted, using GAPDH 
primers. For cDNA synthesis, 1 μl T
11
VN Oligo-dT (0,5 μg/μl) and 1 μg mRNA were incubated 
for 10 min at 70°C and cooled directly after that. cDNA was synthesized by adding a mixture 
containing 0.5 μl RnaseOUT® Ribonuclease inhibitor (Invitrogen, Carlsbad, USA), 0.5 μl 
RNase water (Promega), 4 μl 5 x first strand buffer (Invitrogen), 2 μl DTT (Invitrogen), 1 μl 
dNTP’s and 1 μl M-MLV reverse transcriptase (Invitrogen, 200U). The mixture was held at 
37°C for 50 min. Next, reverse-transcriptase was inactivated by incubating the mixture for 15 




Fragments of several genes were amplified with the primer sets outlined in Table 1. Pooled 
cDNA obtained from brain-dead rats were used as internal references. Gene expression was 
normalized with the mean of β-actin mRNA content. Real-Time PCR was carried out in reaction 
volumes of 15 μL containing 10 μL of SYBR Green mastermix (Applied biosystems, Foster 
City, USA), 0.4 μl of each primer (50 μM), 4.2 μl of nuclease free water and 10 ng of cDNA. 
All samples were analyzed in triplicate. 
Thermal cycling was performed on the Taqman Applied Biosystems 7900HT Real Time PCR 
System with a hot start for 2 min at 50°C followed by 10 min 95°C. Second stage was started 
with 15 s at 95°C (denaturation step) and 60 s at 60°C (annealing step and DNA synthesis). The 
latter stage was repeated 40 times. Stage 3 was included to detect formation of primer dimers 
(melting curve) and begins with 15 s at 95°C followed by 60 s at 60°C and 15 s at 95°C. 
Primers were designed with Primer Express software (Applied Biosystems) and primer 
efficiencies were tested by a standard curve for the primer pair resulting from the amplification 
of serially diluted cDNA samples (10 ng, 5 ng, 2.5 ng, 1.25 ng and 0.625 ng) obtained from 
brain-dead rats. PCR efficiency were found to be 1.8 < ε < 2.0. Real-time PCR products were 
checked for product specificity on a 1.5 % agarose gel.
Results were expressed as 2-Δ ΔCT (CT: Threshold Cycle).
Table 1: Primer sequences used for Real-Time PCR.






















Immunohistochemistry and Banff classification
Serial paraffin sections (4 μm) were fixed in 10% neutral buffered formalin for 
immunohistochemical staining. For Banff classification, paraffin sections were stained 
with hematoxylin-eosin, periodic acid-Schiff and trichrome. A minimum of 20 microscopic 
fields per graft were assessed. Histologic grading was performed according to the Banff ’97 
classification. Sections were blindly evaluated and graded by a renal pathologist. Histologic 
evaluation and grading included transplant glomerulopathy, tubulointerstitial fibrosis, tubular 
atrophy and vasculopathy. The histological scale was from 0 to 3 (0=not present, 1 mild 
alteration, 2 moderate alteration and 3 severe alteration).
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Statistical analysis
Statistical analysis was performed using a non-parametric Kruskal-Wallis test with option for 
multiple comparisons and P < 0.05 regarded as significant (StatsDirect 2.2.8, Aswell, UK). 
Results are presented as mean ± SEM (standard error of the mean). For Banff classification 
Fisher’s exact test was applied.
Results
Donor plasma complement activation
To determine whether treatment with sCR1 before (pre-treatment) or early after induction 
of BD (after-treatment) was able to prevent systemic complement activation in brain-dead 
donor rats, plasma C3d was measured, as it is known to have a relative long half life in 
plasma. After 6 h of BD, plasma C3d levels significantly increased compared to baseline 
levels. In contrast, both in the pre-treatment and after-treatment group, C3d levels were not 
elevated after 6 h of BD (Figure 1). 
Figure 1: Levels of plasma C3d in brain-dead donors or brain-dead + sCR1 donors.
Complement is significantly activated after 6 h of BD, as shown by increased levels of C3d in the donor. 
Generation of plasma C3d after BD in the donor is prevented by a single dose of sCR1 given before or after 
BD. Data is shown as U/ml and expressed as mean values ± SEM. Significant differences compared to BD are 
indicated (* P < 0.05).  
Renal function 
In the donor, plasma creatinine significantly increased 6 h after BD induction compared to 
baseline. The increase in plasma creatinine could not be prevented in both sCR1 treated 
groups prior to organ recovery (Figure 2). After transplantation, however, plasma creatinine 
and urea were significantly lower at day 1 in recipients with a kidney that had been recovered 
from a sCR1 treated donor compared to recipients with an untreated donor kidney. Also after-
treatment, 1 h after the diagnosis of BD in the donor, resulted in a better renal function after 
transplantation. Statistical significance was only found in animals receiving a kidney from a 
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pre-treated donor compared to untreated donors. Both pre- and after-treatments of brain-dead 
donors result in a marked improvement of renal function up to the level of a living donor 
kidney (historic controls, Figure 3).
Figure 2: Plasma creatinine in brain-dead donors or brain-dead + sCR1 donors. 
BD significantly increased plasma creatinine in the donor which could not be prevented by treatment with 
sCR1. Data is shown as umol/L and expressed as mean values ± SEM.  Significant differences compared to 
baseline are indicated (* P < 0.05).  
Renal inflammation
To assess if inhibition of complement in the donor reduces renal inflammation and fibrosis in 
renal allografts after transplantation in the recipient, we performed Real-Time PCR for IL-6, 
IL-1beta, MCP-1, TGF-beta, KIM-1 and E-selectin. No significant differences were found 
between gene expression levels of donor kidneys that were treated with sCR1, 1 h before or 
1 h after BD, compared to untreated donors. In renal allografts, 7 days after transplantation, 
gene expression levels of IL-6, IL-1 beta and TGF-beta were found to be significantly lower 
in kidneys recovered from a sCR1 treated donor (Table 2). 
Banff
Upon histopathology, Banff classification revealed a non-significant difference in rejection 
associated injury at day 7 after transplantation between recipients of a kidney from a sCR1 
treated or untreated donor (Table 3).  
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Figure 3: Renal function after transplantation of recipients receiving a graft from a BD or a BD + sCR1 
treated donor. Plasma creatinine and urea were significantly lower at day 1 after transplantation in recipients 
with a kidney that had been recovered from a sCR1 pre-treated donor compared to recipients of a non-treated 
donor graft. Also treatment with sCR1, 1 h after BD in the donor, prior to organ recovery, results in a better 
renal function after transplantation. Both pre- and after-treatments of brain-dead donors result in a marked im-
provement of renal function up to the level of a living donor kidney (in grey, historic controls). Data is shown 
as relative fold induction compared to BD and expressed as mean values ± SEM. Significant difference at day 
1 between recipients receiving a graft from a sCR1 pre-treated and non-treated brain-dead donor is indicated 
(* P < 0.05).
  
Table 2: Gene expression levels of kidneys at day 7 after transplantation. 
Gene Group Relative fold induction
IL-6
BD 2.50 ± 0.86
SCR1 (pre-BD) 0.75 ± 0.12 
sCR1 (after-BD) 0.70 ± 0.12 *
IL-1beta
BD 1.86 ± 1.17
SCR1 (pre-BD) 1.21 ± 0.94 *
sCR1 (after-BD) 1.68 ± 1.31
MCP-1
BD 1.26 ± 0.07
SCR1 (pre-BD) 1.15 ± 0.07
sCR1 (after-BD) 1.21 ± 0.10
TGF-beta
BD 1.71 ± 0.14
SCR1 (pre-BD) 1.40 ± 0.03
sCR1 (after-BD) 1.11 ± 0.15 *
KIM-1
BD 2.01 ± 1.11
SCR1 (pre-BD) 0.23 ± 0.03
sCR1 (after-BD) 0.58 ± 0.17
E-selectin
BD 2.41 ± 0.32
SCR1 (pre-BD) 1.88 ± 0.44
sCR1 (after-BD) 2.05 ± 0.41
Both pre- and after-treatments of brain-dead donors with sCR1 prior to organ recovery result in lower expression 
levels of inflammatory genes in renal allografts. IL-6, IL-1beta and TGF-beta were significantly lower in treated 
animals compared to non-treated animals. Data is shown as relative fold induction compared to BD and expressed 
as mean values ± SEM. Significant differences between gene expression levels of treated kidneys compared to BD 
kidneys are indicated (* P < 0.05).  
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Table 3: Banff classification of renal allograft 7 days after transplantation in the recipient. 
Banff BD n (%) BD sCR1 pre-treatment 
(%)
BD sCR1 after-treatment 
(%)
I0 0 (0) 0 (0) 0 (0)
I1 0 (0) 0 (0) 0 (0)
I2 2 (33.3) 2 (33.3) 0 (0)
I3 4 (66.6) 4 (66.6) 6 (100)
T0 0 (0) 0 (0) 0 (0)
T1 3 (50) 0 (0) 0 (0)
T2 3 (50) 6 (100) 6 (100)
T3 0 (0) 0 (0) 0 (0)
V0 1 (16.7) 0 (0) 0 (0)
V1 5 (83.3) 6 (100) 4 (66.6)
V2 0 (0) 0 (0) 0 (0)
V3 0 (0) 0 (0) 2 (33.3)
 
Severity of interstitial inflammation (i), tubulitis (t) and intimal arteritis (v) is indicated by the grading scale (0 
= not present, 1 = mild alteration, 2 = moderate alteration and 3 = severe alteration). Numbers in parentheses 
represents the % of animals with a given score. No significant difference was observed between the 3 groups.
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Discussion
The unphysiological state of BD results in a significant renal inflammation and injury in 
potential organ grafts-to-be. These events partially explain the reduced allograft quality of 
BD-allografts after transplantation. Previously, our group demonstrated significant local and 
systemic complement activation in both human and rat brain-dead donors. In the present 
study it is demonstrated that treatment before or after induction of BD with a complement 
inhibiting drug, improves renal function after transplantation. 
In this study we treated brain-dead donor rats with a single dose of the complement inhibiting 
drug sCR1, 1 h before or 1 h after induction of BD. SCR1 accelerates the decay of C3 
convertases and serves as a cofactor for factor I mediated degradation of C3b and C4b, thereby 
inhibiting C3 and C5 convertase formation. Consequently, C3 and C5 will not be activated 
and generation of anaphylatoxins and MAC-formation is inhibited (23). Recombinant sCR1 
is highly potent in inhibiting complement activation (19). When administered to recipients 
in a rat allograft model, sCR1 was successfully shown to protect rats against renal allograft 
injury (11). Following Pratt et al., we used the same dose of 25 mg/kg which totally depresses 
complement activation shortly after administration. 
In our rat brain-dead model, systemic complement activation was significantly activated after 
6 h of BD. Both pre-treatment and after-treatment with sCR1 significantly decreased systemic 
complement activation after 6 h of BD to baseline levels. Importantly, renal function early 
after transplantation was significantly better in allografts obtained from sCR1 treated donors. 
Apparently, treatment of the allograft in the donor protected the graft from severe IRI after 
transplantation. By day 7, renal function had recovered after transplantation in all groups, 
which was compatible with the histopathological findings on day 7. In contrast to the BANFF 
criteria, a significant difference was found for gene expression of inflammatory cytokines 
such as IL-6 and IL-1beta. These findings suggest that protection from early IRI by sCR1 
protects allografts from development of inflammation at a later time point. 
Although the protective effects on IRI are profound, no difference was found in the donor 
kidney before organ recovery when treated with sCR1. While sCR1 depleted C3d levels 
in the blood, renal deposition of C3d and C5b-9 was equal in both treated and untreated 
animals (data not shown). Apparently, sCR1 could not prevent local renal complement 
activation in the donor, since the kidney itself is a substantial producer of complement 
components and possibly sCR1 is unable to penetrate into the renal interstitium. Although 
local renal complement activation occurs in brain-dead donors, the amplification loop of 
complement activation will be attenuated since systemic complement is depleted by sCR1. 
After transplantation of the allograft, with less BD-induced tissue injury due to the protective 
effect of sCR1, the graft becomes less vulnerable to IRI. Therefore, early graft function in 
recipients of a kidney from a sCR1 treated donor was found to be better after transplantation.
Our results indicate that complement inhibition in brain-dead donors improves short-term 
renal function of their grafts up to the level of a living donor kidney after transplantation. As 
the main difference was found in the early phase after transplantation, this most likely reflects 
a protective effect of sCR1 on the enhanced IRI that occurs after transplantation of a BD 
compared with a living graft. Hence, sCR1 could not prevent IRI inherent to transplantation 
of a living donor kidney since renal function was not better than a living graft.
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In contrast to the protective effects on IRI, a single dose of sCR1 given to the donor could 
not prevent rejection associated graft injury in the recipient as classified by the Banff criteria. 
Also, the amount of macrophage influx in renal allografts was equal in all groups at day 7 
(data not shown). We emphasize however that our study was performed in an allograft model 
without any immunosuppression in nephrectomised recipients, which does represent a severe 
model for acute rejection. Moreover, it is known that complement is also strongly activated 
during IRI and rejection in the recipient, while no sCR1 was given to the recipient in this 
study. One could therefore speculate that sCR1, when also given to the recipient, could be of 
additional value to protect against rejection associated injury.
An important finding of our study is that not only pre-treatment, but also after-treatment of 
the donor, 1 h after the diagnosis of BD, improves renal function after transplantation. Pre-
treatment with sCR1 might have consequences for donor management protocols and can 
facilitate treatment in the hospital setting in a non-declared donor. However, this is obviously 
forbidden by law in most countries. From a clinical point of view, we would then recommend 
to treat the donor shortly after the diagnosis of BD with sCR1, as part of the standard donor 
management in the intensive-care unit. Recent literature does not reveal potential negative 
effects of sCR1 for extra-renal donor organs. Moreover, sCR1 was previously used in clinical 
trials in humans which revealed no negative side effects or adverse events with administering 
sCR1 relative to placebo (24;25).
In conclusion, this study shows that targeting complement activation in brain-dead donors 
leads to an improved renal function after renal transplantation in the recipient. Therefore, 
targeting complement activation in the donor, before or even after the diagnosis of BD, might 
be a promising approach to improve graft function of kidneys from brain-dead donors after 
transplantation. 
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Local renal complement activation by the donor kidney plays an important role in the 
pathogenesis of renal injury inherent to kidney transplantation. Contradictory results were 
reported about the protective effects of the donor C3F allele on transplant outcome of deceased 
donor kidneys. The present study was initiated to investigate the influence of the donor C3 
allotype on renal transplant outcome, taking all donor types into account.
Methods
C3 allotypes of 1265 donor-recipient pairs were determined and divided into four genotypic 
groups according to the presence or absence of the C3F allele of the donor or the recipient. 
The four genotypic groups were analyzed for association with primary non-function (PNF), 
delayed graft function (DGF), biopsy proven acute rejection, death-censored graft survival 
and patient survival. In addition, similar analyses were also performed for each donor type 
separately.
Results
Multivariate analysis revealed an independent protective effect of the C3F allele on PNF of 
deceased cardiac death (DCD) donor kidneys. Additionally, no association was found between 
the C3F allotype of DCD donor kidneys and DGF, overall acute rejection, death-censored 
graft survival and patient survival. Regarding living and deceased brain-dead (DBD) donors, 
no association was found between the four genotypic groups and all transplant outcome 
parameters.
Conclusions
This study shows that the donor C3F allele protects against PNF of grafts derived from DCD 
donors. Considering living and DBD donors, our study confirms that the C3 allotype of the 
donor and recipient is not associated with renal allograft outcome.
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Introduction
Long-term renal allograft survival after kidney transplantation is affected by different 
variables including donor type and age, kidney preservation methods, ischemia-reperfusion 
injury (IRI) and acute rejection.1-4 Today, the majority of renal allografts are recovered from 
deceased brain-dead (DBD) donors whereas donation after cardiac death (DCD) has emerged 
as an important alternative donor source in order to enlarge the deceased donor pool. Organs 
recovered from DBD as well as DCD donors have shown to give inferior transplant outcomes 
compared to organs recovered from living (un)related donors.5 In DBD donors, local and 
systemic immune activation occurs and is, at least in part, responsible for the pathogenesis of 
renal injury of kidney grafts to-be. Importantly, a significant part of the brain death induced 
immune activation can be ascribed to local and systemic complement activation which is 
associated with reduced renal allograft function.6, 7 Notably, significant systemic complement 
activation has been demonstrated in DCD donors already before withdrawal of treatment.8
In renal transplantation, it was demonstrated that complement activation plays a substantial 
role in renal IRI and allograft rejection. C3 is the central complement component that can 
be activated by all the three complement pathways.9, 10 In mice it was shown that absence of 
donor C3 in the kidney significantly improves early post-reperfusion injury and late rejection 
associated allograft survival.11, 12 The main producers of C3 in the kidney are tubular epithelial 
cells and the rejecting transplanted kidney can contribute up to 16% of all circulating C3 
compared to 5% in resting kidneys.13 There are two allelic variants of the C3 allotype namely 
the slow variant (C3S) and the fast variant (C3F) which is based on the ability of C3 to 
migrate through a gel-electrophoresis system.14, 15 The C3F allotype is characterized by a 
functional single nucleotide polymorphism (C to G) leading to a substitution of glycine (C3F) 
for arginine (C3S) at position 80. This might affect the ability of C3 to interact with monocyte 
complement receptors.16, 17 The frequency of the C3F allele is highest amongst Caucasians 
(20%) and less frequent in blacks (5%) and Asians (1%). An increased prevalence of the C3F 
allele has been found in several kidney diseases such as IgA nephropathy, systemic vasculitis 
and membranoproliferative glomerulonephritis.18-20 
In kidney transplantation, Brown et al. found an increased long-term graft survival of kidneys 
carrying the C3F allele when transplanted into C3SS recipients.21 This protection was only 
found in recipients of a deceased donor kidney, whereas no such protection was found in 
recipients of a living donor kidney. In contrast, a recent study could not confirm the protective 
effects of the donor C3F allele of kidneys recovered from deceased donors.22 Since local 
and systemic complement are significantly activated in DBD as well as DCD donors, the 
disparity between the two previous studies might be explained by an unequal distribution of 
both donor types among the two study cohorts. 
Based on the conflicting results about the protective effects of the donor C3F allele on allograft 
outcome of deceased donor kidneys, we initiated a final confirmatory study, thereby taking 




Patients and study design
Between March 7, 1993 and February 12, 2008, 1430 patients underwent kidney transplantation 
at the University Medical Center Groningen, The Netherlands. From this original group, 
90 patients were excluded because of three or more kidney transplantations, simultaneous 
transplantation of other organs (pancreas, liver, lung and intestine) and technical problems 
during the operation. A total of 4 patients were lost to follow-up, of 65 transplantations no donor 
and recipient DNA pairs were available and of 6 patients no genotype could be assessed (Figure 
1). Informed consent was given by all patients. Donor, recipient and transplant characteristics 
were obtained and documented as shown in Table 1. 
Figure 1: Kidney transplantations that were included and excluded from the study.
DNA isolation and genotyping
DNA was extracted from peripheral blood samples or splenocytes from deceased donors using a 
commercial kit foll owing the manufacturer’s instructions. Genotyping of the selected C3 single 
nucleotide polymorphism (rs2230199) was performed using the Illumina VeraCode GoldenGate 
Assay kit (Illumina, San Diego, CA, USA), according to the manufacturer’s instructions. 
Genotype clustering and calling were performed using BeadStudio Software (Illumina). The 
overall genotype success rate was 99.5% and 6 samples with a high missing call rate were 
excluded from subsequent analyses.
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Study end-points
The primary end points in this study were: primary non-function (PNF, defined as non-
functioning of the allograft from transplantation on), delayed graft function (DGF, defined as 
the requirement for dialysis within the first week after transplantation), biopsy proven acute 
rejection (all biopsies were re-evaluated according to the Banff 2007 classification) during 
the first year after transplantation, death censored graft survival (defined as the need for 
dialysis or re-transplantation) and patient survival. 
Statistical analysis
Statistical analyses were performed using SPSS (version 18.0) and two sided P values under 
0.05 were considered to indicate statistical significance. To compare the four genotypic 
groups, the Kruskal-Wallis test was performed for continuous variables and the Chi-square 
test for categorical variables. The Mann-Whitney U test was applied to compare continuous 
variables between two genotypic groups. Kaplan-Meier survival curves and logrank tests 
were performed between groups to assess the difference in death censored graft survival rates 
or patient survival. For the univariate association that was found to be statistically significant, 




Baseline characteristics of patients included in our study (n=1265) did not differ significantly 
from those in the original group (n=1430, Supplementary Appendix, Table 1). In donors, the 
frequency of the C3F allele was 0.21 and 0.22 in recipients respectively. These are comparable 
frequencies as reported by others and in accordance with the Hardy-Weinberg equilibrium. 
Univariate analysis was performed to assess association between donor and recipient C3 
allotypes and PNF, DGF, biopsy proven acute rejection, death censored graft survival and 
patient survival. Since the frequency of the C3FF allotype in the general population is low, 
C3FF and C3FS allotypes were combined and compared with the C3SS allotype. Transplants 
were divided into four genotypic groups according to the presence or absence of the C3F 
allele of the donor or the recipient (Figure 1, Table 1). There were no significant differences 
in baseline characteristics between the four genotypic groups (Table 1). Considering all donor 
types together, neither the C3 allotype of the donor nor that of the recipient was associated 
with DGF, PNF, acute rejection, death-censored graft survival and patient survival (Figure 
2A, Table 1). 
As previously indicated, the disparity between the studies on C3 allotyping and renal 
allograft outcome might be explained by an unequal distribution of DBD and DCD donors 
among the two study cohorts. Therefore, similar analyses were also performed for living, 
DBD and DCD donor types separately. Regarding living or DBD donors, no association 
was found between C3 donor and recipient allotype on all transplant outcome parameters 
(data not shown). Also when analyses were performed only for deceased donors (DBD and 
DCD), no effect of the donor C3F allele on transplant outcome was found (Figure 2B). Since 
the presence of the donor C3F allele of kidneys recovered from deceased donors has been 
shown to give superior allograft survival rates when transplanted into C3SS recipients, we 
specifically analyzed this genotypic combination.21 Transplantation of a C3F allelic donor 
kidney into C3SS recipients was not associated with superior transplant outcome compared 
to C3SS into C3SS recipients for all transplant outcome parameters. Also when analyses 
were performed for C3FF allotypes separately compared to all other allotypes, no differences 
were found for all transplant outcome parameters (data not shown).
However, univariate analysis showed that transplantation of C3F allotypic DCD donor kidneys 
was significantly associated with protection against PNF (Table 2). Also death-censored 
graft survival was superior in recipients of a C3F allotypic donor kidney, which can be fully 
attributed to the high incidence of PNF in recipients of a C3S DCD donor kidney (Figure 2C). 
Baseline characteristics did not significantly differ between the donorgroups according to the 
presence of the C3F allele (Table 2). Multivariate analysis was performed with covariates 
that were found to be significantly associated with PNF by univariate analysis and the factors 
known from literature influencing graft outcome. These included donor age, recipient age, 
the number of previous transplants of the recipient, cold ischemia time, first warm ischemia 
time, percentage of panel reactive antibodies (PRA) and the number of human leukocyte 
antigen (HLA) mismatches. Furthermore, since it was commented that the disparity in the 
results between the studies by Brown et al. and Varagunam et al. might be due an unequal 
distribution of primary kidney disease among the genotypic groups, we also included primary 
recipient kidney
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Table 1: Donor, recipient and transplant characteristics and transplant outcome of the four genotypic groups 
















Ageb 47 (7-74) 46 (8-72) 47 (9-69) 47 (7-73) 0.79
Sex no. (%) 
Male 269 (51) 139 (54) 114 (46) 120 (51) 0.31
Female 260 (49) 116 (46) 133 (54) 114 (49)
Donortype no. (%):
               Living
               DBD



























PRA level >5% (%) 14 14 20 14 0.46
























































































































Cold ischemia timeb 18 (1-40) 17 (2-41) 18 (2-39) 17 (1-40) 0.43
HLA no. of 0 mismatches 
(%) 101 (23) 47 (22) 50 (24) 42 (23) 0.99
Transplant outcome
Primary non-function 
no. (%) 31 (6) 9 (4) 12 (5) 8 (3) 0.36
Delayed graft no. (%) 180 (34) 87 (34) 73 (30) 74 (32) 0.60
Biopsy proven acute 
rejection
(first year) no. (%)
Overall
Borderline
Banff IA or IB





















Death censored graft 
failure no. (%) 87 (16) 39 (15) 36 (15) 34 (15) 0.87
Death no. (%) 68 (13) 31 (12) 35 (14) 23 (10) 0.52
aAll P values are two-sided. Kruskal-Wallis test for continuous variables, and Chi-square test for binary variables.
bMedian (range).
Abbreviations: PRA; panel reactive antibody, HLA; human leukocyte antigen, ATG; antithymocyte globulin, moab; 
monoclonal antibody, RA; receptor antagonist.
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disease in our multivariate analysis.23 Multivariate analysis revealed that the C3F allele of 
DCD donor kidneys was an independent protective factor for the development of PNF (odds 
ratio 0.109, 95% CI 0.020 – 0.597, Table 3). Interestingly, the risk to develop PNF was 
highest among C3SS recipients of a C3SS DCD donor kidney (18%). Moderate or severe 
vascular rejection (Banff IIA, IIB, III) was the main cause of PNF in these patients (44%). 
Also, the incidence of acute vascular rejection was significantly higher in the first year after 
transplantation in recipients of a C3SS compared to C3F allelic donor kidneys (Table 2). No 
association between C3F allotypic DCD donor kidneys and overall acute rejection, DGF and 
patient survival was found (Table 2).
donor C3 allotype and renal allograft outCome
134
Table 2: Donor, recipient and transplant characteristics and transplant outcome of DCD donors according to 
the presence or absence of the donor C3F allele. 
Variable SS donor (n=114) FS/FF donor (n=87) P valuea
Donor characteristics



















PRA level >5% (%) 7 4 0.80
Previous transplants (% second) 7 10 0.40
Primary kidney disease no. (%):
Glomerulonephritis
Adult polycystic disease




































































First warm ischemia timeb 18 (9-39) 19 (9-55) 0.94
Cold ischemia timeb 18 (4-38) 17 (7-38) 0.44
HLA no. of 0 mismatches (%) 10 (9) 7 (8) 0.46
Transplant outcome
Primary non-function no. (%) 16 (14) 3 (3) 0.011
Delayed graft function no. (%) 95 (83) 70 (81) 0.60
Biopsy proven acute rejection
(first year) no. (%)
Overall
Borderline
Banff IA or IB













Death censored graft failure no. (%) 29 (25) 14 (16) 0.11
Death no. (%) 15 (13) 6 (7) 0.15
aAll P values are two-sided. Mann-Whitney test for continuous variables, and Chi-square test for binary variables.
bMedian (range).
Abbreviations: PRA; panel reactive antibody, HLA; human leukocyte antigen, ATG; antithymocyte globulin, 
moab; monoclonal antibody, RA; receptor antagonist.
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A. Numbers at 
risk
0 1 2 3 4 5 6 7 8
SS donor, SS 
recipient
529 468 437 378 332 286 226 175 147
FS/FF donor, 
SS recipient
255 231 219 194 162 133 109 90 77
SS donor, FS/
FF recipient
247 221 209 186 162 145 121 100 83
FS/FF donor, 
FS/FF recipient
234 214 203 182 166 135 111 88 69
B. Numbers at 
risk
0 1 2 3 4 5 6 7 8
SS donor, SS 
recipient
418 360 338 303 269 235 187 150 134
FS/FF donor, 
SS recipient
206 183 176 156 137 111 94 79 66
SS donor, FS/
FF recipient
195 170 165 150 136 125 104 86 74
FS/FF donor, 
FS/FF recipient
166 149 143 134 122 103 88 68 54
C. Numbers at 
risk
0 1 2 3 4 5 6 7 8
SS donor 114 91 88 67 52 43 22 10 5
FS/FF donor 87 82 80 72 53 33 21 15 5
Figure 2: Death-censored graft survival among the four genotypic groups according to the presence or absence of 
the donor and recipient C3F allele considering all donortypes together (A) or only deceased donortypes (B). Graft 
survival was not found to be significantly different between the four genotypic groups. In recipients of a DCD 
donor kidney, superior graft survival of C3F donor kidneys can be fully attributed to the high incidence of PNF in 
recipients of a C3S donor kidney (C).
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Table 3: Multivariate analysis of the risk of primary non-function in recipients of a deceased cardiac death 
donor grafta.
Variable Odds ratio (95% CI) P value
C3FS/FF vs C3SS donor 0.130 (0.026 – 0.664) 0.014
Donor age 1.055 (1.004 – 1.108) 0.03
Recipient age 1.031 (0.981 – 1.084) 0.23
Second vs first transplantation 0.582 (0.035 – 9.594) 0.71
Cold ischemia time 1.003 (1.001 – 1.005) 0.004
First warm ischemia time 1.118 (1.018 – 1.228) 0.020
Recipient primary kidney disease 1.147 (0.887 – 1.485) 0.30
PRA percentage 0.903 (0.573 – 1.424) 0.66
HLA mismatch 1.696 (1.044 – 2.754) 0.03
aA logistic-regression model was used to determine the odds ratio for PNF. Abbreviations: CI; confidence 
interval, PRA; panel reactive antibody, HLA; human leukocyte antigen.
                            
  




Complement activation has been shown to play an important role in the pathogenesis of 
renal injury after kidney transplantation. C3 is the central complement component that is 
activated by all complement activation pathways and is therefore essential for complement 
function. Two polymorphisms, C3S and C3F, of the C3 gene have been described, resulting 
in a substitution of glycine (C3F) for arginine (C3S). Recently, two major studies by have 
been published with conflicting results regarding the protective effect of the donor C3F allele 
on renal allograft survival of deceased donor kidneys.21, 22 The present study shows that the 
C3F allele of the donor protects against PNF of grafts derived from DCD donors. Regarding 
living or DBD donors, our study confirms that the C3 allotype of the donor and recipient is 
not associated with renal allograft outcome. 
Earlier studies demonstrated that complement activation has detrimental effects on allograft 
function at different time points during transplantation. It was demonstrated in several rodent 
models that activation of the complement system is an important mediator of renal ischemia-
reperfusion injury.24, 25 Moreover in a mouse allograft model, donor kidneys from C3 deficient 
animals had superior graft survival rates compared to wild type donor kidneys.11 In contrast, 
when kidneys from wild-type mice were transplanted into C3 deficient mice, no such 
protection against transplant injury was found.12 These results indicate that not circulating C3 
in the recipient but local C3 synthesis by the donor kidney is detrimental for renal transplant 
outcome. Besides, local renal complement induction and activation can be a direct result of 
brain death in the donor which is associated with impaired renal allograft function in the 
recipient.6, 7 Complement activation also contributes to the pathogenesis of acute humoral 
rejection which is indicated by the presence of C4d in the peritubular capillaries of human 
kidney biopsies.26 Altogether, these data suggest that complement is involved in renal injury 
inherent to kidney transplantation. 
Analysis of C3 polymorphisms in both the donor and recipient is an elegant, non-invasive, 
method to study the relevance of complement in human kidney transplantation. Brown et al. 
were the first to analyze the effect of the C3 allotype and found superior graft survival rates 
of donor kidneys containing at least one C3F allele when transplanted into C3SS recipients.21 
In a separate study by Varagunam et al., comprising a much larger transplant cohort, these 
results could not be confirmed.22 Unfortunately, it is difficult to compare both studies since 
Brown et al. included only 478 kidney transplants of which approximately 75% were derived 
from deceased donors. Importantly, the protective effect of the donor C3F allele was only 
found in grafts recovered from deceased donors, not from living donors. In contrast, the study 
by Varagunam et al. included solely deceased kidney transplants of 1147 transplantations. 
Moreover, their study had follow-up data available eight years after transplantation of 35% 
compared to 7% in the study by Brown et al. Hence, the study by Brown et al. is likely 
to be underpowered and therefore a final study was required to validate the findings by 
Varagunam and coworkers. Moreover, the studies by Brown et al. and Varagunam et al. did 
not differentiate between the role of the C3 allotype of DBD and DCD donor kidneys. This 
might explain the disparity in findings since the proportion of DBD or DCD donors might be 
significantly different between both study cohorts. 
Our study comprises the largest transplant cohort of 1265 kidney transplantation. Follow-
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up data was available eight years after transplantation of 30% when all donor types are 
considered and 26% among deceased donor types. Therefore, results from our cohort are 
comparable to the study cohort of Varagunam et al. Among recipients of a living donor kidney, 
we confirmed the study of Brown et al. that no effect of the C3F allotype on graft outcome is 
seen. Considering deceased donor kidneys, our study confirms the finding by Varagunam et 
al. that donor and recipient C3 allotype does not influence PNF, DGF, acute rejection, death-
censored graft survival and patient survival. However, when similar analysis were performed 
for DCD donor types separately, the donor C3F allele was an independent protective factor 
against PNF in grafts derived from DCD donors. In agreement with the results from Brown 
et al., also a protective effect of the donor C3F allele on graft survival was found, however 
in our study these results could be fully attributed to the high incidence of PNF in recipients 
of a C3S donor kidney. 
We reason that the C3F allele is mainly protective against PNF of DCD kidneys since 
transplantation of DCD kidneys is associated with severe renal injury due to a first warm 
ischemic time and consequently substantial complement activation. Therefore, the contribution 
of the C3F allele is likely to be more significant under these circumstances. This hypothesis is 
supported by the findings of De Vries et al. who reported significant complement activation 
of the lectin pathway in DCD allografts, not occurring in DBD allografts. Strikingly, only in 
DCD kidneys suffering from PNF, massive lectin pathway activation was found which could 
not be demonstrated in DCD kidneys suffering from DGF. 27   
DCD has emerged as an important donor source to increase the number of donor kidneys. It 
is well known that DCD kidneys have a significantly inferior short-term renal function after 
transplantation with high rates of DGF and PNF.28 Inherent to DGF and PNF is a high rate 
of morbidity, prolonged hospital stay and the need for dialysis, which altogether results in 
higher costs after kidney transplantation. For these reasons, matching DCD donor kidneys 
based on C3 allotype of the donor might significantly reduce expenses in transplantation. 
Furthermore, our analysis might provide better insight into the mechanisms of short term 
DCD graft loss.
In conclusion, this study shows that the donor C3F allele protects against PNF in grafts 
derived from DCD donors. Considering living and DBD donors, our study confirms that the 
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Table 1: Donor, recipient and transplant demographics of the original group and the study group.
Variable Original group(N = 1430)
Study group
(N = 1265) P value
a
Donor characteristics









Donortype (% Living) 23 22 0.78
Recipient characteristics










HLA no. of 0
mismatches (%) 263 (22) 240 (23) 0.50
Cold ischemia timeb 1020 (33–2460) 1063 (33–2460) 0.24
aAll P values are two-sided. Mann-Whitney test for continuous variables, and Chi-square test for binary variables.
bMedian (range).
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In kidney transplantation, complement activation was found to be induced by donor brain 
death, renal ischemia-reperfusion injury and allograft rejection. There are three known 
pathways of complement activation: the classical, lectin and the alternative pathway. The 
lectin complement pathway can be activated upon pattern recognition by mannan binding 
lectin (MBL) or ficolins. Single nucleotide polymorphisms (SNPs) in the genes encoding the 
lectin pathway proteins determine their functional activity and serum levels. The aim of this 
study was to investigate the role of the lectin gene profile of the donor and recipient on post-
transplant outcome.
Material and methods
A total of 12 functional SNPs in the MBL2, FCN2 and MASP2 genes of 1271 donor-recipient 
pairs were determined. Lectin genotypic variants were analyzed for association with primary 
non-function (PNF), delayed graft function (DGF), biopsy proven acute rejection, death-
censored graft survival and patient survival. 
Results
No association was found between the MBL2 or MASP2 genotype of the donor and recipient 
and allograft outcome. Analysis of separate functional SNPs and haplotypes in the FCN2 
gene of the donor and recipient did not reveal an effect on transplant outcome. Also, the joint 
effect of the MBL2 and FCN2 genotype was not associated with allograft outcome.  
Conclusion
This study shows that the genetic profile of the lectin pathway of complement activation of 
the donor and recipient does not influence allograft outcome after kidney transplantation. Our 
study is preliminary and the results need to be confirmed by other studies.
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Introduction
The complement system is part of the innate immune system and has been shown to play 
an important role in the pathogenesis of renal injury inherent to kidney transplantation. 
Complement can be activated at different time points during transplantation namely by donor 
brain death, renal ischemia-reperfusion injury (IRI) and allograft rejection (1-4).
There are three known pathways of complement activation: The classical, lectin and the 
alternative pathway. The lectin pathway is activated when mannose-binding lectin (MBL) 
and/or ficolins interact with carbohydrate ligands. MBL and ficolins are liver-synthesized 
complement proteins, which recognize carbohydrates structures on microbial surfaces and 
altered self-surfaces (5). Subsequently, MBL-associated serine proteases 2 (MASP2) are 
activated which leads to cleavage of C4 and C2, thereby activating the complement cascade 
through generation of a C3 convertase. This ultimately leads to generation of anaphylatoxins 
(C3a, C5a) and formation of the membrane attack complex (MAC), which is a large pore on 
the target cell surface leading to cell death (6;7). 
Within the general population, there is a large interindividual variation in serum MBL 
concentration and activity. Serum MBL concentration is largely determined by genetic 
polymorphisms within the MBL2 gene. Within the coding region, three missense mutations 
within the first exon (+154 C>T, +161 G>A, +170 G>A) of MBL2 significantly affect MBL 
function and levels. These common polymorphisms impair the assembly of a monomeric 
MBL into functional multimeric proteins resulting in low serum level of MBL. Furthermore, 
three polymorphisms described in the promoter region also affect serum MBL levels (-619 
C>G, -290 G>C, -66 C>T). Relative MBL deficiency occurs in almost one half of the white 
population (8). 
Also ficolin-2 (L-ficolin) serum concentrations are significantly affected by polymorphisms 
in the FCN2 gene. Three single nucleotide polymorphisms (SNPs) in de promoter (-986A>G, 
-602G>A, -4A>G) and one in exon 8 (+6424 G>T) have been described, thereby significantly 
affecting serum ficolin-2 levels. Besides, two SNPs in exon 8 (+6359 C>T, +6424 G>T) 
have been shown to give respectively decreased or increased binding capacity towards 
N-acetylglucosamine compared to wildtype genotypes (9). Additionally, a SNP in the MASP2 
gene (D105G) significantly decreases serum levels of MASP2 (10).
MBL deficiency has been associated with a high prevalence of certain infections, especially in 
already immuno-compromised patients such as patients undergoing transplantation (11;12). 
On the contrary, low MBL levels might also prevent tissue injury by interrupting activation 
of the lectin pathway, for example in renal IRI (13;14). In human kidney transplantation, 
Berger et al. recently found an association between high recipient pre-transplant MBL level 
and inferior graft survival rates after transplantation (15;16). Besides, rodent studies have 
indicated an important role of MBL in renal IRI (14;17). 
We hypothesized that kidney donors or recipients with genotype determined high lectin 
levels show inferior transplant outcomes compared to genotype determined low lectin level 
producers.
The aim of this study was to investigate the role of the lectin pathway of complement by 
association of donor and recipient MBL2, FCN2 and MASP2 genotypes on post-transplant 




Patients and study design
Between March 7, 1993 and February 12, 2008, 1430 patients underwent kidney transplantation 
at the University Medical Center Groningen, The Netherlands. From this original group, 
90 patients were excluded because of three or more kidney transplantations, simultaneous 
transplantation of other organs (pancreas, liver, lung and intestine) and technical problems 
during the operation. A total of 4 patients were lost to follow-up and of 65 transplantations 
no donor and recipient DNA pairs were available (Figure 1). Informed consent was given by 
all patients. Donor, recipient and transplant characteristics were obtained and documented.
DNA isolation and genotyping
DNA was extracted from peripheral blood samples or splenocytes from deceased donors 
using a commercial kit following the manufacturer’s instructions. A total of 12 SNPs in the 
MBL2, FCN2 and MASP2 genes were genotyped (Table 1). Genotyping of the selected SNPs 
was performed using the Illumina VeraCode GoldenGate Assay kit (Illumina, San Diego, CA, 
USA), according to the manufacturer’s instructions. Genotype clustering and calling were 
performed using BeadStudio software (Illumina). Three SNPs in the MBL2 gene (rs5030737, 
rs1800450 and rs1800451) were readily ordered (Applied Biosystems Assay-on-Demand) 
and genotyped on an ABI7900HT platform following the manufacturers’ instructions.  
Haplotype reconstruction was performed using the PHASE algorithm (18).
Figure 1: Kidney transplantations that were included and excluded from the study.
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Study end-points
The primary end points in this study were: primary non-function (PNF, defined as non-
functioning of the allograft from transplantation on), delayed graft function (DGF, defined as 
the requirement for dialysis within the first week after transplantation), biopsy proven acute 
rejection (all biopsies were re-evaluated according to the Banff 2007 classification) during 
the first year after transplantation, death censored graft survival (defined as the need for 
dialysis or re-transplantation) and patient survival. 
Statistical analysis
Statistical analyses were performed using SPSS (version 18.0) and two sided P values 
under 0.05 were considered to indicate statistical significance. To compare four genotypic 
groups, the Kruskal-Wallis test was performed for continuous variables and the Chi-square 
test for categorical variables. The Mann-Whitney U test was applied to compare continuous 
variables between two genotypic groups. Kaplan-Meier survival curves and logrank tests 
were performed between groups to assess the difference in death censored graft survival rates 
or patient survival. Survival results were adjusted for potential confounder by multivariate 
Cox regression analysis. Categorical outcome variables were adjusted using multivariate 
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Table 1: Allele and genotype frequencies of the MBL2, FCN2 and MASP2 variants. 




Donor, recipient and transplant characteristics of the 1271 kidney transplantations included in 
our study did not differ significantly from the original group of 1430 transplantations. Table 
1 shows the frequencies of the MBL2, FCN2 and MASP2 variants in our study population. 
Genotyping of the 12 selected SNPs was successful in >97% except for rs3124952 in the 
recipient (83%). The minor allele frequencies (MAFs) of all SNPs were similar to those 
previously reported in Caucasians and in accordance with the Hardy-Weinberg equilibrium 
(19-22)
Since MBL and ficolin-2 serum levels are largely determined by the MBL2 genotype and 
FCN2 haplotype, these were reconstructed from the genotype data of the different MBL2 and 
FCN2 SNPs. MBL2 genotype and FCN2 haplotype frequencies were in agreement with those 
reported by others (Table 2 and 3).









FCN2 AGGTG High 0.261 0.264
AAACG High 0.193 0.188
GGACG Medium 0.349 0.352
AGACG Medium 0.041 0.029
GGATG Medium 0.013 0.019
GGACT Low 0.118 0.129
MBL2 GGCCGG HYPA High 0.292 0.288
CGTCGG LYQA Medium to high 0.207 0.225
CGCCGG LYPA Medium to high 0.057 0.068
CCCCGG LXPA Medium to high 0.209 0.207
GGCTGG HYPD Deficient 0.078 0.070
CGCCAG LYPB Deficient 0.113 0.111
CGTCGA LYQC Deficient 0.023 0.018
Table 3. MBL2 genotypes and their frequencies among high producing (HP), low producing (LP) and deficient 
MBL genotypes. Patients were stratified according to three models: Patients were divided based on the presence or 
absence of the “O” allele (Model A). Patients were divided into MBL deficient genotypes (LXA/O and O/O) and 
MBL sufficient genotypes (all other variants) (Model B). Patients were divided into high producing (HP) versus 






A B C Donors Recipients
HYA/HYA






LP Low 397 (31%) 380 (30%)HYA/O
LYA/O
LXA/O
DF Deficient 175 (14%) 162 (13%)O/O
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MBL2 genotypes and graft outcome
Donors and recipients were divided into high, medium and low producing MBL genotypes as 
previously proposed by others (Table 3) (8). Subsequently, patients were stratified according 
to three models (Table 3): In the first model (A), patients were divided based on the presence 
or absence of the “O” allele. The O allele represents one of the structural variants (D, B, C) 
in exon 1, which has shown to be highly associated with decreased plasma levels of MBL. 
In the second model (B), patients were divided into MBL deficient genotypes (LXA/O and 
O/O) and MBL sufficient genotypes (all other variants). In the third model (C), patients were 
divided into high producing (HP) versus low producing (LP) and deficient MBL genotypes. 
When patients were stratified according to all three models, no association was found between 
the donor or recipient MBL2 genotype and all transplant outcome parameters. Table 3 shows 
the donor, recipient and transplant characteristics when donors and recipients were stratified 
according to model A, with a combined evaluation of donor-recipient MBL genotype pairs. 
Univariate analysis revealed no difference in graft outcome between the four genotypic 
groups, except for PNF (Table 4). Since several baseline characteristics were significantly 
different between the four genotypic groups (donor sex, donor type, cold ischemia time, 
HLA mismatch), a multivariate model was build taken these and other variables into account. 
Also multivariate analysis did not show a significant association between donor or recipient 
MBL genotype and graft outcome, except for PNF (Table 5). The significant difference in 
PNF was found in O allelic recipients of an AA donor kidney. However, significance was lost 
in a separate analysis when transplants were divided by the donor O allele (AA or AO/OO 
donor) or the recipient O allele (AA or AO/OO recipient). Additionally, when high producing 
MBL genotypes were compared with deficient MBL genotypes (“extremes”) no significant 
association was found with PNF or other outcome parameters (data not shown).
FCN2 SNP analyses and graft outcome
To investigate the role of ficolin-2 in human kidney transplantation, the five functional SNPs 
in the FCN2 gene of the donor and recipient were separately associated with graft outcome 
(Table 1). Separate analysis of the five selected SNPs of the donor and recipient revealed no 
association with allograft outcome for all outcome parameters (data not shown).
 
FCN2 haplotype analyses and graft outcome
In addition to single locus analysis within the FCN2 gene, reconstruction of the FCN2 
haplotypes might reveal association with outcome. Six common haplotypes (frequencies 
> 1%) were reconstructed from the SNP genotype data (Table 2). Haplotype frequencies 
were in agreement with previously reported findings in Caucasians (22;23). In line with the 
separate SNP analysis, also haplotype association of the donor or recipient did not show any 
association with graft outcome. Until now, only diplotypes have previously been shown to be 
associated with increased or decreased ficolin-2 levels. Therefore, donors as well as recipients 
were divided into low producing (LP; GGAG and GGAT diplotypes) and high producing 
(HP; AAAG and AGGG diplotypes) groups, based on the publication by Munthe-Fog et 
al (22). Because of the low number of patients who were homozygous for all four SNPs, 
diplotype association could only be performed for donors and recipients separately. Table 
6 shows the donor, recipient and transplant characteristics stratified according to LP or HP 
producing FCN2 diplotype. In concordance with the separate SNP and haplotype tanalysis, 
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FCN2 diplotypes of the donor or the recipient was not associated with graft outcome for 
all outcome parameters. Since lack of association was found by univariate analyses, no 
multivariate analysis was performed.
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Table 4: Donor, recipient and transplant characteristics and transplant outcome of the four genotypic groups 





























               Living
               DBD
               DCD 
120 (25)
274 (58)
79   (17)
52   (19)
184 (63)
44   (18)
42   (15)
198 (69)
48   (17)
68   (30)
131 (57)
31   (14)
0.001
Recipient characteristics












PRA level >5% (%) 12 13 14 10 0.54





48   (10)
249 (89)
31   (11)
259 (90)
29   (10)
210 (91)
20   (9) 0.85










83   (18)
56   (12)
44     (9)
38     (8)
59   (12)
16     (3)




26   (9)
19   (7)
28 (10)






17   (6)
34 (12)
13   (5)




20   (9)
24 (10)
27 (12)


























27     (6)
46   (10)
45   (10)
2       (0)
71   (15)




24     (9)
15     (5)
20     (7)
6       (2)
38   (14)




9       (3)
20     (7)
26     (9)
8       (3)
52   (18)




12     (5)
16     (7)
12     (5)
3       (1)
38   (17)











Cold ischemia timeb 18 (1-40) 18 (2-41) 19 (1-40) 16 (2-38) 0.007
HLA no. of 0 mismatches 
(%) 107 (28) 49 (20) 60 (24) 25 (14) 0.002
Transplant outcome
Primary non-function 
no. (%) 17 (4) 16 (6) 22 (8) 5 (2) 0.013
Delayed graft no. (%) 153 (32) 97 (35) 99 (34) 66 (29) 0.47
Biopsy proven acute 
rejection
(first year) no. (%)
Overall
Borderline
Banff IA or IB
Banff IIA, IIB, III
150 (32)
48     (7)
64   (14)




25   (9) 
82 (28)
20   (7)
38 (13)




19   (8)
0.74
Death censored graft 
failure no. (%)
77   (16) 47 (17) 57 (20) 34 (15) 0.38
Death no. (%) 77 (16) 49 (18) 56 (19) 38 (17) 0.32
aAll P values are two-sided. Kruskal-Wallis test for continuous variables, and Chi-square test for binary variables.
bMedian (range).
Abbreviations: PRA; panel reactive antibody, HLA; human leukocyte antigen, ATG; antithymocyte globulin, 































































































































































































































































































































































































































































































































































































































































Table 6: Donor, recipient and transplant characteristics and transplant outcome of low producing (LP) versus 
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               DBD
               DCD 
38   (23)
100 (60)
29   (17)
7   (17)
29 (71)
5   (12)
0.44 39   (22)
109 (62)



















PRA level >5% (%) 14 7 0.25 14 6 0.04





22   (13)
37 (90)
4   (10)
0.55 162 (92)
15     (9)
123 (92)
11     (8)
0.93













14   (8)
17 (10)
2     (1)
23 (14)
33 (20)
8   (20)
3     (7)
3     (7)
1     (2)
3     (7)
1     (2)




















   7 (5)
  12 (9)
  12 (9)

























8       (5)
12     (7)
16   (10)
3       (2)
27   (16)




4   (10)
3     (7)
4   (10)
2     (5)
5   (12)













4       (2)
8       (5)
16     (9)
1       (1)
34   (19)
1       (1)
129 (96)
  98 (73)
117 (87)
8       (6)
11     (8)
10     (8)
1       (1)
21   (16)











Cold ischemia timeb 17 (2-37) 21 (2-36) 0.11 17 (2-39) 18 (2-38) 0.75
HLA no. of 0 mismatches 
(%)
33 (25) 10 (28) 0.70 32 (23) 24 (21) 0.83
Transplant outcome
Primary non-function no. 
(%)
9 (5) 3 (7) 0.64 11 (6) 3 (2) 0.09
Delayed graft no. (%) 71 (43) 13 (32) 0.21 59 (33) 45 (34) 0.96
Biopsy proven acute 
rejection
(first year) no. (%)
Overall
Borderline
Banff IA or IB




15   (9)
11 (27)
3     (7)
6   (15)




13   (7)
46 (34)




Death censored graft 
failure no. (%)
33 (20) 11 (27) 0.23 32 (18) 21 (16) 0.38
Death no. (%) 28 (17) 5   (13) 0.71 25 (14) 20 (15) 0.73
aAll P values are two-sided. Mann-Whitney test for continuous variables, and Chi-square test for binary variables.
bMedian (range). 
Abbreviations: PRA; panel reactive antibody, HLA; human leukocyte antigen, ATG; antithymocyte globulin, moab; 
monoclonal antibody, RA; receptor antagonist. LP; Low producing diplotypes, HP; high producing diplotypes
156
MASP2 single locus analyses and graft outcome
The D105G SNP in the MASP2 gene causes an exchange of aspartic acid with a glycine at 
position 105 which leads to a MASP2 deficiency in the plasma (10). MASP2 plays a pivotal 
role in lectin pathway activation and therefore we also analyzed the effect of the MASP2 SNP 
for association with transplant outcome. The D105G SNP frequency was found to be 5% in 
donors and 4% in recipients, which is in agreement with those found by others in Caucasians. 
In line with the findings in the MBL2 and FCN2 genes, no association was found between the 
MASP2 D105G SNP and transplant outcome (data not shown).
Lectin gene profile and graft outcome
In a final attempt to assess an association between lectins and graft outcome, we investigated 
whether the joint effects of the MBL2 and FCN2 gene variants of the donor or recipient 
influenced graft outcome. Donors and recipients were stratified according to the presence of 
both the HP FCN2 diplotype and HP MBL genotype and compared with patients having both 
LP FCN2 diplotype and LP MBL2 genotype. In line with our previous finding, no influence 
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Discussion
Complement activation has been shown to play a substantial role in renal injury inherent to 
kidney transplantation. Besides classical and alternative pathway activation, complement can 
be activated through the lectin pathway upon binding of ficolins and MBL with carbohydrates 
and subsequent activation of MASP2. There is growing evidence that the lectin pathway is 
significantly involved in the course of renal IRI and allograft rejection (14;15;17). In contrast, 
the present study shows that genetic variation in the donor and recipient MBL2, FCN2 
and MASP2 genes, thereby significantly affecting their protein functions and levels, is not 
associated with allograft outcome after kidney transplantation.
Renal IRI is an inevitable consequence of kidney transplantation and several groups have 
clearly demonstrated a crucial role for complement activation in the course of renal IRI (2). 
Mice knock-out models have revealed involvement of the alternative pathway, whereas the 
classical pathway is unlikely to play a role in renal IRI (2;26). Besides alternative pathway 
activation, also the lectin pathway is involved in renal IRI since MBL-A and MBL-C deficient 
mice are partially protected against renal IRI (14). In addition to the findings in rodents, renal 
MBL deposition was also demonstrated in a swine model of IRI (13). In humans, MBL 
deposition has been demonstrated in patients suffering from DGF and PNF after kidney 
transplantation (13;17). 
Berger et al. found a significant association between high pre-transplant serum MBL levels 
in the recipient and rejection associated graft loss after kidney transplantation (15). In their 
study, patients were stratified according to a cut-off of 400 ng/ml since levels below have 
earlier been shown to be closely related to MBL variant alleles A/O and O/O, whereas MBL 
levels above 400 ng/ml were related to MBL wild type A/A. Unfortunately, Berger et al. did 
only determine serum MBL levels, whereas no genotyping was performed due to the lack of 
DNA. They were able to confirm their results in patients undergoing simultaneous pancreas-
kidney transplantation. Although the recipient MBL genotype was an independent predictor 
for patient survival, the association between graft survival and the MBL genotype was not 
shown (16). 
The disparity between our findings and the study by Berger et al. might be explained by the 
fact that Berger et al. did not determine functional serum MBL levels. Functional serum MBL 
levels are determined by an enzyme-linked immunosorbent assay (ELISA) in which MBL 
is captured by a mannan-coated plate. In this assay, only high order MBL oligomers will 
be detected since only these are capable of binding to mannan. In contrast, low order MBL 
oligomers will not bind mannan. Instead, Berger et al. determined serum MBL concentrations 
by an ELISA using the mAb 3E7 capture antibody. This assay is designed to measure whole 
MBL (low and high order oligomers) concentration, instead of functional MBL levels. In 
support of their findings, their group has clearly demonstrated a direct association of their 
assay with the MBL genotype and function in healthy individuals. However, it is unlikely that 
this can be extrapolated to renal transplant recipients since functional serum MBL levels are 
severely reduced in patients undergoing dialysis compared to healthy controls (27). In fact, 
Satomura et al. have found even higher MBL levels in dialysis patients compared to controls 
using an ELISA technique similar to Berger et al (28). 
In favour of our study, serum MBL levels in dialysis patients are still largely determined by 
the MBL genotype and therefore MBL genotyping is likely to be a more suitable approach to 
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investigate the role of MBL in kidney transplantation. Moreover, our study comprises a much 
larger transplant cohort (n=1271) compared to the study by Berger et al. (n=266). Notably, 
the association of Berger et al. was only found in deceased donor grafts. However, in separate 
analyses of only deceased donors, we also found no association of the lectin gene profile with 
graft outcome (data not shown). 
The lack of association between MBL genotypes and graft outcome is strengthened by the lack 
of association of the FCN2 genotype on graft outcome. Ficolin deposition has previously been 
demonstrated in C4d positive kidney biopsies of ABO-incompatible transplants and during 
acute rejection episodes (29). In contrast, we found no association between five functional 
SNPs in the FCN2 gene with acute rejection or other transplant parameters. L-ficolin serum 
levels are closely related to four functional SNPs in the FCN2 gene. However, haplotype 
reconstruction has previously revealed a significant contributing effect of the +6424 SNP 
on the -986 SNP thereby severely decreasing L-ficolin serum concentrations. Haplotype 
analysis reflects the natural situation in individuals much better and is therefore likely to be 
a more useful tool for association studies compared to FCN2 single locus analysis. Besides 
separate analysis of the FCN2 SNPs, also haplotype and diplotype analysis did not reveal 
any association with graft outcome. Moreover, also no difference in graft outcome was found 
between donor and recipients with a combined high MBL2 and FCN2 genotype compared to 
patients with both a low MBL2 and FCN2 genotype.
Previous studies have indicated a relation between MBL and the prevalence of renal diseases, 
for instance IgA and diabetic nephropathy (30-32). In our study population, the MAFs of the 
determined SNPs in the MBL gene, as well as the haplotype and genotype frequencies were 
similar in donors as well as recipients. Therefore it is unlikely that the MBL genotype has a 
major impact on the development of end-stage renal disease.
In conclusion, this study shows that the genetic profile of the lectin pathway of complement 
activation of the donor and recipient does not influence allograft outcome after kidney 
transplantation. Although our study has to be confirmed in other transplant cohorts, our 
large study cohort and the lack of association of both MBL and ficolin genotypes with graft 
outcome suggests a minor role for the lectin pathway on allograft outcome.
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Although patients with end-stage renal disease can be maintained with dialysis therapy, the 
superiority of patient survival with renal transplantation makes transplantation the preferred 
method of renal replacement therapy. Although kidney transplantation has become the first 
choice of treatment for these patients, due to donor organ shortage, patients are still dying on 
the waiting list. The major donor pool consists of kidneys recovered from deceased brain-
dead donors (DBD) although living donation and donation after cardiac death (DCD) have 
emerged as alternative sources. Long-term renal allograft survival of deceased donor kidneys 
is determined by different variables including donor condition and age, kidney preservation 
methods, human leukocyte antigen matching, duration of cold and warm ischemia, reperfusion 
injury and acute rejection (1-3). Independent from these variables, the state of brain death 
(BD) in the donor has been established as a risk factor affecting transplant outcome. Kidneys 
from brain-dead donors have an inferior transplant function, decreased survival rates and 
a higher risk to develop acute rejection as compared to kidneys obtained from healthy 
living (un)related donors (4;5). During the last decades, several groups have focused on the 
influence of donor BD on kidney graft viability and survival rates after renal transplantation 
in experimental and clinical settings. Our group and others have observed systemic and local 
immune activation after BD which might be, at least in part, responsible for the renal injury 
found in brain-dead donors (6;7). We hypothesized that a substantial part of this inflammatory 
response can be ascribed to activation of the complement system which has been shown 
to play an important role in the pathogenesis of renal transplant related injury. This thesis 
focuses on complement mediated renal injury of deceased donor kidneys in experimental and 
clinical kidney transplantation.
In Chapter 1, the current knowledge of complement activation in cellular and humoral 
rejection, renal ischemia-reperfusion injury (IRI) and donor BD is outlined. During humoral 
rejection, the interaction between B-cell responses and classical complement pathway 
activation has been acknowledged by the presence of C4d-positive peritubular capillaries 
(8). Cellular rejection is likely to be mediated by complement through activation of antigen 
presenting cells (APCs). C3 deficient APCs have an impaired potency to stimulate allo-
reactive T-cells. Also, C3a and C5a are able to regulate the T-cell response by stimulation of 
APCs through the C3a and C5a receptor (9;10). 
Renal IRI is an inevitable consequence of kidney transplantation. In mice it was demonstrated 
that deficiency of C3, C5 and C6 significantly reduced renal IRI. Evidence exists that both 
C5a and the membrane attack complex are involved in the pathogenesis of renal IRI (11;12). 
In experimental renal transplantation, a major breakthrough was the finding that absence 
of donor C3 in transplanted renal allografts greatly improved kidney allograft survival 
after transplantation. In contrast, when kidneys from wild-type mice were transplanted into 
C3 deficient recipients this was not found to be protective. These results indicate that not 
circulating C3 in the recipient but locally produced C3 by the donor kidney is an important 
mediator of renal transplant related injury (13;14). These results put the role of complement 
activation in an importantly different perspective, as now the donor is such an important 
factor since most organs are not derived from living, but deceased donors. In this review 
the first results are shown that complement is activated as a direct consequence of BD in 
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the donor. Modulation of complement activation in the donor or recipient by complement 
regulator proteins or antibodies against complement components or receptors might be a 
promising approach to improve renal allograft outcome after transplantation. 
Complement activation has shown to be one of a number of factors to participate in renal IRI. 
Also other pathways of the innate immune system, such as Toll-like receptors (TLRs) have 
shown to be responsible for renal IRI (15;16). It is suggested that a crosstalk exists between 
the complement and TLR pathways, thereby orchestrating immune responses with a high 
specificity. In Chapter 2 the innate immune interplay between the complement system and 
TLRs in relation to the pre-transplant renal injury by donor BD and early post-transplant 
renal IRI is outlined. It is suggested that mitogen activated protein kinases might be the key 
molecules linking both the complement and TLR pathways together. As shown for several 
complement components, also knock-outs for TLR2 and TLR4 are protected against renal 
IRI. In the donor, TLR4 and several of its major ligands (heat shock proteins, high-mobility 
group protein B1) are locally upregulated or systemically elevated (lipopolysaccharide) in 
serum by BD (17;18). Based on these findings, future strategies to target complement and 
TLR activation in kidney transplantation could be considered. Treatment of the donor as 
well as the recipient before transplantation might therefore be beneficial for renal transplant 
outcome. These two chapters are followed by Chapter 3 which comprises a general rationale, 
outlining the chapters of this thesis.
In Chapter 4, the nature and extent of the inflammatory response after experimental and 
clinical BD was investigated. Briefly, BD was induced in rats by inflation of an intracranial 
balloon catheter. Animals were sacrificed respectively 0.5, 1 and 4 hours after BD and sham-
operated rats served as controls. In humans, blood samples were obtained from brain-dead 
donors directly after the declaration of BD and just before start of cold organ perfusion, at 
the moment of donation. In living donors, baseline serum samples were obtained before 
start of operation and a second sample before nephrectomy. A similar cytokine pattern was 
seen in the serum of rat and human brain-dead donors with strongly elevated levels of IL-6, 
IL-8 and MCP-1 after BD while IL-1beta and TNF-alpha were not elevated. Since IL-6 is 
the main regulator of the acute phase response (APR) we examined the expression of acute 
phase proteins (APPs) both in the liver and kidney after BD in the rat. Liver and kidneys 
showed a significant upregulation of APP gene expression after 4 hours of BD compared 
to sham-operated animals. Complement C3 was significantly upregulated after 4 hours of 
BD in the donor. Interestingly, after transplantation of BD kidney grafts, no additional C3 
expression was found after transplantation. In contrast, after transplantation of living grafts, 
C3 induction was found to be upregulated, indicating the substantial induction of C3 by donor 
BD. In humans, similar results were found as in rodents, with higher gene expressions of C3 
and a stronger deposition of C3d in kidney biopsies taken before organ recovery from brain-
dead donors. No additional renal C3 expression was found after cold ischemia or reperfusion 
upon the induction of C3 by BD. Interestingly, already in this small group of patients, a 
significant association was found between C3 expression in reperfusion biopsies of BD grafts 
and reduced renal allograft function shortly after transplantation. To investigate a possible 
mechanism through which C3 might be induced in the kidney, tubular cells were stimulated 
with IL-6, IL-8 and MCP-1 to see whether these cytokines were able to induce C3 from renal 
cells. It was found that only IL-6 could induce C3 in vitro, suggesting that IL-6 might be 
responsible for C3 induction during BD. 
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So far only the influence of local C3 induction in deceased donors on graft outcome in the 
recipient was investigated. However, activation of circulating complement, and thereby 
release of complement split products, might also affect renal allograft viability and graft 
outcome in the recipient. It was already known that traumatic brain injury and stroke can 
activate systemic complement in animals and patients. We hypothesized that brain damage 
and BD in the donor results in activation of systemic complement thereby generating C3a, 
C5a and C5b-9. Subsequently, these inflammatory mediators can exert direct effects on 
renal endothelium and tubular epithelium. This might provoke an inflammatory response 
leading to an inferior transplant outcome in the recipient after transplantation. In Chapter 5, 
we measured levels of C4d, Bb, C5b-9 and complement component MBL in 232 deceased 
donors. It was found that complement is significantly activated in the plasma of both DBD 
and DCD donors. Moreover, high donor C5b-9 level is independently associated with acute 
rejection in the recipient. Most interestingly, a higher degree of vascular rejection was found 
in a subset of recipients of which the allograft was exposed to high C5b-9 levels in the donor. 
These results indicate that not only local, but also systemic complement activation in the 
donor is associated with inferior renal allograft outcome. In Chapter 6 we investigated the 
mechanisms through which local and systemic complement activation in the donor affects 
outcome in the recipient. First we showed by a functional assay that systemic complement 
activation in brain-dead donors leads to reduced functional complement activity in human 
brain-dead donors. A proposed mechanism through which systemic complement increases 
immunogenicity of the graft to-be is the release of C5a with subsequent activation of the renal 
C5a receptor (C5aR). It was found that the C5aR is significantly upregulated in kidneys from 
brain-dead donors compared to living donors prior to organ recovery. Immunohistochemistry 
confirmed an increased expression on protein level and revealed that the C5aR was primarily 
localized on the distal tubular epithelium. The combined effect of increased local and systemic 
complement activation and upregulation of the C5aR might be a possible mechanism through 
which systemic complement can increase graft immunogenicity in the donor, leading to acute 
rejection in the recipient. 
In Chapter 7, the hypothesis was validated that complement activation in brain-dead 
donors is an important mediator of transplant outcome in the recipient. In rat brain-dead 
donors, complement activation was inhibited at the level of C3 by administration of soluble 
complement receptor 1 (sCR1). It was found that treatment of the donor one hour before 
or one hour after BD prevents BD-induced systemic complement activation. Importantly, 
renal function was found to be significantly better after transplantation of sCR1 treated donor 
grafts. At day 7 after transplantation, gene expression levels of inflammatory genes were 
significantly decreased. In contrast, acute rejection on day 7 in the recipient could not be 
prevented by sCR1 treatment of the donor. Long term follow-up studies have to investigate 
the influence of this short-term effect of complement inhibition in the donor on renal allograft 
survival and chronic rejection. This could reveal the major effects of early complement 
activation in the donor on longterm renal allograft loss in the recipient.
Although studies on the role of complement in renal transplantation are interesting, most studies 
have been performed in animals. Only few studies have focused on the role of complement 
in clinical renal transplantation. Analyzing the influence of donor and recipient C3 allotypes 
on renal transplant outcome is an elegant, non-invasive, method to study the effects of 
complement activation in human kidney transplantation. Contradictory results were reported 
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about the protective effects of the donor C3F allele on transplant outcome of deceased donor 
kidneys (19;20). Since local and systemic complement are significantly activated in DBD as 
well as DCD donors, the disparity between the previous studies might be explained by an 
unequal distribution of both donor types among the study cohorts. Therefore, in Chapter 8, 
the influence of the donor C3F allotype on renal transplant outcome was investigated, thereby 
taking all donor types into account. It was found that the donor C3F allele protects against 
primary non-function (PNF) in grafts derived from DCD donors. Moderate or severe vascular 
rejection (Banff IIA, IIB, III) was the main cause of PNF in these patients. Also, the incidence 
of acute vascular rejection was significantly higher in the first year after transplantation in 
recipients of a C3SS compared to C3F allelic DCD donor kidneys. No association was found 
between C3F donor allotype and all other outcome parameters. Considering living and DBD 
donortypes, we confirm that the C3 allotype of the donor and recipient is not associated with 
renal allograft outcome. However, one should be careful in the interpretation of the finding 
that allotypic variants of C3 do not affect renal allograft survival. The absence of an effect of 
the C3 polymorphism does not imply that other aspects of C3, such as expression, function, 
or local production, are irrelevant in the outcome of renal transplantation. 
There is growing evidence that the lectin pathway is involved in complement activation 
during renal transplantation. Mouse knock-out models have revealed an important role of 
mannan bindin lectin (MBL) in renal IRI (21). Also in clinical renal transplantation, high pre-
transplant recipient MBL was associated with increased renal allograft loss (22;23). Within 
the general population, there is a large interindividual variation in serum MBL concentration 
and activity. Serum MBL concentration is largely determined by genetic polymorphisms 
within the MBL2 gene (24). Also ficolin-2 (L-ficolin) and MBL-associated serine proteases 2 
(MASP2) serum concentrations are significantly affected by polymorphisms in the FCN2 and 
MASP2 genes (25;26). Therefore, analysis of MBL2, FCN2 and MASP2 polymorphisms of 
the donor and recipient could reveal the importance of the lectin pathway on allograft outcome 
after kidney transplantation. In Chapter 9 donor and recipient polymorphisms in the MBL2, 
FCN2 and MASP2 genes were determined in a large renal transplant cohort. No association 
was found between the MBL genotype of the donor and recipient and allograft outcome. 
Separate analysis of genotypes and haplotypes in the FCN2 of the donor and recipient gene 
did not reveal an effect on transplant outcome. Also, the joint effects of the MBL genotype 
with the FCN2 diplotype did not show association with allograft outcome. Although our 
study has to be confirmed by others, the large cohort size and lack of association of both MBL 
and ficolin genotypes with graft outcome suggests a minor role for the lectin pathway in renal 
allograft outcome.
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Future perspectives
This thesis shows that complement is not only activated during renal IRI but already by BD in 
the donor prior to organ recovery. These results put complement activation after cold ischemia 
and reperfusion, as demonstrated by others, in an importantly different perspective. Not 
cold ischemia and/or reperfusion are the main triggers of complement induction in brain-
dead donor kidneys but the non-physiological state of BD itself. This result changes the 
field of intervention research in brain-dead donors in a crucial way. The best way to target 
complement activation when grafts are recovered from brain-dead donors would be already 
in the intensive care unit (ICU) instead of during organ preservation or in the recipient. 
Our first complement intervention study described in this thesis is promising, since not 
only pre-treatment, but also after-treatment of the donor, 1 hour after the diagnosis of BD, 
improved renal function after transplantation. Obviously, from a clinical point of view, one 
would treat a donor after the diagnosis of BD as part of the standard donor management in the 
ICU. Before such clinical studies can be initiated, we need to know more about the extent and 
nature of complement activation in clinical renal transplantation and the association with graft 
function and survival. This could be investigated by micro-array analysis of renal biopsies 
obtained from a large cohort of renal transplants. Such analysis would give us more insight 
into possible drug targets in complement pathways to improve allograft outcome of kidneys 
from human deceased donors. Ultimately, randomized controlled trials in renal transplant 
donors and recipients have to be initiated using a complement inhibitor versus placebo. 
Several strategies targeting the complement system might be promising in reducing renal 
allograft injury with subsequent improvement of transplant outcome. The complement 
activation cascade can be targeted at different levels to attenuate complement mediated injury 
by using for example soluble complement regulator proteins, antibodies against complement 
components or their split products or complement receptor antagonists. Only few of these 
agents have been used in patients for other indications than kidney transplantation. The C1-
esterase inhibitor is currently approved for routine prophylaxis in patient with hereditary 
angioedema. The C1-esterase inhibitor inactivates C1r and C1s proteases in the C1 complex 
and MASP1 and 2 in the MBL complex. It thereby blocks both the classical as well as the 
lectin pathway of complement activation. Furthermore, and most interesting, it also inhibits 
proteases of the fibrinolytic, clotting and kinin pathways. Therefore, C1-esterase inhibitor is 
likely to be beneficial for graft outcome due to its pleiotropic functions (27). 
Another therapeutic option might be the use of a C5-inhibitor which is currently being 
registered for the treatment of paroxysmal nocturnal hemoglobinuria (PNH). It is a monoclonal 
antibody directed against complement C5 and thereby blocks the conversion to C5a and C5b 
by the C5-convertase (28). Downstream C5 blockade is more favourable, leaving most of 
the complement pathways intact because of the beneficial functions of complement in host 
defence.
A major problem in modulating complement activation by the currently available agents 
is substantial systemic complement inhibition which increases susceptibility to infection. 
Furthermore, the importance of complement in the maintenance of tolerance is affected by 
treatment of the recipient with complement inhibiting agents. Therefore, recently, targeted 
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inhibitors have been developed which have been shown to target specifically to sites of 
complement activation. These inhibitors are therapeutically effective at concentrations that 
do not significantly affect systemic complement activity or susceptibility to infection (29). 
Moreover, such fusion-proteins have recently been shown to protect against cardiac ischemia-
reperfusion injury (30).
Conclusions
Complement activation plays an important role in the pre-transplant renal injury induced 
by donor BD and early post-transplant renal injury as a result of renal IRI. Both local renal 
and systemic complement becomes activated by donor BD and is associated with reduced 
renal allograft outcome after transplantation. Targeting complement activation in brain-dead 
donors improves renal function after transplantation in the recipient. In humans, randomized 
clinical trials have to explore whether complement inhibition in brain-dead donors as well as 
the recipient improves renal allograft outcome after kidney transplantation. 
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Niertransplantatie is de eerste keus behandeling voor patiënten met eindstadium nierfalen, 
maar door het tekort aan orgaandonoren sterven er nog steeds patiënten die op de wachtlijst 
staan. De meeste nieren die worden getransplanteerd zijn afkomstig van hersendode donoren, 
maar om het donoraanbod te vergroten neemt het aantal levende en hartdode donoren de 
laatste jaren in Nederland sterk toe. De lange termijn overleving van deze nieren is afhankelijk 
van verschillende factoren zoals de staat en de leeftijd van de donor, preservatie methoden, 
HLA match, de duur van koude en warme ischemie, reperfusie schade en acute rejectie. 
Onafhankelijk van deze variabelen is gebleken dat hersendood in de donor een risicofactor 
is voor een succesvolle transplantaat uitkomst na niertransplantatie. Nieren van hersendode 
donoren hebben een significant slechtere nierfunctie, slechtere overlevingspercentages en 
een grotere kans op acute rejectie vergeleken met nieren afkomstig van levende gerelateerde 
of niet gerelateerde donoren. De laatste decennia hebben meerdere onderzoeksgroepen 
onderzocht wat de invloed is van hersendood in de donor op de levensvatbaarheid en 
transplantaat overleving van de donornier, zowel in diermodellen als in humane donoren. 
Onze groep en andere onderzoeksgroepen hebben aangetoond dat hersendood in de donor leidt 
tot een ontstekingsreactie in het bloed, maar ook in de donornier. We veronderstelden dat een 
substantieel aandeel van deze ontstekingsreactie kan worden toegeschreven aan activatie van 
het complement systeem. Recentelijk was namelijk aangetoond dat complement activatie een 
belangrijke rol speelt in de schade die ontstaat tijdens ischemie-reperfusie schade en rejectie 
in de ontvanger. Dit proefschrift heeft zich gericht op complement gemedieerde schade aan 
nieren afkomstig van overleden donoren in experimentele en humane niertransplantatie.
In Hoofdstuk 1 wordt de huidige kennis van zaken beschreven over complement activatie 
tijdens cellulaire en humorale rejectie, ischemie-reperfusie schade in de nier en hersendood 
in de donor. Tijdens humorale rejectie wordt de interactie tussen B-cellen en activatie van de 
klassieke complement pathway bevestigd door de aanwezigheid van C4d als een vingerafdruk 
op de peritubulaire capillairen. Cellulaire rejectie wordt gemedieerd door complement via 
de activatie van antigeen presenterende cellen (APCs). Het is aangetoond dat C3 deficiënte 
APCs een verminderde capaciteit hebben om allo-reactieve T-cellen te stimuleren. Daarnaast 
kunnen zowel C3a als C5a de T-cel respons reguleren door APCs te stimuleren via de C3a en 
C5a receptor. 
Ischemie-reperfusie schade aan de nier is een onontkoombaar proces tijdens niertransplantatie. 
Een beschermend effect op ischemie-reperfusie schade aan de nier was al aangetoond in 
C3, C5 en C6 knock-out muizen. Zowel C5a evenals het membrane attack complex zijn 
betrokken bij de pathogenese van nierschade tijdens ischemie-reperfusie. Een grote doorbraak 
in het onderzoek naar niertransplantatie in muizen was de bevinding dat de afwezigheid 
van C3 in de donornier de overleving van het niertransplantaat in de ontvanger significant 
verlengde. In tegendeel, wanneer wild-type nieren werden getransplanteerd in C3 deficiënte 
ontvangers werd geen verlengde transplantaat overleving gevonden. Deze resultaten tonen 
aan dat niet het circulerend complement in de ontvanger, maar het locaal geproduceerde 
C3 in de donornier verantwoordelijk is voor schade aan het niertransplantaat. Deze studie 
zorgde ervoor dat de rol van complement activatie in een geheel ander daglicht kwam te 
staan aangezien complement activatie in de donor nu een belangrijke factor lijkt te zijn. 
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Echter zijn de meeste nieren niet afkomstig van levende, maar van hersendode donoren. 
In dit overzichtsartikel worden de eerste resultaten beschreven dat complement activatie al 
plaats vindt in hersendode donoren voordat de organen worden uitgenomen bij de donor. 
Uiteindelijk zou het ingrijpen in complement activatie in de donor of de ontvanger door middel 
van het toedienen van complement regulatoire eiwitten, antilichamen tegen complement 
componenten of receptoren een veelbelovende manier zijn om transplantaat uitkomsten in 
humane niertransplantatie te verbeteren.
Complement activatie is slechts één van de factoren die een belangrijke rol speelt in de schade 
aan de nier gedurende ischemie-reperfusie. Ook voor andere systemen van het aangeboren 
immuunsysteem, zoals de Toll-like receptor (TLR) pathway, is een belangrijke rol weggelegd. 
Het wordt verondersteld dat deze twee systemen samenwerken waarbij ze de immuunrespons 
op een hoog specifieke wijze coördineren. In Hoofdstuk 2 wordt dit samenspel tussen het 
complement systeem en Toll-like receptoren beschreven in relatie tot de schade als gevolg van 
hersendood in de donor en ischemie-reperfusie schade aan de nier. De link tussen complement 
en Toll-like receptoren wordt toegeschreven aan MAP-kinases. Zoals eerder was aangetoond 
voor verschillende complement factoren, beschermt ook de afwezigheid van TLR2 en 
TLR4 de nier tegen ischemie-reperfusie schade. In de donor worden TLR4 en liganden van 
TLR4 locaal geïnduceerd (HSPs, HMGB1) of systemisch verhoogd (LPS) als gevolg van 
hersendood. Gebaseerd op deze bevindingen zullen toekomstige interventies zich moeten 
richten op de inhibitie van complement en TLR activatie in niertransplantatie. Behandeling 
van zowel de donor als de ontvanger zou daardoor transplantaat uitkomst kunnen verbeteren. 
Deze twee hoofdstukken worden gevolgd door Hoofdstuk 3 welke een algemene rationale 
omvat waar de verdere hoofdstukken van dit proefschrift op een rij worden gezet. 
In Hoofdstuk 4 werd de aard en omvang onderzocht van de ontstekingsreactie die plaatsvindt 
tijdens experimentele en klinische hersendood in de donor. Hersendood werd geïnduceerd 
in de rat door het opblazen van een intracraniële balloncatheter. Ratten werden opgeofferd 
respectievelijk 0.5, 1 en 4 uur na hersendood in de donor. Sham-geopereerde ratten dienden 
als controle. In humane donoren werden bloedmonsters afgenomen van hersendode donoren 
direct na het vaststellen van hersendood en vlak voor koude perfusie van de donor, nog voor 
orgaanuitname. In levende donoren werden baseline samples afgenomen voor de start van 
de operatie en een tweede sample voor nefrectomie. Een gelijkend cytokine-profiel werd 
gevonden in het serum van rat en humane hersendode donoren met sterk verhoogde waarden 
van IL-6, IL-8 en MCP-1 na hersendood terwijl IL-1beta en TNF-alpha niet verhoogd gevonden 
werden. Aangezien IL-6 de hoofd aanjager is van de acuut fase reactie werd de expressie van 
acuut fase eiwitten onderzocht in lever en nieren van hersendode donorratten. Levers en nieren 
lieten een significante inductie zien van verschillende acuut fase eiwitten na 4 uur hersendood 
vergeleken met sham-geopereerde beesten. Complement C3 is significant geïnduceerd in de 
nier, maar niet in de lever na 4 uur hersendood in de donor. In een rat transplantatie model 
werd geen additionele C3 expressie gevonden na transplantatie in de ontvanger bovenop 
de expressie die al gevonden werd in de hersendode donor. Na transplantatie van levende 
donornieren vonden we echter wel een significante C3 inductie na transplantatie. Dit geeft 
aan dat er een substantiële inductie is van C3 door hersendood in de donor. In humane donoren 
werden vergelijkbare resultaten gevonden als in de rat met hogere C3 gen expressies en een 
sterkere C3d depositie in nierbiopten van hersendode versus levende donoren. Er werd geen 
additionele inductie van C3 gevonden als gevolg van koude ischemie of reperfusie bovenop 
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de C3 inductie door hersendood in de donor. In een klein patiëntencohort vonden we al een 
significante associatie van C3 inductie in reperfusie-biopten van hersendode donornieren en 
een slechtere korte termijn nierfunctie na transplantatie. Om een mogelijk mechanisme te 
achterhalen waardoor C3 wordt geïnduceerd in de nier, werden tubuluscellen gestimuleerd 
met IL-6, IL-8 en MCP-1. We vonden dat alleen IL-6 de C3 productie van tubulaire cellen 
kon verhogen, wat suggereert dat IL-6 mogelijk verantwoordelijk is voor de C3 inductie in 
hersendode donornieren.
Tot zover hebben we alleen de invloed van locale C3 inductie in overleden donoren op 
transplantatie uitkomst beschreven. Activatie van circulerend complement echter en het 
daarbij het vrijkomen van complement splitproducten zou de immunogeniteit van het 
donororgaan vergroten en daarmee transplantatie uitkomst kunnen beïnvloeden. Eerder was 
beschreven dat in patiënten met traumatisch hersenletsel of een herseninfarct, systemisch 
complement wordt geactiveerd. We veronderstelden dat er ook systemische complement 
activatie optreedt in hersendode donoren met generatie van C3a, C5a en C5b-9. Deze 
mediatoren zouden een ontstekingsreactie van het nierendotheel of tubulair epitheel kunnen 
veroorzaken wat vervolgens kan leiden tot een slechtere transplantaatoverleving. Daarom 
werden in Hoofdstuk 5 de complement splitproducten C4d, Bb, C5b-9 en complement 
component MBL bepaald in het plasma van 232 overleden donoren. Er werd gevonden dat 
complement significant is geactiveerd in het plasma van hersendode en non-heart beating 
donoren ten opzichte van levende donoren en gezonde vrijwilligers. Daarnaast is een hoog 
C5b-9 in de donor geassocieerd met een grotere kans op acute rejectie in de ontvanger 
na transplantatie. Bovendien werd meer vasculaire rejectie gevonden in een subset van 
ontvangers waarvan de donornier blootgesteld was aan hoge waarden van C5b-9. Deze 
resultaten laten zien dat niet alleen locaal, maar ook systemische complement activatie in 
de donor geassocieerd is met een slechtere transplantaat uitkomst. In Hoofdstuk 6 werd het 
mechanisme onderzocht waarop systemische en locale complement activatie in de donor kan 
leiden tot een verslechterde transplantatie uitkomst in de ontvanger. Eerst werd aangetoond 
dat er een verminderde functionaliteit is van complement in serum van humane hersendode 
donoren. Eén van de mechanismen zou de release van C5a in het bloed en de daaropvolgende 
stimulatie van de C5a receptor (C5aR) op de tubuluscel kunnen zijn. In nierbiopten van 
hersendode donoren werd een verhoogde gen- en eiwitexpressie van de C5aR gevonden al 
voor orgaanuitname. De combinatie van locale alsmede systemische complement activatie 
en inductie van de C5aR in de nier zou een mechanisme kunen zijn waardoor systemisch 
complement acute rejectie in de ontvanger veroorzaakt. 
Nu er aanwijzingen zijn dat zowel locale en systemische complement activatie betrokken zijn 
bij nierschade in de donor, lijkt complement interventie therapie in de donor een mogelijkheid 
om transplantaatuitkomst te verbeteren. In Hoofdstuk 7 werd complement activatie in 
hersendode donorratten geremd met soluble complement receptor 1 (sCR1), welke het 
complement systeem remt op het niveau van C3. Er werd gevonden dat behandeling van 
de donor 1 uur voor of 1 uur na hersendood de systemische complement activatie in de 
donor kan voorkomen. Tevens werd aangetoond dat na behandeling van de hersendode 
donor met sCR1 1 uur voor hersendood, de nierfunctie na transplantatie significant verbeterd 
vergeleken met niet behandelde donornieren. Op dag 7 na transplantatie waren genexpressies 
voor ontstekingsgerelateerde cytokinen significant verlaagd in nieren van sCR1 behandelde 
donoren. In tegendeel, acute rejectie op dag 7 in de ontvanger kon niet worden voorkomen 
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door behandeling van sCR1 in de donor. Lange termijn studies moeten verder uitwijzen of 
dit korte termijn effect van donorbehandeling met complement remmers ook een effect zal 
hebben op transplantaat overleving en chronische rejectie in de ontvanger.
Ook al zijn studies naar de rol van complement activatie in transplantatie interessant, de meeste 
studies zijn uitgevoerd in diermodellen. Slechts een aantal studies hebben zich gericht op de 
rol van complement in humane niertransplantatie. Analyse van de invloed van het C3 allotype 
in de donor en ontvanger op niertransplantatie uitkomst is een elegante, niet-invasieve manier 
om de invloed van complement activatie in humane niertransplantatie te onderzoeken. Twee 
grote studies hebben tegenstrijdige data gevonden over de rol van donor en ontvanger C3 
allotype van nieren afkomstig van overleden donoren op transplantaat overleving. Aangezien 
complement geactiveerd wordt in hersendode en non-heart beating donoren zou het verschil in 
uitkomsten tussen de twee studies verklaard kunnen worden door een ongelijke verdeling van 
deze twee donortypes in de studie cohorten. In Hoofdstuk 8 werd daarom de invloed van het 
C3F allotype op transplantaat uitkomst onderzocht, met inachtneming van de verschillende 
donortypes. Er werd gevonden dat het donor C3F allotype van non-heart beating donornieren 
beschermt tegen primaire non-functie na transplantatie. Matig-ernstig of ernstige vasculaire 
rejectie was de hoofdoorzaak van primaire non-functie in deze patienten. De incidentie van 
acute vasculaire rejectie was eveneens hoger in het eerste jaar na transplantatie in ontvangers 
van een C3SS vergeleken met een C3F non-heart beating donornier. Er werd geen associatie 
gevonden tussen het C3F allotype van de donornier en alle andere transplantatie uitkomst 
parameters. In levende en hersendode donornieren bevestigden we dat het C3 allotype van 
de donor en ontvanger niet geassocieerd is met niertransplantatie uitkomst. Echter moet men 
voorzichtig zijn met het interpreteren van genotypische analyses. De afwezigheid van een 
effect van het C3 allotype wil niet zeggen dat andere aspecten van C3 zoals expressie, functie 
en locale inductie, irrelevant zijn in de uitkomst na niertransplantatie. 
Er komt steeds meer bewijs dat de lectine pathway belangrijk is in complement activatie tijdens 
niertransplantatie. Muizen knock-out modellen hebben laten zien dat MBL een belangrijke 
rol speelt in ischemie-reperfusie schade aan de nier. Ook in humane niertransplantatie 
heeft men laten zien dat een hoog serum MBL in de ontvanger geassocieerd is met rejectie 
geassocieerd transplantaatfalen in de ontvanger. In de algemene populatie bestaat er een grote 
interindividuele variatie in serum MBL concentraties en activiteit. Deze worden hoofdzakelijk 
bepaald door genetische polymorfismen in het MBL2 gen. Ook ficoline-2 (L-ficoline) en 
mannan-associated serine proteases 2 (MASP2) serum concentraties worden bepaald door 
polymorfismen in respectievelijk het FCN2 gen en MASP2 gen. Analyse van MBL2, FCN2 
en MASP2 polymorfismen in de donor en ontvanger zou het belang van de lectine pathway 
in nierschade tijdens transplantatie aan het licht kunnen brengen. In Hoofdstuk 9 werden 
donor en ontvanger polymorfismen van MBL2, FCN2 en MASP2 bepaald in een groot cohort 
van niertransplantatie patiënten. Het MBL2 genotype van de donor en ontvanger was niet 
geassocieerd met transplantaat uitkomst. Analyse van genotypes en haplotypes binnen het 
FCN2 gen van de donor en ontvanger lieten eveneens geen associatie zien met transplantaat 
uitkomst. Ook een gecombineerd effect van het MBL genotype met het FCN2 diplotype 
liet geen associatie zien. Onze studie zal moeten worden bevestigd in andere transplantatie 
cohorten. Gezien het grote aantal transplantaties in ons cohort en het feit dat geen associatie 
werd gevonden tussen zowel de MBL alsmede het ficoline genotype wijst er sterk op dat de 




De resultaten van dit proefschrift laten zien dat complement activatie niet alleen optreedt 
tijdens ischemie-reperfusie van de nier maar al als gevolg van hersendood in de donor 
voor orgaanuitname. Deze resultaten zetten complement activatie als gevolg van koude 
ischemie en reperfusie in een geheel ander daglicht. Niet koude ischemie of reperfusie zijn 
de hoofdoorzaken van complement activatie in hersendode donornieren maar de staat van 
hersendood zelf. Dit plaatst de rol van complement interventie in hersendode donoren in een 
geheel ander perspectief. De beste manier om complement activatie te remmen in nieren van 
hersendode donoren is al op de intensive care unit in plaats van tijdens orgaan preservatie of 
in de ontvanger. 
Onze eerste interventie studie laat zien dat niet alleen voorbehandeling maar ook behandeling 
na vaststellen van hersendood de nierfunctie verbeterd na transplantatie. Vanuit een klinische 
blik zou men een donor willen behandelen nadat de diagnose van hersendood is vastgesteld 
in de donor. Voordat deze klinische studies kunnen worden geïnitieerd moeten we meer weten 
over de omvang en aard van complement activatie in humane niertransplantatie en associatie 
met transplantaat functie en overleving. Dit zou kunnen worden uitgezocht door middel van 
micro-array analyse op nierbiopten afgenomen van een groot cohort van niertransplantaat 
ontvangers. Dit soort analyses geeft ons meer inzicht in mogelijke interventie doelen in 
complement pathways welke niertransplantaat uitkomsten kunnen verbeteren. Uiteindelijk 
zullen gerandomiseerde klinische trials moeten worden opgezet waarin de toepassing van een 
complement remmer in de donor of ontvanger wordt vergeleken met placebo. 
Er zijn verschillende manieren waarop het complement systeem geremd zou kunnen worden om 
nierschade te voorkomen. Dit kunnen bijvoorbeeld soluble complement regulatoire eiwitten 
zijn of antilichamen tegen complement componenten, tegen split producten of complement 
receptor antagonisten. Slechts enkele van deze medicijnen worden al gebruikt in patiënten 
voor andere indicaties dan niertransplantatie. Recombinant of nano-gefilterd bloedplasma 
verworven C1-esterase inhibitor wordt momenteel gebruikt voor routine profylaxe voor 
hereditair angio-oedeem. De C1-esterase inhibitor inactiveert C1r en C1s proteasen in het C1 
complex and MASP1 en 2 in het MBL complex. Daardoor blokkeert het de klassieke evenals 
de lectine pathway activatie van complement activatie. Daarnaast blokkeert het ook proteases 
van het fibrinolytische, het stollings en het kinine systeem. Vanwege de pleiotrope functie is 
de C1-esterase remmer een goede kandidaat om transplantaatuitkomsten te bevorderen.
Een andere voor de hand liggende optie is het gebruik van een C5-inhibitor welke geregistreerd 
is voor de behandeling van paroxysmale nocturnale hemoglobinurie (PNH). Het is een 
monoclonaal antilichaam gericht tegen complement C5 en het blokkeert de conversie van 
C5a en C5b door C5-convertase. Downstream C5 blokkade lijkt gunstiger omdat daarmee 
het grootste deel van het complement systeem intact wordt gehouden vanwege de rol van 
complement in de afweer. 
Een groot probleem in het interveniëren in complement activatie door middel van de huidige 
geneesmiddelen is significante systemische complement remming die optreedt welke de 
gevoeligheid op infecties verhoogd. Daarnaast speelt complement een belangrijke rol in het 
behoud van tolerantie en zal het gebruik van complement remmers hiermee interfereren. 
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Recentelijk zijn er daarom complementremmers ontworpen die specifiek binden op plaatsen 
van complement activatie. Deze remmers zijn therapeutisch actief bij lage doseringen die 
geen remmende werking hebben op het systemisch complement en infectie gevoeligheid. 
Bovendien zijn deze fusie-eiwitten effectief gebleken in cardiale ischemie-reperfusie studies. 
Conclusies
Complement activatie speelt een belangrijke rol in de nierschade als gevolg van hersendood 
in de donor en vroege ischemie-reperfusie schade aan de nier in de ontvanger. Zowel 
locaal als systemisch complement wordt geactiveerd door hersendood in de donor en is 
geassocieerd met een slechtere transplantaat uitkomst na transplantatie. Het remmen van 
complement activatie in de hersendode donor verbetert transplantaatfunctie na transplantatie 
in de ontvanger. In transplantatiepatienten zullen gerandomiseerde klinische trials moeten 
uitwijzen of complement remming in hersendode donoren alsmede de ontvanger transplantaat 




Promoveren doe je niet alleen en daarom wil ik hier een aantal mensen bedanken die dit 
proefschrift mogelijk hebben gemaakt. Zoals een gewaardeerd bondscoach ooit zei: “Bedankt, 
en we zullen het nooit, nooit vergeten.”
Allereerst wil ik mijn promotor, prof. dr. R.J. Ploeg, bedanken voor het mogelijk maken 
van dit proefschrift. Beste Rutger, ik leerde je kennen in 2004 toen ik lid werd van het eerste 
Prometheus-nierteam waarna je me enthousiast hebt gemaakt om wetenschappelijk onderzoek 
te komen doen op het chirurgisch onderzoekslaboratorium (COL). Ik wil je bedanken voor 
de kansen die je me hebt gegeven, je “helikopterview” en nauwe betrokkenheid bij de 
totstandkoming van dit proefschrift. 
Mijn co-promotor dr. M.A.J. Seelen wil ik bedanken voor zijn tomeloze inzet en enthousiasme 
bij de totstandkoming van dit proefschrift. Beste Marc, al bij onze eerste kennismaking wist 
je me enthousiast te maken voor de wetenschap en heb je een stukje van je verslaving op me 
doen overspringen: complement. Ik bewonder je voor de manier waarop je de wetenschap 
benadert en bedrijft. In tijden van twijfel en tegenslag heb je me ontzettend gesteund, waar 
ik je erg dankbaar voor ben.
Dr. H.G.D. Leuvenink, mijn co-promotor. Beste Henri, dank voor de ondersteuning tijdens 
mijn promotie. Aan het begin van dit promotietraject werd ik door jou “geadopteerd” en jouw 
manier van vrije supervisie gaf mij de mogelijkheid mezelf te ontplooien. Ik wil je bedanken 
voor het vertrouwen.
Dr. T.A. Schuurs, beste Theo, jij mag in dit dankwoord zeker niet ontbreken. Al in de eerste 
fase van mijn studie heb je mijn interesse gewekt met het onderzoek dat indertijd werd gedaan 
op het COL. Jij hebt altijd onvoorwaardelijk achter mij gestaan en dit MD/PhD traject was er 
zonder jou niet geweest.
Prof. dr. M.R. Daha, beste Moh, met de komst van jou naar Groningen werd het onderzoek 
van complement in niertransplantatie in den lande verspreid. Jouw kennis over het 
immuunsysteem, in het bijzonder complement, is groot. Vaak heb ik je als een waar orakel 
geraadpleegd met vele vragen, waarop ook altijd nuttige en concrete adviezen volgden. Ik wil 
je bedanken voor jouw bijdrage aan dit proefschrift.
Prof. dr. H. van Goor, beste Harry, jij was al vroeg betrokken bij mijn onderzoek, al voordat 
dit MD/PhD traject werd gestart. Bij jou kon ik altijd terecht met vragen evenals interpretaties 
van immunohistochemische kleuringen. Dank voor je laagdrempeligheid en support. 
Prof. dr. J. L. Hillebrands, beste Jan-Luuk, dank voor het plaatsnemen in de leescommissie 
en voor je nuttige adviezen over diermodellen, technieken en assays.
Ook de overige leden van de leescommissie, prof. dr. E. Heineman en prof. dr. C. van 




Prof. dr. B.A. Yard and dr. S. Hoeger, dear Benito, dear Simone, many thanks for our 
fruitful collaborations and discussions on brain death related research which has resulted in 
an important publication in this field.
Prof. dr. J.A. Lisman, beste Ton, het “lismannetje” is een waar fenomeen geworden. Dank 
voor je laagdrempeligheid, adviezen en de mooie tijd op het COL. 
De analisten van het COL wil ik allen bedanken voor de jarenlange fijne samenwerking op 
het lab. Jacco Zwaagstra wil ik niet alleen bedanken voor zijn alom geprezen nuchterheid. 
Beste Jacco, mogelijk ben zelfs ik dan gepromoveerd, dus de vriezers kunnen eindelijk leeg 
en de vlag kan uit. Waar zou het lab zijn zonder een hoofdanalist als jij! Naast je expertise 
wil ik je bedanken voor de gezelligheid naast het werk. Bedankt voor het “vrijdagmiddag-
geouwehoer” met Jaap Zaad en niet te vergeten je pogingen me aan de rand van het lab 
te deponeren. Petra Suichies-Ottens, beste Petra, als biologie-student heb je me de fijne 
kneepjes van de moleculaire biologie bijgebracht. Altijd was je bereid mee te denken in de 
onderzoeksproblematiek en had jij goede adviezen op talloze technische vragen. Dank voor 
je geduld, discussies en ondersteuning. Janneke Wiersema-Buist, beste Janneke, ik wil je 
bedanken voor de fijne samenwerking, de hoeveelheid immunohistochemische kleuringen 
die je voor me hebt gedaan en je goede adviezen daarin. Ali Huizinga-Van der Vlag, met al 
snel de bijnaam “RNAli” door de berg aan RNA isolaties uit nierbiopten. Dank voor je inzet 
voor deze promotie, waarin je veel van je werk terugvindt. Daarnaast wil ik ook alle andere 
analisten werkzaam op het COL bedanken en in het bijzonder Susanne Veldhuis, Michel 
Weij, Douwe Samplonius, Renee Gras en Jelle Adelmeijer. 
Een belangrijk deel van dit proefschrift was nooit mogelijk geweest zonder de enorme inzet van 
het Prometheus studenten nierteam. Het materiaal dat door jullie werd en wordt verzameld 
is cruciaal geweest voor dit proefschrift en voor komende generaties promovendi. In dit kader 
wil ik speciaal dr. W.N. Nijboer bedanken. Beste Mijntje, jij hebt een enorme effort geleverd 
met het opzetten van Prometheus en mij begeleid in mijn eerste stage, waarvoor veel dank. 
Dit heeft ons samen een mooie publicatie opgeleverd. Ook wil ik de grote roerganger van 
“het nierperfusieteam” Cyril Moers bedanken voor onze goede samenwerking en de daaruit 
voortgevloeide publicatie en bovendien de gezellige congresbezoeken.
Tijdens mijn promotietraject heb ik met diverse lotgenoten de aio kamer/broeikas gedeeld en 
met diverse onderzoekers samengewerkt. Ook hen wil ik via deze weg bedanken:
Eelke Bos, Marco de Bruijn, Carlijn Buis, Bram ten Cate, Lucy Crane, Deborah van 
Dijk, Sanna op den Dries, Greg Hugenholtz, Astrid Klooster, Lyan Koudstaal, Bo Liu, 
Hugo Maathuis, Wijnand Melenhorst, Annelien Morks, Gemma Mulder, Rick Pleijhuis, 
Geert van Rijt, Anne Margot Roskott, Karin Ruitenbeek, Pauline Snijder, Maarten 
Speijers, Michael Sutton, Marco Verkaik en Welmoet Westendorp.
De complement werkgroep: Leo Boneschansker, Julian Kok, Rianne Kroes en Maaike 
van Werkhoven, veel succes met jullie promotie-trajecten! Niet te vergeten Anita Meter, 
dank voor je enorme inzet en fijne samenwerking!
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Gerwin Engels, beste Gerwin, ik wist ook jou te besmetten met het complement-virus en dit 
zal hopelijk een mooi deel uitmaken van jouw proefschrift over longtransplantatie. Naast het 
werk hebben we diverse keren mooie avonden gehad met goed en zeer slecht dineren. Veel 
succes nog met het afronden van jouw proefschrift.
Mijn vrienden en tevens paranimfen, Anton Romeijn en Hans Nienhuis, hartelijk dank dat 
jullie mijn paranimfen willen zijn. Niet alleen waren jullie mijn studie vrienden, we zijn ook 
meerdere keren samen op vakantie geweest. Hans, met jou deel ik o.a. de passie voor het 
onderzoek. Anton, bij jou kan ik goed “het hoofd leegmaken”. Beiden ontzettend bedankt 
voor de prachtige jaren. Van dit mjonco groepje dank ik ook: Faas Dolmans, Rob Rolink en 
Kevin Wevers voor de mooie tijd naast het onderzoek.
De biologen uit jaar 2000, Anne de Graaf, Sander van Rijn, Mark Meerdink, Thomas Bos, al 
dan niet afgestudeerd J. Jullie heb ik denk ik het meest verveeld met mijn onderzoeksverhalen 
en data obsessie. Bedankt voor de borrels, feesten en vakanties. Aansluitend aan deze groep 
wil ik ook Hidde Nijboer, Wiebe Mennes en Sybren de Jong (slaatje) bedanken.
Mijn jaarclubgenoten: Bert-Jan, Corstiaan, Douwe, Eric, Ewout, Laurens, Twan, 
Willem en ook Hubert, wil ik bedanken voor de fantastische tijd naast de studie en promotie. 
Mijn goede vrienden Ruben Overgoor en Manfred Veneboer, veel dank voor de mooie 
avonden en nachten in o.a. Zwolle, Groningen en Utrecht die een uitstekende uitlaatklep 
waren voor de frustraties tijdens dit promotietraject. Het is bijzonder vrienden te hebben 
die je kent vanaf de eerste klas basisschool. De hel van 2009 heeft dit waarschijnlijk nog 
specialer gemaakt! Ik heb er twee goede vrienden bai, Braafheid, C i ao!
Kevin, mijn broer, en Merel, ik wil jullie bedanken voor de gezellige keren dat we elkaar zien. 
Kevin, onze passie voor het onderzoek moet genetisch gepredisponeerd zijn, ik heb respect 
voor je ambities en doorzettingsvermogen. Vanaf de basisschool heb ik met geneeskunde en 
daarna een promotietraject een vergelijkbaar pad gevolgd, nu is het tijd een andere weg in te 
slaan. Merel, jij heb keihard gewerkt voor het traject wat je nu ingaat met ups-and-downs, 
respect daarvoor!
Mijn ouders, wil ik bedanken voor de steun die ik van hen kreeg om na twee studies ook nog 
eens aan een promotie-traject te beginnen. Ook al hadden jullie vaak geen idee waar ik mee 
bezig was of in welke studie/werk/verhuis constructie ik nu weer was beland, jullie waren 






De auteur van dit proefschrift, Jeffrey Damman, werd geboren op 6 december 1981 te Hoonhorst. 
Aansluitend aan het behalen van het Gymnasium diploma aan het Thomas a Kempis college te 
Zwolle, startte hij in 2000 de studie Medische Biologie aan de Rijksuniversiteit Groningen. In 
2006 studeerde hij af in de Medische Biologie met als afstudeer richting transplantatie biologie. 
In 2003 begon hij tevens aan de studie Geneeskunde waar hij onder andere deel uitmaakte 
van het eerste Prometheus studenten nierteam onder leiding van Prof. dr. R.J. Ploeg. Hierdoor 
ontstond belangstelling voor onderzoek in de niertransplantatie geneeskunde waardoor de basis 
werd gelegd voor een MD/PhD traject onder leiding van Prof. dr. R.J. Ploeg, dr. M.A. Seelen en 
dr. H.G. Leuvenink. Na het doorlopen van zijn co-schappen in de Isala Klinieken te Zwolle en 
het St. Antonius Ziekenhuis te Nieuwegein werd hij in februari 2011 bevorderd tot arts. 
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